Amedeo Smart

Free Medical Literature Service

 

Amedeo

Schizophrenia
  Free Subscription

Articles published in
Schizophr Res
    November 2026
  1. DICKERSON F, Origoni A, Katsafanas E, Rowe K, et al
    Cigarette smoking trends among persons with psychiatric disorders: 1999-2026.
    Schizophr Res. 2026;297:472-478.
    >> Share

  2. MARTIADIS V, Raffone F, Cervino A, Olivola M, et al
    Projected mortality impact of increasing second-generation long-acting injectable antipsychotic exposure in Italy: A scenario-based population model.
    Schizophr Res. 2026;297:445-453.
    >> Share

  3. VAN DEN BUUSE M, Sbisa A, Gogos A
    Ovariectomy reverses maternal immune activation-induced deficits in dopamine and NMDA receptor-mediated regulation of prepulse inhibition in female Long-Evans rats.
    Schizophr Res. 2026;297:413-419.
    >> Share

  4. BETZ GF, Vagedes H, Wehr S, Weigel L, et al
    Quality of Life Scale (QLS): A systematic review of measurement properties.
    Schizophr Res. 2026;297:375-383.
    >> Share

  5. WHISKEY E, Oloyede E, Dzahini O, Aziri H, et al
    Off-licence use of clozapine: Lessons from an inner-city NHS trust - Comparison with other NHS Trusts.
    Schizophr Res. 2026;297:194-201.
    >> Share

  6. BOKHARI SA, Elnoor M, Sabri M, Bardi M, et al
    Baseline neutrophil count, benign ethnic neutropenia risk, and clozapine haematological monitoring: A multi-ethnic retrospective cohort study from the United Arab Emirates.
    Schizophr Res. 2026;297:76-88.
    >> Share

    October 2026
  7. SAAD A, Montag C, Gillespie SM, Hadad BS, et al
    Age-associated differences in mentalizing error profiles in schizophrenia: Evidence for a dissociation between hypo- and hyper-mentalizing.
    Schizophr Res. 2026;298:96-103.
    >> Share

  8. NELSON AM, Srinivasan A, Clementz B, Gershon E, et al
    Tobacco use moderates associations between cannabis use, psychiatric symptoms, and cognitive performance in psychosis spectrum disorders.
    Schizophr Res. 2026;298:88-95.
    >> Share

  9. JIMENEZ E, Hinton W, Reeve S, Oduola S, et al
    Loneliness and socio-occupational functioning in psychosis: A systematic review.
    Schizophr Res. 2026;298:121-133.
    >> Share

  10. STEINZ CA, Wahab RJ, Dielemans DAM, Wijnen BFM, et al
    Clinical and demographic characteristics associated with residual symptom severity in remitted first-episode psychosis.
    Schizophr Res. 2026;298:104-116.
    >> Share

  11. PAPPA E, So C, McGowan J, Ng G, et al
    Command auditory verbal hallucinations in a culturally diverse early intervention in psychosis service: Prevalence, clinical associations and phenomenology.
    Schizophr Res. 2026;298:44-53.
    >> Share

  12. VAN DER HEIJDEN H, Cao A, van Gool R, Yekeduz MK, et al
    Altered pain processing and associated neural circuitry disruptions in adolescents with early-onset psychosis.
    Schizophr Res. 2026;298:34-43.
    >> Share

  13. CICOGNOLA C, Eratne D, Kang MJY, Janelidze S, et al
    Astrocytic activity in treatment-resistant and ultra-treatment-resistant schizophrenia.
    Schizophr Res. 2026;298:25-33.
    >> Share

  14. KRONENBUERGER M, Yoshida K, Li PY, Tavakoli E, et al
    Pharmacogenomics of antipsychotic-induced weight gain: A systematic review.
    Schizophr Res. 2026;296:175-198.
    >> Share

    September 2026
  15. LENG A, Percie du Sert O, Lepage M, Ghanem J, et al
    Two-year domain-specific cognitive trajectories following a first episode of psychosis and early intervention: A data-driven study.
    Schizophr Res. 2026;297:659-668.
    >> Share

  16. LONG X, Zhang M, Cheng P, Wang F, et al
    Distinct patterns of putative glymphatic function between early-onset and adult-onset first-episode schizophrenia: Evidence from DTI-ALPS.
    Schizophr Res. 2026;297:628-636.
    >> Share

  17. HALAJ A, Seow TXF, David AS
    Task-based metacognition and insight in schizophrenia spectrum disorders: A systematic review and meta-analysis.
    Schizophr Res. 2026;297:599-610.
    >> Share

  18. FUNG CCS, Chu RST, Chu NWT, Fung VSC, et al
    Patterns, predictors and outcomes of the joint trajectories of positive and negative symptoms in patients with early psychosis: 12-year follow-up of the randomized controlled trial on extended early intervention.
    Schizophr Res. 2026;297:590-598.
    >> Share

  19. GIORDANO GM, Melillo A, Galderisi S, Mucci A, et al
    Defining and operationalizing negative symptom constructs in schizophrenia: A practical guide for clinicians, researchers, and industry stakeholders.
    Schizophr Res. 2026;297:578-589.
    >> Share

  20. NOMURA N, Kikuchi Y, Takeuchi H
    Low-dose versus standard-dose antipsychotic treatment in first-episode schizophrenia: A secondary analysis of EUFEST data.
    Schizophr Res. 2026;297:637-642.
    >> Share

  21. LIU W, Xia X, Hong Z, Deng Z, et al
    Interleukin-17 potentially links prolactin to positive symptoms in first-episode drug-naive schizophrenia: An exploratory cross-sectional study.
    Schizophr Res. 2026;297:619-627.
    >> Share

  22. STRAUSS GP, Raugh IM, Cowan T, Luther L, et al
    Toward the third generation of negative symptom assessment in schizophrenia: A systematic review of digital phenotyping measures.
    Schizophr Res. 2026;298:54-87.
    >> Share

  23. ALEDORT E, Walsh-Messinger J, Mueller BR, Kamalakar K, et al
    Peripheral sudomotor reflex activity as a candidate autonomic biomarker for psychosis: associations with symptoms and cognition.
    Schizophr Res. 2026;297:561-568.
    >> Share

  24. GAO T, Smith RC, Li X, Zhang S, et al
    Anterior cingulate GABA and functional connectivity associated with initial treatment response in first-episode schizophrenia.
    Schizophr Res. 2026;297:551-560.
    >> Share

  25. LAPORTE D, Weir H, Greenburgh A, Baldwin H, et al
    Neighbourhood-level variations in psychosis prevalence and involuntary psychiatric admissions.
    Schizophr Res. 2026;297:542-550.
    >> Share

  26. ULIANA DL, Grace AA
    Hippocampal mechanisms and neural circuitry of negative symptoms in schizophrenia.
    Schizophr Res. 2026;297:535-541.
    >> Share

  27. MANZONI D, Benner JF, Velthorst E, Crafa D, et al
    The role of negativity bias and facial affect recognition in the increased odds of first-episode psychosis in ethnic minority populations: Findings from the EU-GEI case-control study.
    Schizophr Res. 2026;297:525-534.
    >> Share

  28. SHIMADA T, Yamanushi A, Tanaka S, Kobayashi M, et al
    Exercise interventions for cognitive impairment in schizophrenia: An umbrella review.
    Schizophr Res. 2026;297:522-524.
    >> Share

  29. MYERS AW, Bertrand CE, Mittal VA
    Risk of ketamine exposure in individuals at clinical high-risk for psychosis.
    Schizophr Res. 2026;297:520-521.
    >> Share

  30. CHATZISOFRONIOU G, Cohen A
    From AI hallucinations to psychosis: Representational entanglement as a computational bridge.
    Schizophr Res. 2026;297:518-519.
    >> Share

  31. LOSHIN J, Culbreth A, Stein A, Joncas E, et al
    Transdiagnostic symptoms and the masking of neurocognitive impairment across the early stages of psychosis.
    Schizophr Res. 2026;297:499-508.
    >> Share

  32. TAYLOR CE, Mulligan LD
    Sleep quality and quality of life in people with non-affective psychosis: A systematic review of relationships across phases and age groups.
    Schizophr Res. 2026;297:486-498.
    >> Share

  33. PERFALK E, Damgaard JG, Danielsen AA, Ostergaard SD, et al
    Predicting clozapine initiation among patients with schizophrenia via machine learning trained on electronic health record data.
    Schizophr Res. 2026;297:461-471.
    >> Share

  34. VAN DER VELDE DM, de Haan L, Batalla A, Sommer IE, et al
    Polysubstance use after remission in first-episode psychosis: Associations with positive symptoms and self-care.
    Schizophr Res. 2026;297:454-460.
    >> Share

  35. MORITZ S, Flachsenberg ME, Meinhart A, Ishikawa R, et al
    Should schizophrenia be renamed? Patients' preferences and what anti-stigma campaigns may learn from the history of the term "Black" in the United States.
    Schizophr Res. 2026;297:438-444.
    >> Share

  36. JIN JW, Winkler CJ, Blunt HB, Riblet NB, et al
    Effect of dopamine partial agonist antipsychotics on suicide risk in persons with schizophrenia and schizoaffective disorders: A systematic review and meta-analysis.
    Schizophr Res. 2026;297:430-437.
    >> Share

  37. WANG X, Tang Q, Xu H, Keshavan MS, et al
    Characteristics of treatment-naive individuals with chronic schizophrenia and the reported reasons for non-treatment: A two-year follow-up study in Northwest China.
    Schizophr Res. 2026;297:420-429.
    >> Share

  38. CHEN J, Zhang F, Zhang R, Ji M, et al
    Glymphatic system alterations in schizophrenia evaluated by the DTI-ALPS index: A systematic review and meta-analysis.
    Schizophr Res. 2026;297:403-412.
    >> Share

  39. CORRELL CU, Durgam S, Kozauer SG, Chen C, et al
    Long-term safety and tolerability of lumateperone 42 mg in patients with stable symptoms of schizophrenia: Results from a 1-year open-label study.
    Schizophr Res. 2026;297:393-402.
    >> Share

  40. WANG S, Chen Q, Zheng F, Huang H, et al
    Adjunctive n-3 PUFA supplementation improves niacin skin flush response and shows biomarker-stratified signals in schizophrenia.
    Schizophr Res. 2026;297:384-392.
    >> Share

  41. ESCELSIOR A, Zizzi A, Dibiase G, Ploner L, et al
    Visual dysfunction and psychosis: A systematic review and meta-analysis.
    Schizophr Res. 2026;297:353-374.
    >> Share

  42. GALVAN J, Lopez-Morinigo JD, Salazar de Pablo G, Sepulveda M, et al
    Parkinsonism and psychopathology severity in real-world outpatients with schizophrenia: A cross-sectional PRISM study.
    Schizophr Res. 2026;297:345-352.
    >> Share

  43. FRADKIN SI, Mazumdar I, Chan CC, Heisig S, et al
    Acoustic features and social cognition in schizophrenia and schizotypal personality disorder.
    Schizophr Res. 2026;297:330-339.
    >> Share

  44. JANE GRA, Varughese NR, Prabha R, Chichra A, et al
    Serum Clozapine Levels and Dose-Exposure Relationships in Indian Patients: A Cross-Sectional Study.
    Schizophr Res. 2026;295:170-175.
    >> Share

  45. GORINA D, Del Piccolo MC, Georgiades A, Vieira S, et al
    Predictors of engagement and response in cognitive behaviour therapy for psychosis: A systematic review.
    Schizophr Res. 2026;297:314-329.
    >> Share

    August 2026
  46. LIU X, Zhou Y, Tan L, Li Z, et al
    The efficacy of physical exercise on body mass index in schizophrenia patients: A systematic review and meta-analysis on exercise prescription, intensity, and delivery.
    Schizophr Res. 2026;297:295-303.
    >> Share

  47. MADSEN SO, Donath VM, Strauss GP, Glenthoj LB, et al
    Affect and pleasure in social contexts among patients with schizophrenia and negative symptoms: An ecological momentary assessment study.
    Schizophr Res. 2026;297:287-294.
    >> Share

  48. LU M, Zhang S, Dong J, Chen Y, et al
    Configurational patterns associated with psychiatric disability among patients with schizophrenia: A fuzzy-set qualitative comparative analysis.
    Schizophr Res. 2026;297:277-286.
    >> Share

  49. BONFILS KA, Hammer LA, Subotnik KL, Ventura J, et al
    Relationships between empathy, symptoms, and functioning in first episode psychosis.
    Schizophr Res. 2026;297:263-269.
    >> Share

  50. DIELEMANS DAM, Huizer K, van der Pluijm M, Thijssen A, et al
    Baseline inflammatory profile is associated with short-term antipsychotic-induced weight gain in first-episode psychosis: results from the OPTiMiSE study.
    Schizophr Res. 2026;297:254-262.
    >> Share

  51. KITTLESON AR, Chatterjee A, Lebovitz J, Rogers BP, et al
    The embodied self in psychosis: Relationships among insula functional connectivity and emotional embodiment in schizophrenia-spectrum disorders.
    Schizophr Res. 2026;297:241-253.
    >> Share

  52. MARCHI M, Travascio A, Pollice G, Grenzi P, et al
    Predictors of social and occupational functioning in help-seeking youths accessing an early intervention in psychosis programme: A real-world cohort study using machine learning algorithms.
    Schizophr Res. 2026;297:231-240.
    >> Share

  53. WORTHY G, Cocks K, Pascoe B, Reaney M, et al
    Derivation of score interpretation thresholds in clinical outcome assessments measuring cognitive impairment associated with schizophrenia.
    Schizophr Res. 2026;297:219-227.
    >> Share

  54. NOWICKA M, Jarczewska-Gerc E, Marszal-Wisniewska M
    Letter to the editor: Application of mental simulation and implementation intentions in the therapeutic management of drug-resistant auditory hallucinations in schizophrenia - Preliminary study.
    Schizophr Res. 2026;297:213-218.
    >> Share

  55. MOYAL M, Consoloni T, Haroche A, Sebille SB, et al
    Anterior cingulate cortex sulcal patterns associated with catatonia across schizophrenia and mood disorders.
    Schizophr Res. 2026;297:202-210.
    >> Share

  56. AKOURI-SHAN L, Le TP, Firmin R, Ventura J, et al
    Self-stigma and stigma resistance after a first episode of psychosis: Clinical, cognitive, and functional correlates.
    Schizophr Res. 2026;297:191-193.
    >> Share

  57. EL HAJ C, Prasad AA
    Subregional reduction in CB1 receptor in dopamine neurons in postmortem schizophrenia midbrain.
    Schizophr Res. 2026;297:182-190.
    >> Share

  58. KLEIN HS, Fan RH, Ge T, Asgharnejad M, et al
    Corrigendum to "exploratory anchor-based analyses to determine minimal clinically important differences for the brief assessment of cognition in schizophrenia and the schizophrenia cognition rating scale" [Schizophr. Res. 2026 July 25. doi:10.1016/j.s
    Schizophr Res. 2026 Aug 18:S0920-9964(26)00258.
    >> Share

  59. IOANNOU M, Kouvaras E, Zacharouli K, Bargiota SI, et al
    Dentate gyrus immaturity and region-specific synaptic and autophagy alterations across hippocampal subfields in schizophrenia.
    Schizophr Res. 2026;297:172-181.
    >> Share

  60. UZUN UYSAL E, Uysal OA, Cilesiz MU, Memis H, et al
    Reduced plasma synaptotagmin-11 levels in schizophrenia: A preliminary study.
    Schizophr Res. 2026;297:169-171.
    >> Share

  61. HOU C, Huang H, Jiang S, Li H, et al
    Distinctive subcortical connectivity predicts treatment response in first-episode schizophrenia.
    Schizophr Res. 2026;297:149-156.
    >> Share

  62. BORNHEIMER LA, DeVylder J, Smith MJ, Brdar NM, et al
    Cognitive-behavioral suicide prevention for psychosis in community mental health: A pilot randomized clinical trial.
    Schizophr Res. 2026;297:140-148.
    >> Share

  63. SOLDOVIERI CBC, Elleuch D, Ahrens J, Bambini V, et al
    Social functioning and formal thought disorder in schizophrenia: A Bayesian meta-analysis.
    Schizophr Res. 2026;297:131-139.
    >> Share

  64. JO HG, Votinov M, Hupen P, Wagels L, et al
    Machine learning-based integration of surface morphometric features identifies diagnostic and symptom-related cortical signatures of schizophrenia.
    Schizophr Res. 2026;297:120-128.
    >> Share

  65. CARRICO SM, Fan L, Pinkham AE
    Interoception in schizophrenia and its relation to symptomatology, social functioning, and emotion recognition.
    Schizophr Res. 2026;297:112-119.
    >> Share

  66. BLANCHARD JJ, Davis BL, Schuchardt KE
    Anhedonia in schizophrenia and psychosis spectrum disorders: An integrative review.
    Schizophr Res. 2026;297:97-108.
    >> Share

  67. BAKSTEIN E, Kudelka J, Schneider J, Slovakova A, et al
    Medium-term prediction of clinically relevant outcomes in first-episode schizophrenia patients.
    Schizophr Res. 2026;297:89-96.
    >> Share

  68. LIU Y, Wang Y, Tian S, Hu X, et al
    Allostatic load, sleep patterns, and genetic susceptibility in relation to severe mental illness: A prospective cohort study.
    Schizophr Res. 2026;294:124-132.
    >> Share

  69. KANG JT, Shields AM, Mizuno Y, De Biase M, et al
    A systematic review on the effects of clozapine on B-lymphocytes and immunoglobulins.
    Schizophr Res. 2026;294:198-214.
    >> Share

  70. VERDOUX H, Schulte P, Lepetit A, Montastruc F, et al
    Risk and management of cancer in clozapine users: A systematic review.
    Schizophr Res. 2026;294:99-109.
    >> Share

    July 2026
  71. TARRICONE I, Bettinardi O, Leuci E, Parmeggiani C, et al
    Real-world effectiveness of a multicomponent early intervention program for first episode psychosis in Emilia Romagna (Italy): Timeliness, specificity and fairness.
    Schizophr Res. 2026;296:227-234.
    >> Share

  72. INCHAUSTI F, Garcia-Poveda NV, Pinotti M, Fonseca-Pedrero E, et al
    Metacognition, identity, and durable recovery in adolescent early psychosis: A five-year mixed-methods follow-up.
    Schizophr Res. 2026;297:68-75.
    >> Share

  73. STILES BJ, Fraser MI, Gleeson JF, Alvarez-Jimenez M, et al
    Psychometric properties of the Self-Compassion Scale - Short Form in young adults with psychosis: Proceed with caution.
    Schizophr Res. 2026;297:58-67.
    >> Share

  74. D'AMBROSIO S, Tonoli F, Mayeli A, Smagula SF, et al
    The interplay between subjective time perspective, circadian rhythms, and social functioning in schizophrenia spectrum disorders: Insights from the DiAPASon study.
    Schizophr Res. 2026;297:46-57.
    >> Share

  75. JIANG C, Wang L, Zhang S, Ge X, et al
    Unnatural death in Chinese patients with schizophrenia spectrum disorder: Age distribution, sex and seasonal patterns.
    Schizophr Res. 2026;297:37-45.
    >> Share

  76. SUN X, Feng Y, Zhang J, Tang P, et al
    Association between depressive symptoms, CRP and metabolism-related indicators in Han Chinese patients with chronic schizophrenia.
    Schizophr Res. 2026;297:26-36.
    >> Share

  77. KLEIN HS, Fan RH, Ge T, Asgharnejad M, et al
    Exploratory anchor-based analyses to determine minimal clinically important differences for the Brief Assessment of Cognition in Schizophrenia and the Schizophrenia Cognition Rating Scale.
    Schizophr Res. 2026;297:17-25.
    >> Share

  78. SOBRAL MVS, Menechini RB, Marcal JBC, de Vasconcelos AV, et al
    Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2026;297:8-16.
    >> Share

  79. CHI J, Han Y, Zhang X, Zhang C, et al
    Metabolomics analysis reveals BMI-related metabolic characteristics in schizophrenia patients.
    Schizophr Res. 2026;296:218-226.
    >> Share

  80. DAUB J, Volkmer S, Altinok DCA, Brandt GA, et al
    Subjective space and time experience in schizophrenia spectrum disorders and mood disorders: Psychometric properties and clinical correlates of the semi-structured STEP interview.
    Schizophr Res. 2026;296:208-217.
    >> Share

  81. KOSTER M, Vermeulen J, Ziermans T, van Hooijdonk CFM, et al
    Neuromelanin-MRI and tobacco smoking in first episode psychosis patients and controls.
    Schizophr Res. 2026;297:1-7.
    >> Share

  82. DEL OLMO-ENCABO P, Aquino-Servin A, Paris-Gomez I, Sarro S, et al
    Cohesion profiles across language-related symptoms in schizophrenia.
    Schizophr Res. 2026;296:199-207.
    >> Share

  83. DESAI R, Abdur-Rahman Z, Boscoe A, Vitalis J, et al
    Prevalence of psychosis in South Asia: A systematic review and meta-analysis.
    Schizophr Res. 2026;296:163-174.
    >> Share

  84. ANDERSON Z, Pokorny V, Kenney J, Gold JM, et al
    The effect of monetary versus point-based rewards on effort-cost decision making in individuals at clinical high risk for psychosis.
    Schizophr Res. 2026;296:155-162.
    >> Share

  85. YANG M, Hou J, Yang H, Yuan X, et al
    Inflammatory markers and niacin skin flush response in men with chronic schizophrenia.
    Schizophr Res. 2026;296:147-154.
    >> Share

  86. EYUBOGLU MS, Demirlek C, Demir M, Cesim E, et al
    A comprehensive investigation of social cognition across different stages of psychosis: A staging model comparison including familial high-risk, ultra high-risk, first episode and chronic patients.
    Schizophr Res. 2026;296:138-146.
    >> Share

  87. SANDRONI V, Szoke A, Peyre H, Amoretti S, et al
    IQ and subclinical psychosis: The role of psychosocial stressors and core schemata.
    Schizophr Res. 2026;296:130-137.
    >> Share

  88. MASHIMA Y, Shinagawa K, Suzuki H, Onaya M, et al
    Post-conclusion belief inflexibility bias assessed by a modified beads task in schizophrenia.
    Schizophr Res. 2026;296:121-129.
    >> Share

  89. JUNG S, Lee DH, Hong M, Kim MK, et al
    Association of COVID-19 vaccination with improved treatment adherence in patients with schizophrenia: A propensity score-matched cohort study.
    Schizophr Res. 2026;296:111-120.
    >> Share

  90. FERRARI M, Pawliuk N, Shah J, Abdel-Baki A, et al
    An appraisal of practice guidelines for early intervention services for psychosis: Using AGREE II (Appraisal of Guidelines for Research and Evaluation) to enhance the quality and trustworthiness of guidelines in the future.
    Schizophr Res. 2026;295:282-291.
    >> Share

  91. BLAKSTAD EG, Wortinger LA, Jorgensen KN, Nerland S, et al
    Structural brain alterations of the subcortical limbic system in schizophrenia and bipolar disorders.
    Schizophr Res. 2026;296:91-101.
    >> Share

  92. ZHAO J, Li Z, Xiong Y, Zhang D, et al
    Aperiodic activity modulation during visual oddball paradigm in clinical high-risk individuals and relationship with psychosis conversion.
    Schizophr Res. 2026;296:83-90.
    >> Share

  93. WANG L, Li T, Jin F, Zhang X, et al
    Static and dynamic brain region activation abnormalities in schizophrenia: Evidence from fNIRS.
    Schizophr Res. 2026;296:75-82.
    >> Share

  94. MIYAGAWA R, Takayama A, Ogawa Y, Kawakami K, et al
    Initiation patterns of long-acting injectable antipsychotics in a claims-based proxy cohort approximating first-episode schizophrenia: A longitudinal descriptive study using a Japanese claims database.
    Schizophr Res. 2026;296:67-74.
    >> Share

  95. SANDS BR, Hall NT, Caserio C, Schreiber AM, et al
    Identifying in-the-moment alterations in socioemotional connection in youth at clinical high risk for psychosis and their caregivers via positivity resonance.
    Schizophr Res. 2026;296:60-66.
    >> Share

  96. MOTE J, Gard DE, Mueser KT, Fulford D, et al
    Positive affect during social interactions predicts goal progress and social motivation in daily life for people with schizophrenia.
    Schizophr Res. 2026;296:54-59.
    >> Share

  97. DONG Y, Wang J, Guan S, Zhu Y, et al
    Quality evaluation of randomized controlled trials of antipsychotic drugs for schizophrenia published in Chinese journals.
    Schizophr Res. 2026;296:43-53.
    >> Share

  98. KIRPINAR MM, Aksoy Poyraz C, Yildirim I, Polat CD, et al
    Predictors of early discontinuation of clozapine under rapid titration in a Turkish tertiary inpatient setting.
    Schizophr Res. 2026;293:8-16.
    >> Share

  99. YANG M, Huang J, Liu L, Yi C, et al
    FL-SDGIN: A federated graph learning approach for schizophrenia diagnosis integrating static and dynamic brain functional networks.
    Schizophr Res. 2026;296:29-42.
    >> Share

    June 2026
  100. LAPPIN JM, Bolton P, Smith G, Chua XY, et al
    Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial.
    Schizophr Res. 2026;296:19-28.
    >> Share

  101. WALPOLE SJ, Lum JS, Chesworth R, Walker AK, et al
    Inflammation-associated alterations in mGluR transcript expression in the human nucleus accumbens independent of schizophrenia diagnosis.
    Schizophr Res. 2026;296:1-10.
    >> Share

  102. WEITTENHILLER LP, Abplanalp SJ, Green MF, Reavis EA, et al
    One social interaction after another: Dynamic modeling of social experience in schizophrenia.
    Schizophr Res. 2026;295:274-281.
    >> Share

  103. PAREDES R, Grigoras V, Ferroni F, Ardizzi M, et al
    Reduced synaptic plasticity and E/I imbalance drive peripersonal space boundaries expansion in schizophrenia.
    Schizophr Res. 2026;295:264-273.
    >> Share

  104. CAVALERI D, Crocamo C, Cucchi G, Bartoli F, et al
    Complete blood count-derived inflammatory markers and symptom phenotypes in schizophrenia spectrum disorders: A hierarchical clustering analysis.
    Schizophr Res. 2026;295:253-263.
    >> Share

  105. SMAGULA SF, Kim YS, Lee E, Wallace ML, et al
    Moderators of behavioral activation versus treatment as usual effects on negative symptoms in patients with Schizophrenia Spectrum Disorder.
    Schizophr Res. 2026;295:248-252.
    >> Share

  106. HARRIS NM, Holter KM, Niswender CM
    Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia.
    Schizophr Res. 2026;295:236-247.
    >> Share

  107. OLIVARES-BERJAGA D, Rodriguez N, Martinez-Pinteno A, Rubio-Unguetti L, et al
    Increased brain VDAC1 protein levels correlate with behavioural performance in a ketamine murine model of schizophrenia and are attenuated by the mGluR2 modulator JNJ-46356479.
    Schizophr Res. 2026;295:228-235.
    >> Share

  108. HUANG Y, Zhang J, Ling J, Zhao L, et al
    Comparative efficacy of oral and long-acting injectable paliperidone on social functioning in schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2026;295:212-225.
    >> Share

  109. TEAGUE V, Guilfoyle S, Pocha P, Chelvam TP, et al
    Is a higher antipsychotic dose required to treat relapse in remitted first episode psychosis? A systematic review and meta-analysis.
    Schizophr Res. 2026;295:210-211.
    >> Share

  110. GOH KK, Wu TH, Chen CH, Chen PY, et al
    The U-shaped relationships between prolactin level and insulin resistance in patients with schizophrenia under olanzapine treatment.
    Schizophr Res. 2026;295:202-209.
    >> Share

  111. MASON A, Logeswaran Y, Opper F, Khan H, et al
    The effectiveness and tolerability of trauma-focused interventions for trauma symptoms in individuals who have psychosis: A systematic review and meta-analysis.
    Schizophr Res. 2026;295:187-201.
    >> Share

  112. CHEN J, Dong Y, Li Y, Liu N, et al
    Energy metabolism dysregulation in schizophrenia with non-thyroidal illness syndrome: Roles of citric acid and Tyrosol-4-sulfate.
    Schizophr Res. 2026;295:179-186.
    >> Share

  113. FISCHER BA, Saadeh M, Roche D, Wijtenburg SA, et al
    Letter to the editor: Higher anterior cingulate glutamatergic metabolites in schizophrenia with past alcohol use disorders.
    Schizophr Res. 2026;295:176-178.
    >> Share

  114. LOCH AA, Queluz FH, Waurzenczak B, Gondim JM, et al
    Predicting transition to psychiatric disorders in clinical high-risk for psychosis subjects using machine learning and facial features.
    Schizophr Res. 2026;295:161-169.
    >> Share

  115. MIECZNIKOWSKI KB, Blom TJ, Nasrallah HA
    Hyperlipidemia correlated with better neurocognition in patients with schizophrenia.
    Schizophr Res. 2026;295:156-160.
    >> Share

  116. SPEYER H, Rabinowitz J, Luthringer R, Tamba BI, et al
    Moderate to severe negative symptoms predict low risk of symptoms worsening in schizophrenia patients in CATIE.
    Schizophr Res. 2026;295:150-155.
    >> Share

  117. ABOUKAOUD M, Amiaz R, Hoch B, Davidson M, et al
    Xanomeline/trospium and suicide-related events in schizophrenia: An early pharmacovigilance analysis.
    Schizophr Res. 2026;295:146-149.
    >> Share

  118. LUTHER L, Fulford D
    Digital therapeutics for negative symptoms of psychosis: Where do we go from here?
    Schizophr Res. 2026;295:138-145.
    >> Share

  119. SHIVAKUMAR G, Szymaniak K, Bell E, Malhi GS, et al
    Schizoaffective disorder - A conglomerated disorder that needs an amalgamation of ideas.
    Schizophr Res. 2026;292:60-68.
    >> Share

  120. DALLOUL N, Kandala S, Moran E, Barch DM, et al
    Negative symptoms and resting state functional connectivity: Leveraging ecological momentary assessment and individual-specific techniques.
    Schizophr Res. 2026;292:28-40.
    >> Share

  121. RICHARDS SE, Davis A, Blake C, Errington H, et al
    Challenges and priorities in researching and managing altered perceptual experiences: Shared academic and lived experience perspectives.
    Schizophr Res. 2026;292:12-20.
    >> Share

  122. POLETTI M, Bevione F, Iftime VN, Lacidogna MC, et al
    Altered mirroring and self-face processing in schizophrenia: A systematic review.
    Schizophr Res. 2026;295:129-137.
    >> Share

    May 2026
  123. CRABTREE E, Brock E, Lewandowski KE
    Elevated impulsivity in psychosis is associated with mood, anxiety, and general symptoms.
    Schizophr Res. 2026;295:120-128.
    >> Share

  124. LINDENMAYER JP, Khan A, Insel BJ, Kothare H, et al
    Psychometric analysis of speech-based digital biomarkers of alogia symptoms in treatment resistant schizophrenia: Comparison with clinical ratings of expressive negative symptoms.
    Schizophr Res. 2026;295:110-119.
    >> Share

  125. ATAOV G, Balaban OD, Cirakli Z, Yesilkaya UH, et al
    Can electroconvulsive therapy attenuate glial stress in schizophrenia? Longitudinal evidence from serum GFAP and S100B.
    Schizophr Res. 2026;295:91-100.
    >> Share

  126. HOLKER J, Clouse A, Gilday SAJ, Jensen J, et al
    Motivation and pleasure deficits reflect altered network embedding of normal brain deviations in schizophrenia.
    Schizophr Res. 2026;295:82-90.
    >> Share

  127. WU M, Li Z, Wang Y, Zhang X, et al
    A network analysis of psychotic symptoms, neurocognition, alexithymia, empathy, and suicidal intent in patients with chronic schizophrenia.
    Schizophr Res. 2026;295:72-81.
    >> Share

  128. STRAUSS GP, Zhang Z, Arnold LE, Hutcheson AL, et al
    Subjective perceptions of negative symptoms among outpatients with schizophrenia and their relatives or caregivers: Definitions, importance, measurement, and desired improvement.
    Schizophr Res. 2026;295:61-71.
    >> Share

  129. FOO CYS, Leonard CJ, McLaughlin MM, Johnson KA, et al
    A mixed methods study of program-level factors influencing patient and family engagement in first episode psychosis coordinated specialty care.
    Schizophr Res. 2026;295:52-60.
    >> Share

  130. SUN L, Bo Y, Li D, Yao P, et al
    Plasma metabolomic signature of frailty and risk of late-onset schizophrenia: A prospective cohort study.
    Schizophr Res. 2026;295:29-38.
    >> Share

  131. WANG J, Yang M, Wang Z, Xue K, et al
    Changes in neurovascular coupling of cerebral blood flow and functional connectivity strength in first-episode schizophrenia patients after antipsychotic treatment.
    Schizophr Res. 2026;295:11-20.
    >> Share

  132. RICH HM, Pokorny VJ, Osborne KJ, Geiger M, et al
    Atypical semantic priming in individuals at clinical risk for psychosis.
    Schizophr Res. 2026;295:3-10.
    >> Share

  133. IGARASHI Y, Norii T, Ohno E, Wakisaka R, et al
    Foreign body airway obstruction in schizophrenia: Findings from a prospective multicenter registry.
    Schizophr Res. 2026;295:1-2.
    >> Share

  134. NADER G, Raymond R, Trad R, Ducharme M, et al
    The role of global DNA methylation and epigenetic aging in the suicidality of patients with schizophrenia.
    Schizophr Res. 2026;294:192-197.
    >> Share

  135. ABPLANALP SJ, Strauss GP, Bucci P, Mucci A, et al
    Negative symptoms of schizophrenia demonstrate measurement bias across sociodemographic variables.
    Schizophr Res. 2026;294:185-191.
    >> Share

  136. LI Y, Lu C, Zhang J, Yue K, et al
    Sex-specific associations between serum uric acid, psychopathology, and cognition in deficit schizophrenia.
    Schizophr Res. 2026;294:176-184.
    >> Share

  137. CARROLL D, Rintell LS, D'Angelo EJ, Lopez D, et al
    Exploring the burden of care: A model for understanding caregiver burden in children with psychosis.
    Schizophr Res. 2026;294:166-175.
    >> Share

  138. LAN M, Wang L, Wang B, Cao T, et al
    Dynamic and integrative visual processing abilities in schizophrenia.
    Schizophr Res. 2026;294:155-163.
    >> Share

  139. RYU S, Kim JW, Jhon M, Chung YC, et al
    Perplexity and pseudo-perplexity as objective measures of linguistic deficits in schizophrenia: Evidence from a Korean-Speaking cohort.
    Schizophr Res. 2026;294:147-154.
    >> Share

  140. WIJNRUIT J, Voorhout K, Lumsden V, Verheijde-Zeyl C, et al
    Corrigendum to "Twenty-two year outcome of a first psychotic episode in Suriname." [Schizophrenia Research, vol. 294, 2026, pages 73-75. SCHRES10980].
    Schizophr Res. 2026 May 5:S0920-9964(26)00142.
    >> Share

  141. EDWARDS CJ, Pillny M, Beck K, Cella M, et al
    A scoping review of targeted psychological interventions for negative symptoms in schizophrenia.
    Schizophr Res. 2026;294:140-146.
    >> Share

  142. SHEPHERD R, Stacey D, Janetzki J, Clark SR, et al
    Disentangling the relationship between psychiatric disorders, cardiometabolic abnormalities, and antipsychotics: A systematic review of genomic studies.
    Schizophr Res. 2026;291:119-134.
    >> Share

  143. YANG Q, Wu HQ, Zhu ZH, Yin XY, et al
    Association of plasma DISC1 levels with expression of negative symptoms of first-episode schizophrenia.
    Schizophr Res. 2026;294:133-139.
    >> Share

    April 2026
  144. VAN DER WALT K, Campbell M, Susser E, Jonker D, et al
    Distinct attentional deficits after catatonia in schizophrenia.
    Schizophr Res. 2026;294:116-123.
    >> Share

  145. KU BS, Arrant EJ, Walker EF
    Neighborhood Characteristics and Psychosis Risk Across Development.
    Schizophr Res. 2026;294:96-98.
    >> Share

  146. HAZELTON K, Stein A, Gallardo M, Fernandes D, et al
    Trajectories of crystallized cognition over 28 years: Testing the neurodegenerative hypothesis of schizophrenia.
    Schizophr Res. 2026;294:110-115.
    >> Share

  147. DE OLIVEIRA CA, Soares MVR, de Pinho CSN, Pinto JP, et al
    A high-resolution plasma proteomic framework for stratifying treatment resistance and ultra-resistance in schizophrenia.
    Schizophr Res. 2026;294:86-95.
    >> Share

  148. ANTENS MHH, Kamperman AM, van Aken BC, Castelein S, et al
    Intellectual functioning and personal recovery in individuals with schizophrenia spectrum disorder.
    Schizophr Res. 2026;294:76-85.
    >> Share

  149. CHENG L, Xu X, Yang H, Du J, et al
    A multimodal fNIRS-based machine learning model for symptom assessment and treatment response prediction in schizophrenia.
    Schizophr Res. 2026;294:63-72.
    >> Share

  150. WEI Y, Huang Y, Cui H, Xu L, et al
    Cross-disorder brain morphological similarity in schizophrenia: Associations with symptom severity and treatment outcome.
    Schizophr Res. 2026;294:52-62.
    >> Share

  151. HARVEY PD, Kaul I, Chataverdi S, Patel T, et al
    Effects of Xanomeline and Trospium Chloride for Negative Symptoms Associated With Physical Activity in Younger and Older Adults with Schizophrenia: Results From a 52-Week, Open-label Clinical Trial.
    Schizophr Res. 2026;294:44-51.
    >> Share

  152. LIN CE, Chen LF, Sack AT, Chang HA, et al
    Task-based fNIRS biomarkers of HD-tDCS treatment for negative symptoms in schizophrenia.
    Schizophr Res. 2026;294:35-43.
    >> Share

  153. JANSSEN H, van den Berg KC, Keijsers GPJ, Marcelis MC, et al
    Associations between characteristics of emotional mental imagery and auditory verbal hallucinations in individuals with psychosis spectrum disorders.
    Schizophr Res. 2026;294:27-34.
    >> Share

  154. PRETTYMAN GE, Kales E, Didier P, Savage C, et al
    Impaired intrinsic motivation in psychosis risk relates to ventral striatum activation to self-generated reinforcement signals.
    Schizophr Res. 2026;294:7-16.
    >> Share

  155. PILLNY M, Edwards CJ, Riehle M
    Beyond the emotion paradox: Avenues to understanding anhedonia in schizophrenia.
    Schizophr Res. 2026;294:17-26.
    >> Share

  156. MILLER CR, Taylor SF, Breier A, Vohs JL, et al
    Factor analysis of two COMPASS psychopathology symptom scales for first-episode psychosis.
    Schizophr Res. 2026;294:1-6.
    >> Share

  157. GAGO E, Montalvo I, Cabezas A, Ortega L, et al
    Perinatal stress as a moderator of the effects of hormonal dysregulation on cognition and symptoms in early psychosis.
    Schizophr Res. 2026;293:147-155.
    >> Share

  158. NAGENDRA A, Mesholam-Gately RI, Shafrin J, Keshavan MS, et al
    Corrigendum to "Reframing schizophrenia as a neurodevelopmental syndrome: The scientific and social imperative" [Schizophr. Res. Volume 292, June 2026, pages 96-102].
    Schizophr Res. 2026 Apr 15:S0920-9964(26)00117.
    >> Share

  159. COHEN I, Bukowski E
    Predictors of antidepressant prescribing in schizophrenia: A retrospective analysis.
    Schizophr Res. 2026;293:144-146.
    >> Share

  160. GARCIA-SAN NICOLAS C, Diaz-Pons A, Paras C, Ortiz-Garcia de la Foz V, et al
    Exposome and cognition in psychosis: an exploratory study in sex-specific patterns in patients and their unaffected siblings.
    Schizophr Res. 2026;293:134-143.
    >> Share

  161. PASCOE B, Cocks K, Clarke N, Langevin N, et al
    Structural and construct validity assessment of the schizophrenia cognition rating scale (SCoRS) using data from three international phase 3 randomized controlled trials (CONNEX programme).
    Schizophr Res. 2026;293:124-133.
    >> Share

  162. WU CJ, Lin JJ, Huang CC, Tseng HH, et al
    Development and evaluation of a predictive biomarker model based on the niacin flush pathway for differentiating schizophrenia and bipolar disorder.
    Schizophr Res. 2026;293:113-123.
    >> Share

  163. WERST MJA, Tiraboschi GA, Paquin V
    Digital cultures and the exposome of psychosis.
    Schizophr Res. 2026;293:109-112.
    >> Share

  164. KAMP D, Riesbeck M, Lowe A, Weide K, et al
    Predictors of gains in social functioning after cognitive remediation in schizophrenia: Results from the multicenter ISST (Integrated Social Cognition and Social Skills Therapy) trial.
    Schizophr Res. 2026;293:99-108.
    >> Share

  165. HAMZAI HV, D'Arcey J, Jagtap S, Leibovitz T, et al
    The role of cognitive schemas in personal recovery, symptom severity, and functioning in schizophrenia-spectrum disorders.
    Schizophr Res. 2026;293:91-98.
    >> Share

  166. KU BS, Arrant EJ, Yuan QE, Aberizk KM, et al
    Social withdrawal and hippocampal volume among adolescents at clinical high risk for psychosis and healthy comparisons: The moderating role of neighborhood residential stability.
    Schizophr Res. 2026;293:81-90.
    >> Share

  167. GAO Y, Yan H, Hu R, Liu S, et al
    Effect of transcranial alternating current stimulation on auditory verbal hallucinations in patients with treatment-resistant schizophrenia.
    Schizophr Res. 2026;293:72-80.
    >> Share

  168. OH H, Goncalves CC, Arend JL, Blosnich JR, et al
    Sexual and gender minorities and psychosis research.
    Schizophr Res. 2026;293:67-68.
    >> Share

  169. DAZZAN P, Shivakumar G, Szymaniak K, Bell E, et al
    Restoring scientific resilience through European collaboration.
    Schizophr Res. 2026;290:30-33.
    >> Share

    March 2026
  170. FRENCH C, Sawyer C, Fabian H, Hassan L, et al
    The Remote Exercise And Lifestyle (REAL) intervention for first-episode psychosis: feasibility and preliminary effects of online group fitness training.
    Schizophr Res. 2026;293:58-66.
    >> Share

  171. SAARIKIVI J, Hjellvik V, Tiihonen J, Lahteenvuo M, et al
    Predicting future mortality risk in first-episode psychosis: External validation of the MIRACLE-FEP machine learning model.
    Schizophr Res. 2026;292:116-123.
    >> Share

  172. ANDERSEN NK, Fagerlund B, Jepsen JRM, Hjorthoj C, et al
    Factors associated with employment and hospitalizations in early-onset psychosis: a clinical study with register-based follow-up.
    Schizophr Res. 2026;293:48-57.
    >> Share

  173. PAN A, Yuan K, Xiu M, Guan X, et al
    Sleep-architecture signatures for differential diagnosis of schizophrenia, bipolar, and major depressive disorders: A polysomnography-based multinomial modeling study.
    Schizophr Res. 2026;293:39-47.
    >> Share

  174. BAGALI K, Uppinkudru C, Pathak H, Parlikar R, et al
    Corrigendum to "Aberrant motor cortical plasticity in antipsychotic-resistant schizophrenia: A cross-sectional study using transcranial direct current and magnetic stimulation" [Schizophr. Res., volume 290 (2026), pages 48-56].
    Schizophr Res. 2026 Mar 25:S0920-9964(26)00097.
    >> Share

  175. KONSTAS K, Gupta T
    Blunted affect in schizophrenia.
    Schizophr Res. 2026;293:32-38.
    >> Share

  176. BLACKMAN G, Bell V
    Secondary psychosis revisited: Advancing detection, assessment and treatment.
    Schizophr Res. 2026;293:30-31.
    >> Share

  177. POLETTI M, Preti A, Raballo A
    Duration of Active Attenuated Psychosis (DAAP): Extending time-based illness modelling to the clinical high-risk state.
    Schizophr Res. 2026;293:27-29.
    >> Share

  178. CROWLEY P, Boland F, Thompson A, McGorry P, et al
    The duration of active psychosis and relationship with early psychosis outcomes.
    Schizophr Res. 2026;293:17-26.
    >> Share

  179. DAZZAN P, Torous J
    Introducing the new "Innovation and Technology Section" in Schizophrenia Research.
    Schizophr Res. 2026 Mar 25:S0920-9964(26)00098.
    >> Share

  180. RICCI V, Chiappini S, Martinotti G, Maina G, et al
    From substance-induced psychosis to schizophrenia: Predictors of treatment response and transition to chronic psychotic illness-A systematic review.
    Schizophr Res. 2026 Mar 24:S0920-9964(26)00062.
    >> Share

  181. LYNCH ST, Renard KB, Chaia AI, Cohen LJ, et al
    Aripiprazole two-month long-acting injectable may increase time to readmission compared to aripiprazole one-month in patients with schizophrenia and schizoaffective disorder.
    Schizophr Res. 2026;293:1-7.
    >> Share

  182. ZHAO C, Lin B, Naderi E, Moazzen S, et al
    Genetic susceptibility of cardiometabolic outcomes in schizophrenia spectrum disorders.
    Schizophr Res. 2026;292:103-115.
    >> Share

  183. NAGENDRA A, Mesholam-Gately R, Shafrin J, Keshavan MS, et al
    Reframing schizophrenia as a neurodevelopmental syndrome: The scientific and social imperative.
    Schizophr Res. 2026;292:96-102.
    >> Share

  184. TANG JY, Wong GH, Zhou H, Zhou J, et al
    Ten-year risk prediction models for atherosclerotic cardiovascular disease in Chinese patients with schizophrenia-spectrum disorders: A population-based cohort study.
    Schizophr Res. 2026;292:88-95.
    >> Share

  185. CANO JF, Galindo-Pita S, Mendez D, Vallejo-Silva A, et al
    Association between Toxoplasma gondii IgG seropositivity and schizophrenia: A case-control study in Colombia.
    Schizophr Res. 2026;292:79-87.
    >> Share

  186. SABE M, Grof P, Sackett NB, Tai S, et al
    Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review.
    Schizophr Res. 2026;292:69-78.
    >> Share

  187. TARGUM SD, Watson C, Claxton A, Nicolas P, et al
    Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia.
    Schizophr Res. 2026;292:53-59.
    >> Share

  188. PALANIYAPPAN L, Sreeraj VS, Venkatasubramanian G, Voppel A, et al
    Why is it hard to assess thought disorder? Clarifying the third domain of psychosis.
    Schizophr Res. 2026;292:41-52.
    >> Share

  189. FREEMAN D, Rosebrock L, Waite F
    Patient expectations for outcome with psychological intervention for psychosis.
    Schizophr Res. 2026;292:21-27.
    >> Share

  190. DENG W, Servaas MN, Kos C, Marsman JC, et al
    Motor activity-based prediction of the presence of apathy in schizophrenia.
    Schizophr Res. 2026;292:1-11.
    >> Share

  191. SONDERGAARD A, Hemager N, Wilms M, Rohd SB, et al
    Associations between Sleep Problems, Psychotic Experiences and Mental Disorders in Children at Familial High Risk of Schizophrenia or Bipolar Disorder and Population-based controls - The Danish High Risk and Resilience Study.
    Schizophr Res. 2026;291:99-106.
    >> Share

  192. SHI S, Wang J, Li H, Qiu J, et al
    Prevalence of covert cerebrovascular changes in schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2026;291:107-118.
    >> Share

    February 2026
  193. ZENG V, Hoang D, Song SH, Trotti R, et al
    Mediodorsal and pulvinar thalamus reductions across the psychosis spectrum.
    Schizophr Res. 2026;291:88-98.
    >> Share

  194. POKORNY VJ, Kaka T, Vargas T, Pinkham AE, et al
    Phantom vibrations: An understudied marker of clinical risk for psychosis.
    Schizophr Res. 2026;291:81-87.
    >> Share

  195. KESHAVAN M, Good M
    Response to Gama-Marques et al. commentary: Re-rethinking psychosis.
    Schizophr Res. 2026;291:80.
    >> Share

  196. AHLE G, Henriksen MG, Molstrom IM, Rasmussen AR, et al
    Predictors of violence against others in non-affective psychosis: A systematic review and meta-analysis.
    Schizophr Res. 2026;291:68-79.
    >> Share

  197. LOUREIRO CM, Fachim HA, Bissoli GC, Corsi-Zuelli F, et al
    MC4R methylation and antipsychotic-related metabolic changes in early psychosis: findings from two prospective cohorts.
    Schizophr Res. 2026;291:57-67.
    >> Share

  198. MULLER MK, de Almeida ER, van der Tuin S, Balafas SE, et al
    The association between daily reports of psychotic experiences and life worthiness in early risk stages for psychosis and across gender.
    Schizophr Res. 2026;291:37-56.
    >> Share

  199. ULIANA DL, Popa MO, Paradowski M, Elvers KT, et al
    Novel positive allosteric modulators of alpha 5 subunit-containing GABA(A) receptors (alpha5-GABA(A)Rs) reverse the hyperdopaminergic state in a neurodevelopmental model of schizophrenia.
    Schizophr Res. 2026;291:27-36.
    >> Share

  200. UHRENHOLT N, Ganeshalingam A, Arnfred S, Gaede P, et al
    Improved quality of life with semaglutide in schizophrenia: Secondary analyses from a randomized controlled trial.
    Schizophr Res. 2026;291:20-26.
    >> Share

  201. MUNTANE G, Valle A, Ramon-Canellas P, Martorell L, et al
    The impact of CNV burden on age at onset of schizophrenia.
    Schizophr Res. 2026;291:12-19.
    >> Share

  202. JIN M, Li H, Yan L, Wang H, et al
    Radiomics-based prediction of early antipsychotic treatment response for first-episode schizophrenia.
    Schizophr Res. 2026;291:1-11.
    >> Share

  203. AU-YEUNG C, Christophe NK, Lavigne KM, Raucher-Chene D, et al
    Chicken or the egg: The relationship between cognitive deficits and negative symptoms in first episode psychosis.
    Schizophr Res. 2026;290:125-133.
    >> Share

  204. TODA-THORNE K, Luther L
    Asociality in schizophrenia: A review of historical foundations, measures, mechanisms, and treatments.
    Schizophr Res. 2026;290:114-124.
    >> Share

  205. GUEST RM, Addington J, Bearden CE, Cadenhead KS, et al
    Contributions of regional cortical thickness and surface area to cognitive functioning in psychosis-risk.
    Schizophr Res. 2026;290:98-105.
    >> Share

  206. FRITZE S, Altinok DCA, Volkmer S, Brandt GA, et al
    Hippocampus in the symptom architecture of schizophrenia spectrum disorders: A network analysis approach.
    Schizophr Res. 2026;290:88-97.
    >> Share

  207. PURUSHOTHAMAN D, Tayfur SN, Song Z, Li F, et al
    Changes in cannabis use following legalization: Effects in first-episode psychosis.
    Schizophr Res. 2026;290:86-87.
    >> Share

  208. DO LAN P, Isvoranu AM, Kleim B, Heekeren K, et al
    Resilience factors and their role in clinical high-risk for psychosis.
    Schizophr Res. 2026;290:106-113.
    >> Share

  209. GAMA-MARQUES J, Schumacher MM, Finsterer J
    Re-rethinking psychosis: Time to retire "functional", "explanatory" and "primary".
    Schizophr Res. 2026;290:84-85.
    >> Share

  210. HUI CLM, Chang WC, Chan EWT, Suen YN, et al
    The effects of extended early intervention services on clinical and functional outcomes in first-episode psychosis.
    Schizophr Res. 2026;290:73-83.
    >> Share

  211. ASCHENBRENNER EJ, Voluse AC
    Predicting the prognosis of primary and substance-associated psychoses using urine drug screens: A 5-year retrospective longitudinal study using medical records.
    Schizophr Res. 2026;290:57-64.
    >> Share

  212. BAGALI K, Uppinkudru C, Pathak H, Parlikar R, et al
    Aberrant motor cortical plasticity in antipsychotic-resistant schizophrenia: A cross-sectional study using transcranial direct current and magnetic stimulation.
    Schizophr Res. 2026;290:48-56.
    >> Share

  213. KRAKOWSKI M, Czobor P
    Disentangling violence in schizophrenia: Interactions between symptom trajectories, conduct disorder, and pharmacotherapy.
    Schizophr Res. 2026;290:42-47.
    >> Share

  214. VARDEN GJERDE K, Bartz-Johannessen C, Loberg EM, Steen VM, et al
    Neural and vascular cellular adhesion molecules are associated with cognitive function in patients with schizophrenia-spectrum disorders: A longitudinal study.
    Schizophr Res. 2026;290:34-41.
    >> Share

  215. BLACKMAN G, Morrin H, Carstairs C, Fanshawe JB, et al
    Psychopathology distinguishing secondary ("organic") psychoses: A systematic review and meta-analysis.
    Schizophr Res. 2026;289:106-111.
    >> Share

  216. KUZO N, Gaspari D, Carpi F, Hiemke C, et al
    Pharmacokinetic correlates of clinical response in a retrospective naturalistic cohort of patients treated with long-acting injectable antipsychotics.
    Schizophr Res. 2026;288:38-46.
    >> Share

    January 2026
  217. SISMAN O, Onen S
    Corrigendum to "prevalence and multidimensional impact of sarcopenia in schizophrenia: Associations with oxidative stress, functioning, and symptom severity" [Schizophr. Res. volume 289, March 2026, pages-61-70].
    Schizophr Res. 2026 Jan 28:S0920-9964(26)00024.
    >> Share

  218. CHEN BY, Lin JJ, Tseng HH, Huang CC, et al
    Small EVs miRNA profiles and their expressions in EVs-depleted plasma as an optimal combination panel for treatment-resistant schizophrenia.
    Schizophr Res. 2026;290:17-29.
    >> Share

  219. FONSECA L, Ito LT, Ziebold C, Rohde LA, et al
    Executive function mediates the effects of genetic liability to schizophrenia on behavior and functioning in a community sample of children and adolescents.
    Schizophr Res. 2026;290:9-16.
    >> Share

  220. MITTAL VA, Chang WC, Walker EF
    Negative symptoms across developmental stages in psychosis spectrum.
    Schizophr Res. 2026;289:100-105.
    >> Share

  221. WANG LC, Lu AK, Zhu ZH, Hou WL, et al
    Association between reduced plasma dopamine beta-hydroxylase levels and immediate memory impairment in first-episode drug-naive schizophrenia.
    Schizophr Res. 2026;289:94-99.
    >> Share

  222. MASHAL MA, Chen CS, Ramsay IS, Vinogradov S, et al
    Letter to the editor: Enhancing cognitive control in schizophrenia with transcranial direct current stimulation and targeted cognitive training.
    Schizophr Res. 2026;289:89-93.
    >> Share

  223. CHEN H, Xiang H, Zhang M, Wen Y, et al
    Antipsychotic-disease duration interaction on glymphatic function in first-episode schizophrenia: Evidence from DTI-ALPS.
    Schizophr Res. 2026;289:79-88.
    >> Share

  224. SISMAN O, Onen S
    Prevalence and multidimensional impact of sarcopenia in schizophrenia: Associations with oxidative stress, functioning, and symptom severity.
    Schizophr Res. 2026;289:61-70.
    >> Share

  225. CESSA R, Ghiani A, Cenk E, Bertamini M, et al
    Perceptual organization and its visual subcomponents in schizophrenia and schizotypy: A systematic review.
    Schizophr Res. 2026;289:46-60.
    >> Share

  226. KELLY DL, Lee CM, Vyas G, Buchanan RW, et al
    Randomized double-blind inpatient study of a gluten-free diet for negative symptoms in people with schizophrenia.
    Schizophr Res. 2026;289:33-45.
    >> Share

  227. CAO P, Han Y, Zou L, Gao S, et al
    A multimodal fusion analysis of structural and functional abnormalities in acute onset treatment-resistant schizophrenia.
    Schizophr Res. 2026;289:25-32.
    >> Share

  228. SUGISAKI T, Sugawara N, Shinozaki M, Yokoyama N, et al
    Frailty and fall risk in schizophrenia: Which components drive the risk of falls?
    Schizophr Res. 2026;289:18-24.
    >> Share

  229. HONG Y, Jiang J, Li J, Tang X, et al
    Magnetic seizure therapy preserves delayed memory and 40-Hz auditory steady-state responses compared with electroconvulsive therapy in schizophrenia.
    Schizophr Res. 2026;289:10-17.
    >> Share

  230. JEYAPALAN J, Taipale H, Tanskanen A, Tiihonen J, et al
    Antipsychotic use and associating factors among persons with substance-induced psychosis and first-episode psychotic disorder- A nationwide register-linkage study.
    Schizophr Res. 2026;289:1-9.
    >> Share

  231. CHAN A, Lu A, Menon T, Wong S, et al
    Association between negative symptoms and health-related quality of life and functional outcomes in persons with schizophrenia: A systematic review.
    Schizophr Res. 2026;288:95-103.
    >> Share

  232. KAUL I, Claxton A, Chaturvedi S, Patel T, et al
    Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5).
    Schizophr Res. 2026;288:86-94.
    >> Share

  233. NEFF MA, Raffensperger KV, Moore RC, Depp CA, et al
    Predictions of different elements of everyday functional outcomes in bipolar disorder and schizophrenia: Cognition, social cognition, clinical symptoms, and mood states as predictors.
    Schizophr Res. 2026;288:77-85.
    >> Share

  234. TORRENS WA, Pablo JN, Berryhill ME, Haigh SM, et al
    Perturbed sensory memory associated with schizotypy symptom load.
    Schizophr Res. 2026;287:129-137.
    >> Share

  235. RODRIGUEZ-CABO B, Catalan A, Aymerich C, Salazar de Pablo G, et al
    Unveiling the prognosis of adult Catatonia: A systematic review.
    Schizophr Res. 2026;287:21-36.
    >> Share

    December 2025
  236. IMAM I, Johnson KA, Saluja A, Mesholam-Gately RI, et al
    Improving systems & communities of psychosis care: Proceedings from the 2024 Mass-STEP Conference.
    Schizophr Res. 2025;288:66-68.
    >> Share

  237. TENGFEI C, Shiyu W, Longyu S, Lei C, et al
    S100A8 dysregulation as a neuroimmune nexus: Bridging childhood inflammatory infections to adult schizophrenia-like behaviors via the ELNI model.
    Schizophr Res. 2025;288:47-56.
    >> Share

  238. PENG S, Geng X, Huen WWK, Fang CZ, et al
    Dual glymphatic roles in first-episode schizophrenia and clinical high-risk for psychosis: Evidence from diffusion tensor image analysis along the perivascular space index.
    Schizophr Res. 2025;288:26-34.
    >> Share

  239. ZHANG L, Zhang Z, Strauss GP
    Neighborhood environmental deprivation predicts the generalized neurocognitive deficit in schizophrenia.
    Schizophr Res. 2025;288:18-25.
    >> Share

  240. SCHUCH JM, Pratt DN, Haase CM, Qu Y, et al
    Reevaluating the assessment of nonverbal behavior in psychosis symptomatology: A call for cultural sensitivity.
    Schizophr Res. 2025;288:1-2.
    >> Share

  241. SENKO D, Zavolskova M, Efimova O, Morozova A, et al
    Comparative lipidomic alterations in the anterior cingulate cortex in schizophrenia and major depression.
    Schizophr Res. 2025;287:147-155.
    >> Share

  242. MUSKET CW, Rupert PE, Kuo SS, Roalf DR, et al
    Shared genetic effects among schizophrenia, substance use disorder, and hippocampal volume in a multiplex extended pedigree sample.
    Schizophr Res. 2025;287:138-146.
    >> Share

  243. DESTE G, Barlati S, Nibbio G, Boggian I, et al
    Effectiveness of Integrated Neurocognitive Therapy compared to Physical Exercise and Treatment As Usual in schizophrenia: Results from a multi-center randomized controlled study.
    Schizophr Res. 2025;287:122-128.
    >> Share

  244. ODKHUU S, Kim WS, Li L, Setiani A, et al
    Distinct neuroimaging signatures of OSSO compared to schizophrenia and healthy controls using graph theoretical analysis.
    Schizophr Res. 2025;287:113-121.
    >> Share

  245. WANG SC, Hsu JW, Tsai SJ, Bai YM, et al
    Fracture risk in the offspring of individuals with schizophrenia: A cohort study of 71,698 children.
    Schizophr Res. 2025;287:107-112.
    >> Share

  246. GONZALES L, Saperstein A, Erlich M, Medalia A, et al
    Stigma as related to cognition in psychotic disorders: A scoping review of the literature.
    Schizophr Res. 2025;286:16-25.
    >> Share

    November 2025
  247. DETORE NR, Johnson K, Eberlin ES, Imam I, et al
    Fidelity to the first episode psychosis coordinated specialty care model in Massachusetts: Comparison to clinical outcomes and national programs.
    Schizophr Res. 2025;287:99-106.
    >> Share

  248. ZHANG K, Xia X, Dai J, Deng Z, et al
    Association between decreased peripheral serum complement C3 levels and aberrant brain topology of morphological similarity networks in first-episode, drug-naive schizophrenia.
    Schizophr Res. 2025;287:91-98.
    >> Share

  249. ROIG-HERRERO A, San-Jose-Revuelta LM, Navarro-Gonzalez R, de Luis-Garcia R, et al
    Effects of disease duration and antipsychotics on brain age in schizophrenia.
    Schizophr Res. 2025;287:82-90.
    >> Share

  250. DAS N, Dhamija R, Mistak D, Diaz LD, et al
    Epidemiological analysis of schizophrenia and incarceration: A multi-center exploration of the criminalization of mental illness in the United States.
    Schizophr Res. 2025;287:73-81.
    >> Share

  251. SEIF P, Del Re EC, Tamminga CA, Pearlson GD, et al
    Does insight improve during the course of psychosis?
    Schizophr Res. 2025;287:63-70.
    >> Share

  252. PARIS J, Laurendi O, Arnet V, Galletly C, et al
    Cannabis use and cardiometabolic risk in schizophrenia.
    Schizophr Res. 2025;287:54-62.
    >> Share

  253. SERAFIM PHM, Gadelha A, Massuda R, Louza M, et al
    The challenges in measuring symptoms of schizophrenia: An exploratory graph analysis of the Positive and Negative Syndrome Scale (PANSS).
    Schizophr Res. 2025;287:46-53.
    >> Share

  254. FAN YS, Ye M, Xu Y, Xu Y, et al
    Spatio-temporal information transition abnormalities across brain functional networks in early-onset schizophrenia.
    Schizophr Res. 2025;287:37-45.
    >> Share

  255. CIAROLLA A, Bobilev AM, Dybowski F, Fang Y, et al
    The hippocampal-cortical system cerebral blood flow in schizophrenia: Primary disease versus antipsychotic medication effects.
    Schizophr Res. 2025;287:3-15.
    >> Share

  256. ABDULLAH M, Lin SH, Huang LC, Yang YK, et al
    Assessing plasma and brain glutamate in treatment resistant and non-resistant schizophrenia: a peripheral-central disconnect.
    Schizophr Res. 2025;287:16-20.
    >> Share

  257. SRIHARI VH, Keshavan MS
    Learning health systems for first-episode psychosis: Insights from North America.
    Schizophr Res. 2025 Nov 11:S0920-9964(25)00376.
    >> Share

  258. BUCK B, Whiting E, Hallgren K, Monroe-DeVita M, et al
    Pilot randomized controlled trial of Bolster, an mHealth intervention for caregivers to young people with early psychosis.
    Schizophr Res. 2025;286:132-141.
    >> Share

  259. WANG YC, Fan HY, Huang QH, Liu XC, et al
    Quality of life in patients with schizophrenia: A systematic review and meta-analysis of case-control studies.
    Schizophr Res. 2025;286:112-124.
    >> Share

  260. JESTE DV, Green MF
    Guest editorial: Social determinants of health in the psychosis spectrum.
    Schizophr Res. 2025;286:110-111.
    >> Share

  261. KAJI D
    Exploring hippocampal dysfunction in schizophrenia with pluripotent stem cell models.
    Schizophr Res. 2025;286:100-109.
    >> Share

  262. DAZZAN P, Palaniyappan L
    TEMPORARY REMOVAL: Experiential Science in Schizophrenia Research: our new dedicated section.
    Schizophr Res. 2025 Nov 3:S0920-9964(25)00375.
    >> Share

  263. YE A, Zhang D, Liu X, Xu L, et al
    Two-month antipsychotic exposure induces domain-specific eye movement alterations in clinical high-risk individuals.
    Schizophr Res. 2025;285:196-203.
    >> Share

    October 2025
  264. IMAMOGLU A, Penn DL, Harvey PD, Pinkham AE, et al
    Impaired recognition of neutral faces in schizophrenia is linked to hostile attribution bias and paranoia.
    Schizophr Res. 2025;286:97-99.
    >> Share

  265. WANG K, Sun Y, Xia C, Yang X, et al
    Subfield-specific hippocampal microstructural alterations in schizophrenia: A high-resolution DTI study.
    Schizophr Res. 2025;286:89-96.
    >> Share

  266. MYERS EJ, Lysaker PH, Rand KL, Salyers MP, et al
    Disorganization and disintegration in schizophrenia: Metacognitive capacity across levels of conceptual disorganization.
    Schizophr Res. 2025;286:82-88.
    >> Share

  267. XAVIER G, Ota V, Kajitani GS, Mauer JH, et al
    Dysregulation of miR-335-5p, miR-30d-5p, and miR-744-5p in extracellular vesicles from first-episode psychosis patients: Implications for biomarker discovery.
    Schizophr Res. 2025;286:74-81.
    >> Share

  268. FABRIS D, Andrade LM, Freitas IS, Gomes FV, et al
    Cannabidiol attenuates behavioral and electrophysiological changes in the MAM model of schizophrenia in male and female rats.
    Schizophr Res. 2025;286:63-73.
    >> Share

  269. CAMON E, Masier S, Mota NB, D'Agostino A, et al
    Machine learning and graph-based connectivity metrics identify language disruption in psychosis: Novel insights from dream reports in an Italian cohort.
    Schizophr Res. 2025;286:55-62.
    >> Share

  270. JI T, Yu B, Ma R
    Cerebellar-cortical dysfunction and schizophrenia: Advances in neurocognition and therapeutic strategies.
    Schizophr Res. 2025;286:37-46.
    >> Share

  271. KWOK SYCL, Li Y, Chu MH, Singh H, et al
    The effectiveness of enhanced WELLFOCUS positive psychotherapy for people with schizophrenia: A randomised controlled trial in halfway houses in Hong Kong.
    Schizophr Res. 2025;286:26-36.
    >> Share

  272. TABATA K, Toriumi K, Suzuki K, Takagi H, et al
    Schizophrenia with hypozincemia: Clinical features and symptom severity.
    Schizophr Res. 2025;286:9-15.
    >> Share

  273. LUTHER L, Mathis RF, Keller WR, Buchanan RW, et al
    Aberrant visual attention is associated with social judgements of attractiveness and negative symptoms in schizophrenia.
    Schizophr Res. 2025;286:1-8.
    >> Share

  274. DENAROSO GE, Liu J, Ered A, Woodward ND, et al
    Nonlinear associations between reported childhood trauma and cognitive impairment in schizophrenia spectrum disorders.
    Schizophr Res. 2025;285:360-368.
    >> Share

  275. SPANEVELLO C, Alameda L, Solida A, Empson LA, et al
    Correlates and trajectories of alcohol and cannabis misuse in the early phase of psychosis: Do we need substance specific interventions?
    Schizophr Res. 2025;285:349-359.
    >> Share

  276. JEON P, Mackinley M, Dempster K, Ford S, et al
    Activity-dependent modulation of glutamate, glutamine and glutathione in first-episode schizophrenia: A 7T functional MRS study.
    Schizophr Res. 2025;285:339-348.
    >> Share

  277. RANKKA U, Lokki ML, Vahermaa V, Laurikainen H, et al
    Complement C4 gene copy numbers modulate serum immune protein profiles in patients with first-episode psychosis and healthy controls in a sex-specific manner.
    Schizophr Res. 2025;285:330-338.
    >> Share

  278. ZHOU Z, Han Y, Xiao S, Li X, et al
    Deciphering the neural signatures of auditory hallucinations in early-onset schizophrenia: A topological brain network analysis.
    Schizophr Res. 2025;285:323-329.
    >> Share

  279. DI GIORGIO A, Massaro A, Bergamelli E, Libri C, et al
    Attitudes of Italian psychiatrists towards the use of Long-Acting Injectable antipsychotics in the management of schizophrenia relapse: insights from the ALIA study.
    Schizophr Res. 2025;285:313-322.
    >> Share

  280. FATTAL J, Nadig A, Ristanovic I, Osborne KJ, et al
    Altered top-down modulation of electrodermal responses to sudden auditory stimuli in individuals at clinical high risk for psychosis.
    Schizophr Res. 2025;285:304-312.
    >> Share

  281. DIMITRIADES ME, Schumacher E, Arudchelvam J, Fattinger S, et al
    The infraslow fluctuation of sigma power during sleep in young individuals with schizophrenia.
    Schizophr Res. 2025;285:295-303.
    >> Share

  282. MOLLON J, Lanzagorta N, Mathias SR, Rodrigue A, et al
    Corrigendum to "The burden of early onset psychosis: Diagnostic complexity, high comorbidity, and poor functioning in patients and their relatives" [Schizophr. Res. Volume 285, November 2025, Pages 165-174].
    Schizophr Res. 2025 Oct 13:S0920-9964(25)00357.
    >> Share

  283. MOE AM, Cai X, Li C, Wastler HM, et al
    Perceived burdensomeness and thwarted belongingness prospectively influence real-world social support-seeking behavior among emerging adults with first-episode psychosis.
    Schizophr Res. 2025;285:288-294.
    >> Share

  284. ADEWUYA AO, Oladipo OE, Emsley R, Asmal L, et al
    Pathways linking adverse childhood experiences to psychosis risk in Lagos, Nigeria: A structural equation modeling approach.
    Schizophr Res. 2025;285:276-285.
    >> Share

  285. SEGURA AG, Verdolini N, Valli I, Garcia-Rizo C, et al
    Polygenic risk score of glycemic homeostasis, Type 2 Diabetes Mellitus and glycemic components in first episode psychosis.
    Schizophr Res. 2025;285:265-275.
    >> Share

  286. STANICA AM, Remiszewski N, Shen C, Sponheim SR, et al
    Subcortical brain abnormalities and cognitive function in individuals with psychosis and their unaffected relatives: A normative modeling approach.
    Schizophr Res. 2025;285:255-264.
    >> Share

  287. ALTINOK DCA, Fritze S, Volkmer S, Brandt GA, et al
    Emotional maltreatment shapes the relationship between psychosocial functioning and hippocampal structure in schizophrenia spectrum disorders.
    Schizophr Res. 2025;285:242-254.
    >> Share

  288. CROWLEY P, Healy J, McNamara N, Twomey R, et al
    Duration of active psychosis: A scoping review of definition, measurement, and relationship with outcomes.
    Schizophr Res. 2025;285:232-241.
    >> Share

  289. KAMPHUIS S, Arias-Magnasco A, Gangadin S, Begemann M, et al
    Association between the exposome score for schizophrenia and functioning in remitted first-episode psychosis: results from the HAMLETT study.
    Schizophr Res. 2025;285:223-231.
    >> Share

  290. NOVACEK DM, Subotnik KL, Ventura J, Casaus LR, et al
    Corrigendum to "Positive symptoms and medication adherence in response to oral versus long-acting injectable risperidone in black, latino, and white first-episode psychosis patients" [Schizophr Res. (2025) 160-166].
    Schizophr Res. 2025 Oct 3:S0920-9964(25)00336.
    >> Share

  291. XIA W, Hau C, Burns J, Ryan S, et al
    Smartphone intervention apps for schizophrenia: A review of the academic literature and app stores.
    Schizophr Res. 2025;285:204-214.
    >> Share

    September 2025
  292. HIRJAK D, Volkmer S, Pokorny V, Mittal VA, et al
    Advancing the sensori-/psychomotor domain in schizophrenia spectrum disorders: From clinical observation to translational innovation.
    Schizophr Res. 2025;285:185-195.
    >> Share

  293. MOLLON J, Lanzagorta N, Mathias SR, Rodrigue A, et al
    The burden of early onset psychosis: Diagnostic complexity, high comorbidity, and poor functioning in patients and their relatives.
    Schizophr Res. 2025;285:165-174.
    >> Share

  294. CAROL EE, Rodriguez J, Guvenek-Cokol PE, Kim HJ, et al
    Learning health systems in early interventions for psychosis: Establishing consumer voices in clinical high-risk for psychosis care.
    Schizophr Res. 2025;285:149-154.
    >> Share

  295. DAMME KSF
    The hippocampus: At the nexus of risk and resilience for schizophrenia.
    Schizophr Res. 2025;285:141-148.
    >> Share

  296. KESHAVAN MS, Good M
    Rethinking psychosis: Time to retire "organic", "idiopathic" and "secondary"?
    Schizophr Res. 2025;285:132-133.
    >> Share

  297. XIE S, Glassman M, Vyas G, Nwulia E, et al
    Longitudinal analysis of absolute neutrophil count (ANC) variability and neutropenia incidence in African American schizophrenia patients by ACKR1 genotype.
    Schizophr Res. 2025;285:124-131.
    >> Share

  298. PANTOJI M, Balachander S, Prajapati P, Arumugham SS, et al
    Does adjunctive electro-convulsive therapy improve the speed of treatment response in schizophrenia? A systematic review and week-by-week meta-analyses of controlled clinical trials.
    Schizophr Res. 2025;285:114-123.
    >> Share

  299. WEZENBERG BN, Koster M, van Wingen G, de Haan L, et al
    Association between sleep disturbances and gray matter volume in individuals at clinical high-risk for psychosis and healthy controls: A longitudinal MRI study (NAPLS-3).
    Schizophr Res. 2025;285:105-113.
    >> Share

  300. FLORES AT, Barrio C, Yu L, Harvey PD, et al
    Psychometric validation of social cognition measures in U.S. Hispanic individuals with schizophrenia.
    Schizophr Res. 2025;285:95-104.
    >> Share

  301. ORAKI KOHSHOUR M, Barth TK, Huber C, Klingl A, et al
    Comparing the proteome profiling of plasma-derived extracellular vesicles in individuals with schizophrenia and healthy controls: a pilot study.
    Schizophr Res. 2025;285:87-94.
    >> Share

  302. LIU W, Carnelley KB, Newman-Taylor K
    How does attachment affect help-seeking in people with paranoia and psychosis? The role of emotion regulation, self-stigma, and perceived support.
    Schizophr Res. 2025;285:75-86.
    >> Share

  303. ORLOVIC I, Markos IS, Blazekovic I, Peitl V, et al
    Thalamic hyperperfusion in early schizophrenia: Associations with cognitive deficits and negative symptoms.
    Schizophr Res. 2025;285:60-69.
    >> Share

  304. HORSDAL HT, Jensen AS, Antonsen S, Pedersen MG, et al
    Examining relationships between the Danish Composite Deprivation Index and risk of developing schizophrenia: A national multilevel analysis.
    Schizophr Res. 2025;285:52-59.
    >> Share

  305. IVLEVA EI, Palka JM, Bobilev AM, Fang Y, et al
    Hippocampal subfield activity in schizophrenia: Effects of the disease course.
    Schizophr Res. 2025;285:39-51.
    >> Share

  306. XU M, Gao D, Hu A, Qian H, et al
    Social isolation and its influencing factors among family caregivers of individuals with schizophrenia: A social-ecological systems theory perspective.
    Schizophr Res. 2025;285:30-38.
    >> Share

  307. HAMMER LA, Springfield CR, Russell MT, Twilbeck B, et al
    Minority stress and schizophrenia-like experiences in sexual and gender minority adults.
    Schizophr Res. 2025;285:27-29.
    >> Share

  308. BAREIS N, Wang Y, Olfson M, Gerhard T, et al
    Machine learning for novel phenotyping in schizophrenia.
    Schizophr Res. 2025;285:19-26.
    >> Share

  309. SU Q, Liu Y, Ji L, Sun X, et al
    The relationship between age of onset, peripheral plasma protein markers and social cognition in first-episode drug-naive schizophrenia.
    Schizophr Res. 2025;285:11-18.
    >> Share

  310. HSU JW, Chen LC, Lin WC, Bai YM, et al
    Reduced levels of vascular endothelial growth factor were associated with psychopathology in youth with first-episode schizophrenia.
    Schizophr Res. 2025;284:269-274.
    >> Share

  311. NKIRE N, Kingston T, Kinsella A, Russell V, et al
    Prediction of long-term outcome by duration of the psychosis prodrome: Mixed effects models reveal continuity across 7 years but variation across quartile splits.
    Schizophr Res. 2025;284:263-268.
    >> Share

  312. HOTER ISHAY G, Roe D
    Patterns of service utilization and its relation to outcome in a first-episode psychosis program.
    Schizophr Res. 2025;284:256-262.
    >> Share

  313. WATERS Z, Ohan JL, Perry Y, Baird S, et al
    Perceived stigma and self-stigma in young people at ultra-high risk for psychosis: Associations with identity-related, psychological and functional outcomes.
    Schizophr Res. 2025;284:248-255.
    >> Share

  314. INO H, Akabayashi A, Takimoto Y, Mori K, et al
    Effect of social resources on readmission prevention and the influence of informal coercion in acute schizophrenia: a retrospective quasi-experimental cohort study.
    Schizophr Res. 2025;285:1-10.
    >> Share

  315. SANJARI MOGHADDAM H, Aarabi MH, Kiani I, Cattarinussi G, et al
    Microstructural alterations of the corpus callosum in affective and non-affective early psychosis: A diffusion magnetic resonance imaging study.
    Schizophr Res. 2025;284:237-247.
    >> Share

  316. NASHASHIBI L, Harlev D, Grinapol S, Karny T, et al
    Ethnic bias in risk assessment of patients with early-onset first episode psychosis.
    Schizophr Res. 2025;284:231-236.
    >> Share

  317. LIU D, Choi KW, Lizano P, Yuan W, et al
    Construction of extra-large scale screening tools for risks of severe mental illnesses using real world healthcare data.
    Schizophr Res. 2025;283:59-66.
    >> Share

  318. FASSLER L, Moritz S, Schories F, Bajbouj M, et al
    Effects of an unguided self-help intervention for distressing auditory verbal hallucinations in a heterogenous sample of voice hearers: A randomized controlled trial and explorative cluster analysis.
    Schizophr Res. 2025;283:36-47.
    >> Share

    August 2025
  319. SALEM D, Clark SM, Roche DJO, Singh NJ, et al
    T cells are associated with negative symptoms in persons with anti-gliadin antibody positive schizophrenia and related disorders.
    Schizophr Res. 2025;284:222-230.
    >> Share

  320. NIU Z, Jia L, Tian L, Liu Y, et al
    Evaluating the abnormal neural variability in schizophrenia: A TMS-EEG study.
    Schizophr Res. 2025;284:214-221.
    >> Share

  321. KITTLESON AR, Woodward ND, McHugo M, Liu J, et al
    A two-year longitudinal investigation of insula subregional cortical thickness and surface area in early psychosis.
    Schizophr Res. 2025;284:204-213.
    >> Share

  322. HUMBLE MB, Mobarrez F, Eklund D, Bejerot S, et al
    Aquaporin-4 positive extracellular vesicles and cytokines in cerebrospinal fluid in schizophrenia and obsessive-compulsive disorder, and associations with peripheral cytokines.
    Schizophr Res. 2025;284:195-203.
    >> Share

  323. EMPSON LA, Golay P, Baumann PS, Favrod J, et al
    Refining targets for urban remediation in early psychosis.
    Schizophr Res. 2025;284:186-194.
    >> Share

  324. BADENOCH JB, Rickards H, McCutcheon RA, Nair A, et al
    Psychosis in Huntington's disease: a review and comparison with schizophrenia.
    Schizophr Res. 2025;284:175-185.
    >> Share

  325. NOVACEK DM, Subotnik KL, Ventura J, Casaus LR, et al
    Positive symptoms and medication adherence in response to oral versus long-acting injectable risperidone in black, latino, and white first-episode psychosis patients.
    Schizophr Res. 2025;284:160-166.
    >> Share

  326. BAGROWSKA P, Wannan C, Polari A, Yuen HP, et al
    Therapy process factors in early psychosis: The effect of working alliance on clinical symptoms and cognitive biases in Ultra High Risk young people.
    Schizophr Res. 2025;284:151-159.
    >> Share

  327. KARACAM DOGAN M, Fusar-Poli L, Arias-Magnasco A, Pries LK, et al
    Examining psychological protective mechanisms as moderators of the association between autistic traits and psychosis expression in a general population twin sample.
    Schizophr Res. 2025;284:133-140.
    >> Share

  328. SURAJ-PRAZMOWSKA J, Marczyk B, Smierciak N, Szwajca M, et al
    Young first-episode psychosis patients exhibit impaired microvascular function in the skin and low systemic nitric oxide availability, independent of classical cardiovascular risk factors.
    Schizophr Res. 2025;283:188-199.
    >> Share

  329. MEYER-KALOS PS, Neill M, Owens G, Russell M, et al
    NAV-FS: A first episode psychosis services fidelity scale adapted for the NAVIGATE model.
    Schizophr Res. 2025;284:125-132.
    >> Share

  330. TAYFUR SN, Hazan H, Li F, Song Z, et al
    The potential of AI for scale development: A self-report psychosis symptoms measure using ChatGPT.
    Schizophr Res. 2025;284:111-113.
    >> Share

  331. HUANG D, Xiang Z, Liu K, Lv L, et al
    Disrupted static and dynamic small-world brain network topologies in patients with schizophrenia.
    Schizophr Res. 2025;284:101-110.
    >> Share

  332. ZHANG J, Zhang G, Zhao Q, Peng Y, et al
    Genetic overlap between household income and psychiatric disorders.
    Schizophr Res. 2025;282:95-104.
    >> Share

  333. MCBRIDE LE, Gentry MM, Pinkham AE, Granholm E, et al
    The intersection of structural social factors, loneliness, and social activity in individuals with psychotic disorders.
    Schizophr Res. 2025;282:76-84.
    >> Share

  334. WILDGRUBER D, Hesse K, Eckstein KN, Richter J, et al
    Combining cognitive behavioral therapy and group training for social skills and cognition to improve negative symptoms in patients with psychotic disorders: a randomized controlled pilot trial.
    Schizophr Res. 2025;282:38-48.
    >> Share

    July 2025
  335. JI YS, Liu FY, Wei Y, Liu YF, et al
    Sex differences in the peripheral blood transcriptome and their associations with neuroimaging and cognition in schizophrenia.
    Schizophr Res. 2025;284:77-85.
    >> Share

  336. LIMA TSA, Corsi-Zuelli F, Souza AJ, Colodete DAE, et al
    Low-dose methotrexate as a potential treatment for schizophrenia via astrocytic and neuroimmune modulation.
    Schizophr Res. 2025;284:67-76.
    >> Share

  337. STRAUSS GP, Luther L, Raugh IM, Zhang S, et al
    Environmental deprivation is associated with reward processing impairments and negative symptoms in schizophrenia.
    Schizophr Res. 2025;284:59-66.
    >> Share

  338. FANSHAWE JB, Lawrence R, Ghanem DA, Pauli L, et al
    The role of the electroencephalogram (EEG) in determining the aetiology of psychosis: a systematic review and meta-analysis of diagnostic test accuracy.
    Schizophr Res. 2025;284:48-58.
    >> Share

  339. DU A, Kennedy L, Addington J, Bearden CE, et al
    Victimization and engagement with the legal system among individuals at clinical high risk (CHR) for psychosis.
    Schizophr Res. 2025;284:7-15.
    >> Share

  340. DONDE C, Pereira M, Nalborczyk L, Roux P, et al
    Characterizing early auditory deficits in schizophrenia using drift-diffusion modeling.
    Schizophr Res. 2025;284:23-31.
    >> Share

  341. AKPANEKPO EI, Chowdhury NZ, Butler T
    Early mental health treatment and reoffending among justice-involved youth diagnosed with psychosis.
    Schizophr Res. 2025;284:16-22.
    >> Share

  342. CATTARINUSSI G, Sambataro F, Dazzan P
    Climate change, air pollution, and schizophrenia: Moving the field forward.
    Schizophr Res. 2025;284:1-6.
    >> Share

  343. ANTAKI F, Kerexeta-Sarriegi J, Reis APR, Zhu Z, et al
    The association of retinal age gap with schizophrenia: a cross-sectional analysis.
    Schizophr Res. 2025;283:180-187.
    >> Share

  344. HU H, Xia M, Chen L, Hu Y, et al
    Hippocampal perfusion abnormalities and treatment effects in acute phase of first-episode schizophrenia.
    Schizophr Res. 2025;283:173-179.
    >> Share

  345. PELIZZA L, Leuci E, Quattrone E, Palmisano D, et al
    Autism-spectrum traits in First Episode Psychosis: Psychopathological and prognostic considerations from a 2-year follow-up study.
    Schizophr Res. 2025;283:163-172.
    >> Share

  346. KHANDKER R, Mohit B, Fonseca E, Fleming S, et al
    Treatment discontinuation and switching of antipsychotics among adult patients with schizophrenia in the United States.
    Schizophr Res. 2025;283:152-162.
    >> Share

  347. CARPENDALE EJ, Bell MC, Cullen AE, Dickson H, et al
    Differentiation of childhood risk profiles for schizophrenia according to the development of verbal and performance intelligence.
    Schizophr Res. 2025;283:144-151.
    >> Share

  348. YAO B, Hall MH, Tusuzian E, Cohen B, et al
    Childhood adverse events and their association with psychotic symptoms and quality of life in young adults with first episode psychosis and unaffected siblings.
    Schizophr Res. 2025;283:137-143.
    >> Share

  349. DAS N, Choudhary S, Nagendra S, Dutt S, et al
    Digital phenotyping correlates of cognitive performance in schizophrenia spectrum disorders from a longitudinal study.
    Schizophr Res. 2025;283:130-136.
    >> Share

  350. SAKURAI T, Birnbaum M, Chua YHV, Isa T, et al
    Ecological and momentary assessment and intervention for schizophrenia: Use of smartphone apps and video games.
    Schizophr Res. 2025;283:122-129.
    >> Share

  351. VILA-BADIA R, Espinosa V, Colomer-Salvans A, Serra-Arumi C, et al
    Childhood sexual abuse in first-episode psychosis: The relevance in cognitive bias.
    Schizophr Res. 2025;283:98-106.
    >> Share

  352. ZHANG T, Yang X, Mu P, Huo X, et al
    Stage-specific computational mechanisms of working memory deficits in first-episode and chronic schizophrenia.
    Schizophr Res. 2025;282:203-213.
    >> Share

  353. GELNER H, Krezolek M, Aleksandrowicz A, Piwinska J, et al
    The role of demographic variables in the effectiveness of metacognitive training for psychosis: A meta-analysis.
    Schizophr Res. 2025;283:85-97.
    >> Share

  354. FAUVIAUX T, Parisi M, Marin L, Vattier V, et al
    "The second I laid eyes on him I knew": First impressions predict willingness to interact with individuals with schizophrenia.
    Schizophr Res. 2025;283:77-84.
    >> Share

  355. SAMANTARAY S, Goyal N, Kesavan M, Venkatasubramanian G, et al
    Impaired corollary discharge as a predictor of reality monitoring deficits in schizophrenia: Implications for auditory verbal hallucinations.
    Schizophr Res. 2025;283:67-76.
    >> Share

  356. GUIOMAR R, Catoira B, Castilho P, Baeken C, et al
    Optimisation and development of new tDCS montages to target the cerebellum in schizophrenia: An electrical current modeling study.
    Schizophr Res. 2025;283:48-58.
    >> Share

  357. COMPTON MT
    Food and nutrition insecurity among individuals with schizophrenia and related psychotic disorders.
    Schizophr Res. 2025;283:21-26.
    >> Share

  358. GIBBS K, McHugo M, Moussa-Tooks A, Woodward ND, et al
    Hippocampal volume in affective and non-affective psychosis.
    Schizophr Res. 2025;283:11-20.
    >> Share

  359. PAREDES R, Ferri F, Romei V, Series P, et al
    Increased excitation enhances the sound-induced flash illusion by impairing multisensory causal inference in the schizophrenia spectrum.
    Schizophr Res. 2025;283:1-10.
    >> Share

  360. TAYFUR SN, Yoviene Sykes LA, Tek C, Srihari VH, et al
    Utilization of a psychosis consultation service: Early lessons from a statewide initiative.
    Schizophr Res. 2025;282:198-202.
    >> Share

  361. HUTTON P, Taylor CDJ, Kelly J, Emsley R, et al
    Accelerating the development of a psychological intervention to restore treatment decision-making capacity in patients with schizophrenia-spectrum disorder: An umbrella trial.
    Schizophr Res. 2025;282:184-197.
    >> Share

  362. KIM E, Kim S, Kim SW, Nam BW, et al
    Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs.
    Schizophr Res. 2025;281:180-190.
    >> Share

  363. AKERELE CA, Koralnik LR, Lafont E, Gilman C, et al
    Nutrition and brain health: Implications of Mediterranean diet elements for psychiatric disorders.
    Schizophr Res. 2025;281:30-44.
    >> Share

  364. DWORKIN A, Jimenez-Jimenez D, Ravenscroft C, Turco F, et al
    TMS-EEG in postictal psychosis of epilepsy.
    Schizophr Res. 2025;282:176-183.
    >> Share

    June 2025
  365. MAJUMDAR V, Kumar PB, Arasappa R, Hegde S, et al
    The mediating influence of serum Klotho levels and the KL-VS heterozygosity on telomere shortening in schizophrenia.
    Schizophr Res. 2025;282:166-175.
    >> Share

  366. PARK B, Holbrook A, Rast P, Light GA, et al
    Trial-by-trial ERP-behavior relationships in psychosis: Between- and within-person variability in performance monitoring adjustments.
    Schizophr Res. 2025;282:158-165.
    >> Share

  367. CAO BF, Chen HW, Xu ZY, Zhong Q, et al
    Effects of second-generation antipsychotics and long-term atherogenic indices trajectories on metabolic syndrome in patients with schizophrenia.
    Schizophr Res. 2025;282:150-157.
    >> Share

  368. ZAVAGLIA E, Joober R, Iyer SN, MacDonald K, et al
    Implementation of a digital measurement-based care approach in an early intervention service for psychosis: the PEPP-Montreal electronic data capture protocol and its alignment with learning health system principles.
    Schizophr Res. 2025;282:141-149.
    >> Share

  369. BALDINI V, Pasquino F, De Ronchi D, Plazzi G, et al
    Sleep disturbances in individuals with first episode psychosis and clinical high-risk states: A systematic review.
    Schizophr Res. 2025;282:123-132.
    >> Share

  370. O'DONOGHUE B, Eaton S, Lyne J, Thompson A, et al
    Determining the cumulative incidence of treated schizophrenia and predictors of transition in an early intervention for psychosis service.
    Schizophr Res. 2025;282:116-122.
    >> Share

  371. MIRHASHEMI E, Bachman P, Krishnan G, Asarnow RF, et al
    Altered neural oscillations are associated with improved working memory performance in schizophrenia following D-cycloserine administration.
    Schizophr Res. 2025;282:85-94.
    >> Share

  372. YANG J, Zhu X, Xiao L
    Response to the Letter to the editor: Aripiprazole or metformin for hyperprolactinemia in women with schizophrenia: A 6-month, real-world chart review study.
    Schizophr Res. 2025;282:114-115.
    >> Share

  373. CORRELL CU, Janetzky W, Brieden A
    Predictors of symptomatic and wellbeing remission in real-world samples of patients living with schizophrenia treated with aripiprazole once-monthly by means of constrained confidence partitioning.
    Schizophr Res. 2025;282:105-113.
    >> Share

  374. CHEN B, Ma R, Zhang S, Liu Y, et al
    Letter to the editor: Aripiprazole or metformin for hyperprolactinemia in women with schizophrenia: A 6-month, real-world chart review study.
    Schizophr Res. 2025;282:74-75.
    >> Share

  375. ZHAI Z, Gao T, Cen H, Li X, et al
    Aberrant prefrontal-hippocampal connectivity of cross-modal associative memory impairment in schizophrenia.
    Schizophr Res. 2025;282:64-73.
    >> Share

  376. TISHLER TA, Ellingson BM, Salvadore G, Baker P, et al
    Corrigendum to "Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study" [Schizophr
    Schizophr Res. 2025 Jun 6:S0920-9964(25)00197.
    >> Share

  377. JIANG D, Wang R, Ma D, Tang C, et al
    Prevalence and predictors of metabolic abnormalities and metabolic syndrome among patients with schizophrenia in China.
    Schizophr Res. 2025;282:28-37.
    >> Share

  378. PIANI MC, Jandl M, Koenig T, Nordgaard J, et al
    Pre-reflective and reflective abnormalities in cortical midline structures in schizophrenia.
    Schizophr Res. 2025;282:19-27.
    >> Share

    May 2025
  379. HAKAMI MA
    Molecular signatures and emerging therapeutic targets in schizophrenia: A biomarker-centric perspective in psychiatric disorders.
    Schizophr Res. 2025;282:1-18.
    >> Share

  380. SCOTT I, Selloni A, Bilgrami Z, Cotter M, et al
    The inventory of psychotic-like anomalous self-experiences (IPASE): Stability and relationships with attenuated psychotic symptoms and remission in individuals at-risk for psychosis.
    Schizophr Res. 2025;281:286-294.
    >> Share

  381. SCHOEMAKER G, Mocking RJT, Medema S, Koeter MWJ, et al
    Distribution of red blood cell fatty acids in stable patients with a schizophrenia spectrum disorder and healthy controls.
    Schizophr Res. 2025;281:275-285.
    >> Share

  382. SAPERIA S, Prosserman A, Flores Anaya E, Hahn M, et al
    The pleasure expectancies scale (PLEX): A brief measure of expectancies for pleasure in schizophrenia.
    Schizophr Res. 2025;281:268-274.
    >> Share

  383. BLOTNER J, Hechinger R, Shenton ME, Coleman MJ, et al
    Negative symptoms, cognition, and community functioning in early psychosis.
    Schizophr Res. 2025;281:260-267.
    >> Share

  384. HAU C, Xia W, Ryan S, Firth J, et al
    Smartphone monitoring and digital phenotyping apps for schizophrenia: A review of the academic literature.
    Schizophr Res. 2025;281:237-248.
    >> Share

  385. LAVONIUS V, Keltikangas-Jarvinen L, Lyytikainen LP, Hamal Mishra B, et al
    Polygenic risk for schizophrenia predicting Big Five personality traits in individuals without non-affective psychosis.
    Schizophr Res. 2025;281:229-236.
    >> Share

  386. SHANKAR S, Ravishankar KS, Krishna Sundari M
    Comparison of Auditory Brainstem Response (ABR) findings in drug-naive schizophrenia patients and healthy comparison subjects.
    Schizophr Res. 2025;281:218-222.
    >> Share

  387. CROSSLEY NA, Guloksuz S
    Minimum data standards for schizophrenia and the EnvironmenT (MINDSET) research harmonization exercise.
    Schizophr Res. 2025;281:216-217.
    >> Share

  388. LAKE AM, Reddy IA, Havranek R, Davis LK, et al
    Clinical Characteristics associated with functional seizures in individuals with psychosis.
    Schizophr Res. 2025;281:209-215.
    >> Share

  389. LI J, Zhang X, Liu F, Pang L, et al
    Rethinking the core symptom of schizophrenia: An exploration of disorganized thought centrality in psychosis.
    Schizophr Res. 2025;281:201-208.
    >> Share

  390. ZHOU H, Yuan X, Xie P, Wang A, et al
    Distinct processing stages of cross-modal conflict in schizophrenia: The role of auditory cortex underactivation.
    Schizophr Res. 2025;281:191-200.
    >> Share

  391. APRILE SF, Rodolico A, Di Francesco A, Cutrufelli P, et al
    Exploring weight gain and body image in schizophrenia spectrum disorders: a systematic review of qualitative studies.
    Schizophr Res. 2025;281:177-179.
    >> Share

  392. GAMA-MARQUES J
    Still regarding the potential value of unconjugated bilirubin (UCB) as a biomarker candidate for schizophrenia and schizoaffective psychoses.
    Schizophr Res. 2025;281:175-176.
    >> Share

  393. LING L, Wang M, Du W, Wang J, et al
    Development and validation of a neutrophil-lymphocyte ratio-based nomogram for suicidal ideation in first-episode drug-naive schizophrenia patients: A large-scale cross-sectional study.
    Schizophr Res. 2025;281:164-174.
    >> Share

  394. CAMPBELL ML, Odokonyero R, Akena D, Alemayehu M, et al
    Sociodemographic influences on substance use in psychosis in an African cohort.
    Schizophr Res. 2025;281:157-163.
    >> Share

  395. MEROLA GP, Patti A, Catania G, Boy OB, et al
    Phenomenological psychopathology meets machine learning: A multicentric retrospective study (Mu.St.A.R.D.) targeting the role of Aberrant Salience assessment in psychosis detection.
    Schizophr Res. 2025;281:147-156.
    >> Share

  396. JANG YJ, Yassin W, Mesholam-Gately R, Gershon ES, et al
    Corrigendum to "Jang YJ, et al. Characterizing the relationship between personality dimensions and psychosis-specific clinical characteristics" [Schizophr Res. 276 (2025) 88-96 10.1016/j.schres.2025.01.002 (Epub ahead of print, PMID: 39864301, Jan 25)
    Schizophr Res. 2025 May 7:S0920-9964(25)00179.
    >> Share

  397. BORNHEIMER LA, Lapidos A, Simmonite M, Suzuki T, et al
    Stress sensitivity, negative affect, and functioning in an early psychosis clinic.
    Schizophr Res. 2025;281:125-131.
    >> Share

  398. UPPINKUDRU C, Roy N, Bharath RD, Venkatasubramanian G, et al
    Sustained attenuation of sensorimotor network functional connectivity with acute and maintenance phase risperidone treatment in first-episode schizophrenia.
    Schizophr Res. 2025;281:122-124.
    >> Share

  399. MEINHART A, Schmueser A, Moritz S, Boge K, et al
    Effects of mindfulness- and acceptance-based interventions for individuals with schizophrenia spectrum disorders: A systematic meta-review.
    Schizophr Res. 2025;281:91-107.
    >> Share

  400. TATSUMI K, Parfitt A, Weissfeld L, Opler M, et al
    Assessing negative symptoms of schizophrenia in the context of remote independent ratings: a psychometric evaluation of BNSS and PANSS.
    Schizophr Res. 2025;281:108-114.
    >> Share

  401. TAMPI RR, Joshi P, Jeste DV
    Psychosis associated with dementia: evaluation and management.
    Schizophr Res. 2025;281:82-90.
    >> Share

  402. SHIN J, Wu J, Kim HJ, Xi W, et al
    Neighborhood-level social determinants of suicidality in youth with schizophrenia: An EHR-based study.
    Schizophr Res. 2025;281:74-81.
    >> Share

  403. KORALNIK LR, Lafont E, Akerele C, Bonner M, et al
    Mediterranean and standard American diet consumption in psychosis and non-psychosis affective disorders groups: Symptoms and cognition.
    Schizophr Res. 2025;281:60-73.
    >> Share

  404. LUCKHOFF HK, Smit AM, Phahladira L, Kilian S, et al
    Childhood trauma associations with changes in body mass index over 12 months of treatment in first-episode schizophrenia spectrum disorders.
    Schizophr Res. 2025;281:52-59.
    >> Share

  405. BARTOLOMEO LA, James SH, Berglund AM, Raugh IM, et al
    Digital phenotyping evidence for the reduced positivity offset as a mechanism underlying anhedonia among individuals at clinical high-risk for psychosis.
    Schizophr Res. 2025;281:45-51.
    >> Share

    April 2025
  406. JIA N, Yin X, Zhu Z, Hou W, et al
    Comprehensive transcriptome analysis and lncRNA-miRNA-mRNA establishment of schizophrenia based on induced pluripotent stem cells.
    Schizophr Res. 2025;281:22-29.
    >> Share


  407. Commentary on "Speaking of yourself: A meta-analysis of 80 years of research on pronoun use in schizophrenia".
    Schizophr Res. 2025;281:20-21.
    >> Share

  408. RAMIREZ-BERMUDEZ J, Espinola-Nadurille M, Restrepo-Martinez M, Martinez-Angeles V, et al
    Autoimmune psychosis: Psychopathological patterns and outcome after immunotherapy.
    Schizophr Res. 2025;281:10-19.
    >> Share

  409. TRUJILLO T, Mirzakhanian H, Addington J, Bearden CE, et al
    High rates of suicidality and parasuicidal behavior in individuals at clinical high-risk for psychosis: Implications for suicide risk assessment and suicide prevention.
    Schizophr Res. 2025;281:1-9.
    >> Share

  410. SALUJA A, Johnson KA, Ongur D, Lanca M, et al
    Changes in first-episode psychosis care delivery and outcomes throughout the COVID-19 pandemic: Insights from a learning healthcare system in Massachusetts.
    Schizophr Res. 2025;280:130-139.
    >> Share

  411. ZHU B, Liang L, Huang Y, Wang H, et al
    Exploring the relationship between the gut microbiota and cognitive function in schizophrenia patients with distinct weights.
    Schizophr Res. 2025;280:103-113.
    >> Share

  412. KIDD SA, Rosenbaum D, Rotenberg M, Kenny GP, et al
    Climate change and schizophrenia: Implications and directions.
    Schizophr Res. 2025;280:114-116.
    >> Share

  413. TOUFEILI A, Vigod SN, Zaheer J, Hussain Z, et al
    Reproductive health experiences of women and non-binary people with early psychosis: a qualitative study.
    Schizophr Res. 2025;280:95-102.
    >> Share

  414. KNOWLES EEM, Peralta JM, Rodrigue AL, Mathias SR, et al
    Differential gene expression study in whole blood identifies candidate genes for psychosis in African American individuals.
    Schizophr Res. 2025;280:85-94.
    >> Share

  415. YANG J, Zhu X, Wang W, Wang H, et al
    Aripiprazole or metformin for hyperprolactinemia in women with schizophrenia: A 6-month, real-world chart review study.
    Schizophr Res. 2025;280:76-84.
    >> Share

  416. FOLEY JA, Bell V
    CBT for psychosis in Parkinson's disease: A framework for how and why.
    Schizophr Res. 2025;280:69-75.
    >> Share

  417. GUEST RM, Aberizk K, Addington J, Bearden CE, et al
    Cultural variables influence performance on the MATRICS Consensus Cognitive Battery among people at clinical high risk for psychosis.
    Schizophr Res. 2025;280:60-68.
    >> Share

  418. CHEN SN, Wang YY
    Reply to dynamic network analysis of schizophrenia spectrum traits, affective symptoms, and social functioning-Opportunities and challenges.
    Schizophr Res. 2025;280:59.
    >> Share

  419. ZHU H, Wu Z, Wang J, Zhang E, et al
    DLG2 rs11607886 polymorphism associated with schizophrenia and precuneus functional changes.
    Schizophr Res. 2025;280:50-58.
    >> Share

  420. LU C, Huang D, Su J, Huang Z, et al
    Letter to the editor regarding: Dynamic network analysis of schizophrenia spectrum traits, affective symptoms, and social functioning-Opportunities and challenges.
    Schizophr Res. 2025;280:48-49.
    >> Share

  421. YOO S, Montazeri A, McNulty H, Potvin Kent M, et al
    Global evaluation of the impact of food fortification with folic acid on rates of schizophrenia.
    Schizophr Res. 2025;280:39-47.
    >> Share

  422. CHIU CW, Chen BY, Lin JJ, Tseng HH, et al
    Developing a risk assessment model for treatment-resistant schizophrenia: The role of niacin receptor GPR109A and prostaglandin receptors DP(1), EP(2), and EP(4) in the niacin-induced flushing pathway.
    Schizophr Res. 2025;280:30-38.
    >> Share

  423. LIU M, Tian S, Liu X, Zhang H, et al
    Analysis of differentially expressed genes in schizophrenia based on bioinformatics and corresponding mRNA expression levels.
    Schizophr Res. 2025;280:22-29.
    >> Share

  424. PATEL PK, Thies MB, Moyett A, Arkin S, et al
    Avolition predicts variability in optimal risk-taking in early psychosis.
    Schizophr Res. 2025;280:15-21.
    >> Share

  425. FORTIER A, Tikasz A, Athanassiou M, Zouaoui I, et al
    Hippocampus subfield volume reductions in treatment-resistant schizophrenia.
    Schizophr Res. 2025;280:10-14.
    >> Share

  426. MATHIS WS, Gibbs-Dean T, Cahill JD, Srihari VH, et al
    HONE: A learning health system platform for advancing early intervention in first episode psychosis.
    Schizophr Res. 2025;280:1-9.
    >> Share

  427. GREVE AN, Hemager N, Piche G, Burton BK, et al
    Perceived social support in parents with schizophrenia or bipolar disorder and their co-parents: The Danish high risk and resilience study VIA 7.
    Schizophr Res. 2025;279:137-143.
    >> Share

  428. RETHA S, Hilmar L, Lebogang P, Sanja K, et al
    Corrigendum to "Psychopathology trajectories and relapse in first episode schizophrenia with assured long-acting injectable adherence over 24 months" [Schizophr. Res. volume 276 (2025), 8-14/article number].
    Schizophr Res. 2025 Apr 5:S0920-9964(25)00125.
    >> Share

  429. PALOMINOS C, Kirdun M, Nikzad AH, Spilka MJ, et al
    A single composite index of semantic behavior tracks symptoms of psychosis over time.
    Schizophr Res. 2025;279:116-127.
    >> Share

  430. LIU K, Chen HW, Wang SA, Zhang CY, et al
    Association between serum bilirubin and type 2 diabetes mellitus risk: Findings from a schizophrenia cohort.
    Schizophr Res. 2025;279:106-115.
    >> Share

  431. CHEN L, Wang Z, Wang Y, Jiang H, et al
    Alterations in fatty acid metabolism in patients with schizophrenia in a multi-omics perspective.
    Schizophr Res. 2025;279:94-105.
    >> Share

  432. NIELSEN JRW, Dietz M, Jefsen OH
    Blink rates in patients with schizophrenia compared to healthy controls: A meta-analysis.
    Schizophr Res. 2025;279:87-93.
    >> Share

  433. ROBINSON DG, Schooler NR, John M, Cahill JD, et al
    The problem of missing data for learning health systems focused on first-episode psychosis.
    Schizophr Res. 2025;279:79-86.
    >> Share

  434. DIOMINO A, Yuan Q, Cadenhead KS, Addington J, et al
    The role of childhood social fragmentation and perceived discrimination on maladaptive core schemas later in life among young adults at clinical high risk for psychosis and healthy comparisons.
    Schizophr Res. 2025;279:71-78.
    >> Share

  435. POOLE-WRIGHT K, Patel A, Gaughran F, Murray R, et al
    Prevalence and associations of fatigue in psychosis: A systematic review and meta-analysis.
    Schizophr Res. 2025;279:59-70.
    >> Share

  436. BELLO I, Stefancic A, Florence AC, Wall M, et al
    OnTrackNY: A public sector learning healthcare system for youth and young adults with early psychosis.
    Schizophr Res. 2025;279:50-58.
    >> Share

  437. YUAN Q, Chen Y, Xu Y, Dimitrov LV, et al
    Cluster profiles of distressing psychotic-like experiences among children and associations with genetic risk, prenatal cannabis exposure, and social-environmental characteristics.
    Schizophr Res. 2025;278:119-127.
    >> Share

    March 2025
  438. LYNE J, Piacenza F, Crowley P, Smyth J, et al
    Negative symptoms in psychosis: A scoping review of qualitative studies.
    Schizophr Res. 2025;279:40-49.
    >> Share

  439. PERALTA V, de Jalon EG, Moreno-Izco L, Sanchez-Torres AM, et al
    What does really matter in the premorbid background of psychosis leading to long-term disability? A 21-year follow-up cohort study of first-episode psychosis.
    Schizophr Res. 2025;279:31-39.
    >> Share

  440. ELLEUCH D, Chen Y, Luo Q, Palaniyappan L, et al
    Speaking of yourself: A meta-analysis of 80 years of research on pronoun use in schizophrenia.
    Schizophr Res. 2025;279:22-30.
    >> Share

  441. PIANI MC, Jandl M, Morishima Y, Nordgaard J, et al
    Self-disorders in schizophrenia - and ERP study of pre-reflective and reflective self-experience.
    Schizophr Res. 2025;279:13-21.
    >> Share

  442. PELIZZA L, Leuci E, Quattrone E, Palmisano D, et al
    Compulsory treatment across a 2-year follow-up within an "Early Intervention in Psychosis" program in Italy: Incidence rates and baseline predictors.
    Schizophr Res. 2025;279:1-12.
    >> Share

  443. TIAN J, Dong S, Nomura N, Siafis S, et al
    Corrigendum to "Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials" [Schizophr. Res. Volume 274, December 2024, pages 360-373].
    Schizophr Res. 2025 Mar 26:S0920-9964(25)00099.
    >> Share

  444. VOHS JL, Cahill J, Taylor SF, Heckers S, et al
    Forging a learning health system for early psychosis: Insights from the academic community EPINET.
    Schizophr Res. 2025;278:109-118.
    >> Share

  445. DENIS D, Baran B, Mylonas D, Spitzer C, et al
    Corrigendum to "Sleep oscillations and their relations with sleep-dependent memory consolidation in early course psychosis and first-degree relatives" [Schizophr. Res. 274 (2024) 473-485].
    Schizophr Res. 2025 Mar 26:S0920-9964(25)00096.
    >> Share

  446. YOVIENE SYKES LA, Levine N, Tayfur SN, Gibbs-Dean T, et al
    The STEP Learning Collaborative: A statewide Learning Healthcare System (LHS) for first episode psychosis.
    Schizophr Res. 2025;278:96-108.
    >> Share

  447. DE ALMEIDA QUEIROZ S, de Novais Junior LR, de Carvalho ABP, da Silva TV, et al
    Cannabidiol reverses myeloperoxidase hyperactivity in the prefrontal cortex and striatum, and reduces protein carbonyls in the hippocampus in a ketamine-induced schizophrenia rat model.
    Schizophr Res. 2025;278:82-95.
    >> Share

  448. ZHANG S, Jin W, Fan S, Wang Q, et al
    Association of insight with stigma and its moderating factors among patients with stable schizophrenia.
    Schizophr Res. 2025;278:75-81.
    >> Share

  449. LOCARNO LR, Lasagna CA, Kraft JD, Suzuki T, et al
    Examining the joint and unique contributions of contour integration and visuospatial memory to altered eye gaze perception in schizophrenia.
    Schizophr Res. 2025;278:65-74.
    >> Share

  450. DU L, Huang H, Pu Z, Shi Y, et al
    A potential diagnostic biomarker for schizophrenia based on local functional connectivity using dynamic regional phase synchrony.
    Schizophr Res. 2025;278:57-64.
    >> Share

  451. LOURENCO P, Bastos T, Pizarro A, Corredeira R, et al
    The long-term effects of a 24-week outdoor exercise program in persons with schizophrenia: Results of a 12-week follow-up period.
    Schizophr Res. 2025;278:47-56.
    >> Share

  452. CRESTOIS N, Kempton MJ, Twumasi R
    A systematic review and meta-analysis of employer discrimination towards people living with psychosis.
    Schizophr Res. 2025;278:35-46.
    >> Share

  453. PELUFFO L
    A reflection on schizophrenia's "voices" based on personal experience.
    Schizophr Res. 2025;277:188-189.
    >> Share

  454. KUBOTA R, Uchino T, Okubo R, Akiyama H, et al
    Factor structure of social cognition in schizophrenia: Investigation of four core domains.
    Schizophr Res. 2025;278:26-34.
    >> Share

  455. ALVIM PHP, Cavalari VC, Bianchini AJ, Frizon GF, et al
    Toxoplasmosis infection and schizophrenia: Elevated IgM reactivity index as a predictor of symptom worsening in chronic schizophrenia.
    Schizophr Res. 2025;278:20-25.
    >> Share

  456. WANG S, Dong Y, Qiu Y, Sun X, et al
    Prediction of treatment response in drug-naive schizophrenia patients from the perspective of targeted metabolomics.
    Schizophr Res. 2025;278:9-16.
    >> Share

  457. HUANG HC, Wu BJ, Yu CH, Liu CZ, et al
    LEPR gene polymorphisms and pneumonia risk in Taiwanese schizophrenia patients under clozapine treatment.
    Schizophr Res. 2025;278:1-8.
    >> Share

  458. EVANS SL, Kumari V, Kempton MJ, Rogers J, et al
    MRI data sharing in psychosis: Key challenges and a new Open Access resource for researchers.
    Schizophr Res. 2025;277:185-187.
    >> Share

  459. LIU Z, Wang X, Chen W, Huang J, et al
    Comparison of clinical symptoms and symptom structure across different onset ages in schizophrenia inpatients.
    Schizophr Res. 2025;277:177-184.
    >> Share

  460. JIANG C, Wang J, Sun Y, Tan S, et al
    Unveiling distinct representations of P3a in schizophrenia through two-stimulus and three-stimulus auditory oddball paradigms.
    Schizophr Res. 2025;277:159-168.
    >> Share

  461. ABERIZK K, Sefik E, Yuan Q, Cao H, et al
    Relations of temporoparietal connectivity with neighborhood social fragmentation in youth at clinical high-risk for psychosis.
    Schizophr Res. 2025;277:151-158.
    >> Share

  462. ETIENNE M, Verdoux H
    Impact of long-acting injectable antipsychotics in early psychosis: An umbrella review.
    Schizophr Res. 2025;277:140-150.
    >> Share

  463. ZHANG L, Zhang C, Yan H, Han Y, et al
    Changes in degree centrality and its associated genes: A longitudinal study of patients with schizophrenia undergoing pharmacological treatment.
    Schizophr Res. 2025;277:130-139.
    >> Share

  464. DOW JF, Cerundolo N, Konstas K, Carol EE, et al
    Implementing early psychosis services: Experiences from the laboratory for early psychosis center.
    Schizophr Res. 2025;277:124-129.
    >> Share

  465. QIN X, Wang Q, Li H, Wang J, et al
    Effects of tDCS with concurrent cognitive performance targeting the dorsolateral prefrontal cortex and the posterior parietal cortex on EEG microstates in schizophrenia.
    Schizophr Res. 2025;277:117-123.
    >> Share

  466. CHENG B, Wen Y, Wei W, Cheng S, et al
    Polygenic enrichment analysis in multi-omics levels identifies cell/tissue specific associations with schizophrenia based on single-cell RNA sequencing data.
    Schizophr Res. 2025;277:93-101.
    >> Share

  467. LEUTWYLER H, Mock J, Hubbard E, Bussell T, et al
    Social and environmental factors during the smoking cessation process: The experiences of adults with serious mental illnesses.
    Schizophr Res. 2025;277:111-116.
    >> Share

    February 2025
  468. MARSTELLER JA, Goldberg RW, Boumaiz Y, Jumper MBE, et al
    Building a two-state learning healthcare system for persons with first episode psychosis.
    Schizophr Res. 2025;277:74-85.
    >> Share

  469. VON KANEL S, Pavlidou A, Nadesalingam N, Chapellier V, et al
    Manual dexterity and grip force are distinctly linked to domains of neurological soft signs in schizophrenia spectrum disorders.
    Schizophr Res. 2025;277:65-73.
    >> Share

  470. KAISER KA, Thompson JL, Butler PD, Ahmed AO, et al
    Effects of visual remediation on Ebbinghaus illusion task performance in people with schizophrenia: A preliminary study.
    Schizophr Res. 2025;277:57-64.
    >> Share

  471. KAMP D, Lowe A, Weide K, Riesbeck M, et al
    Efficacy of integrated social cognitive remediation vs neurocognitive remediation in schizophrenia: Results from the multicenter randomized controlled ISST (Integrated Social Cognition And Social Skills Therapy) study.
    Schizophr Res. 2025;277:44-56.
    >> Share

  472. VERAS AB, Ribeiro KM, Peixoto C, Horato N, et al
    Schizophrenia spectrum disorders with comorbid panic: A systematic review.
    Schizophr Res. 2025;277:33-41.
    >> Share

  473. TAKEUCHI H
    Are all antipsychotic dose reduction trials in stable schizophrenia the same?
    Schizophr Res. 2025;277:31-32.
    >> Share

  474. ABDEL-BAKI A, Ferrari M, Leblanc A, Arbaud C, et al
    SARPEP, a rapid-learning healthcare system of early intervention services for psychosis in Quebec, Canada: Feasibility, acceptability and early impacts.
    Schizophr Res. 2025;277:20-30.
    >> Share

  475. SUN X, Xu Y, Wu Y, Li M, et al
    Sex differences in the relationship between the vascular endothelial growth factor and cognition in drug-naive schizophrenia.
    Schizophr Res. 2025;277:9-17.
    >> Share

  476. ORTH RD, Todd IL, Dwyer KR, Bennett ME, et al
    Socially relevant affective learning in psychosis: Relations to deficits in motivation and pleasure and cognitive ability.
    Schizophr Res. 2025;277:1-8.
    >> Share

  477. FAGGIANO A, Gherbesi E, Carugo S, Grassi G, et al
    Myocardial mechanics in schizophrenia and bipolar disorder: A gap to fill.
    Schizophr Res. 2025;276:243-249.
    >> Share

  478. HAGEN JM, Cornelissen A, Veeneman RR, van der Heijden HS, et al
    Skin advanced glycation end products, indicating cumulative oxidative stress, associated with schizophrenia but not with psychosis-like experiences.
    Schizophr Res. 2025;276:237-242.
    >> Share

  479. JIAO X, Hu Q, Zhu W, Ren W, et al
    A letter to the editor: Abnormalities in auditory lateralization during spatial mismatch negativity tasks in male patients with schizophrenia.
    Schizophr Res. 2025;276:234-236.
    >> Share

  480. HAN S, Gilmartin M, Sheng W, Jin VX, et al
    Integrating rare variant genetics and brain transcriptome data implicates novel schizophrenia putative risk genes.
    Schizophr Res. 2025;276:205-213.
    >> Share

  481. HECHINGER RM, Javaras KN, Lewandowski KE
    Comorbidity of anorexia nervosa and schizophrenia: A systematic review.
    Schizophr Res. 2025;276:185-193.
    >> Share

  482. AGUIRRE JM, Diaz Dellarossa C, Barbagelata D, Vasquez J, et al
    Cognitive function at first episode in patients subsequently developing treatment-resistant schizophrenia.
    Schizophr Res. 2025;276:178-184.
    >> Share

  483. LIU L, Xia Y, Chen L, Zou F, et al
    Binaural hearing impairment in patients with schizophrenia: A multicenter study.
    Schizophr Res. 2025;276:175-177.
    >> Share

  484. ALARCON-YAQUETTO DE, Stewart R, Perera G, Pinto da Costa M, et al
    Impact of loneliness and living alone on negative symptoms in severe mental illness: An electronic health record data analysis.
    Schizophr Res. 2025;276:196-201.
    >> Share

    January 2025
  485. KEMP KC, Tso IF, Taylor SF, Moe AM, et al
    Social stress in schizophrenia: Unique contributions to social cognition and social functioning.
    Schizophr Res. 2025;276:167-174.
    >> Share

  486. ERESHEFSKY S, Gemignani R, Savill M, Sanford KC, et al
    A mixed-methods study exploring the benefits, drawbacks, and utilization of data in care: Findings from the EPI-CAL early psychosis learning health care network.
    Schizophr Res. 2025;276:157-166.
    >> Share

  487. SHARMA D, Bharadaj SK, Bharadaj S, Chakraborty S, et al
    MicroRNA-regulated suppression of some overexpressed genes in schizophrenia and their evolutionary significance.
    Schizophr Res. 2025;276:143-156.
    >> Share

  488. DELAY C, Link P, Holden J, Granholm E, et al
    Using pupillometry to predict outcome in cognitive behavioral therapy for negative symptoms of schizophrenia.
    Schizophr Res. 2025;276:135-142.
    >> Share

  489. DE WITH J, van der Pluijm M, de Haan L, Schirmbeck F, et al
    The role of the behavioural inhibition and activation system in the association between attachment style and positive or negative symptoms in patients with psychosis and unaffected siblings.
    Schizophr Res. 2025;276:127-134.
    >> Share

  490. HARVEY PD, Kaul I, Chataverdi S, Patel T, et al
    Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophrenia.
    Schizophr Res. 2025;276:117-126.
    >> Share

  491. CHAKRABORTY A, Mukesh N, Annamneedi A
    Synaptic dysfunctions in schizophrenia: Commonalities and divergences in Chinese and Indian populations.
    Schizophr Res. 2025;276:106-107.
    >> Share

  492. JANG YJ, Yassin W, Mesholam-Gately R, Gershon ES, et al
    Characterizing the relationship between personality dimensions and psychosis-specific clinical characteristics.
    Schizophr Res. 2025;276:88-96.
    >> Share

  493. MA Y, Bai L, Jiang Y, Wang J, et al
    Ambient coarse particulate matter pollution and hospital admissions for schizophrenia.
    Schizophr Res. 2025;276:79-87.
    >> Share

  494. GLEESON JFM, Ludwig K, Stiles BJ, Piantella S, et al
    Systematic review and meta-analysis of family-based interventions for early psychosis: Carer and patient outcomes.
    Schizophr Res. 2025;276:57-78.
    >> Share

  495. NOGUEIRA C, Pereira ED, Coelho JCF, Moreno-Poyato AR, et al
    Positive mental health interventions for people with schizophrenia: A scoping review.
    Schizophr Res. 2025;276:40-56.
    >> Share

  496. FRITZE S, Brandt GA, Volkmer S, Daub J, et al
    Loneliness is associated with different structural brain changes in schizophrenia spectrum disorders and major depression.
    Schizophr Res. 2025;276:31-39.
    >> Share

  497. JELSMA A, Schirmbeck F, van der Pluijm M, Simons C, et al
    Obsessive-compulsive symptoms and personal recovery in patients with schizophrenia spectrum disorders: A cross-sectional study.
    Schizophr Res. 2025;276:24-30.
    >> Share

  498. BLACKMAN G, DeLaney J, MacCabe JH, Khandaker G, et al
    Sub-clinical systemic inflammation as a determinant of admission duration in psychosis.
    Schizophr Res. 2025;276:17-23.
    >> Share

  499. ELKIS H, Correll CU, Melzer-Ribeiro DL
    Response to the Letter to the Editor "Reflections on a study of electroconvulsive therapy for clozapine-refractory schizophrenia" (Jolly et al. Schizophrenia Research, 267 (2024) 32-33).
    Schizophr Res. 2025;276:15-16.
    >> Share

  500. RETHA S, Hilmar L, Lebogang P, Sanja K, et al
    Psychopathology trajectories and relapse in first episode schizophrenia with assured long-acting injectable adherence over 24 months.
    Schizophr Res. 2025;276:8-14.
    >> Share

  501. LOPEZ MA, Reznik SJ, Klodnick VV, Cohen D, et al
    Creating a collaborative culture of learning within a network of community mental health early psychosis programs in Texas.
    Schizophr Res. 2025;276:1-7.
    >> Share

  502. KOPELOVICH SL, Straub K, Vaswani-Bye A, Brian RM, et al
    Co-production of a state-funded centralized psychosis and psychosis risk screening, assessment, and referral service.
    Schizophr Res. 2025;275:196-207.
    >> Share

  503. TAYFUR SN, Song Z, Li F, Hazan H, et al
    Insight and suicidality in first-episode psychosis: The mediating role of depression.
    Schizophr Res. 2025;275:189-195.
    >> Share

    December 2024
  504. SANAHAN R, Sreeraj VS, Suhas S, Kumar V, et al
    Response to clozapine and its predictors in treatment-resistant schizophrenia spectrum disorders: A retrospective chart review.
    Schizophr Res. 2024;275:179-188.
    >> Share

  505. RUSSELL MT, Linton IS, Vohs JL, Minor KS, et al
    Optimizing recovery in first-episode psychosis: A systematic review of psychosocial interventions.
    Schizophr Res. 2024;275:166-178.
    >> Share

  506. BROBAKKEN MF, Nygard M, Guzey IC, Morken G, et al
    The long-lasting impact of high-intensity training via collaborative care in patients with schizophrenia: A 5-year follow-up study.
    Schizophr Res. 2024;275:156-165.
    >> Share

  507. KIM EY, Kim J, Jeong JH, Jang J, et al
    Machine learning prediction model of the treatment response in schizophrenia reveals the importance of metabolic and subjective characteristics.
    Schizophr Res. 2024;275:146-155.
    >> Share

  508. KIMHY D, Vakhrusheva J, Zemon V
    Affective predictors of social support in individuals with schizophrenia.
    Schizophr Res. 2024;275:137-145.
    >> Share

  509. WADA A, Yamada R, Yamada Y, Sumiyoshi C, et al
    Autistic trait severity in early schizophrenia: Role in subjective quality of life and social functioning.
    Schizophr Res. 2024;275:131-136.
    >> Share

  510. POUGET JG, Cohen E, Ray JG, Wilton AS, et al
    Association between maternal schizophrenia and risk of serious asthma exacerbations in childhood.
    Schizophr Res. 2024;275:123-130.
    >> Share

  511. LI J, Pang L, Liu F, Lu Z, et al
    Disentangling the topological symptom structure of schizophrenia: A network analysis.
    Schizophr Res. 2024;275:115-122.
    >> Share

  512. ISHIZUKA M, Otsuka S, Miyata J, Yoshihara Y, et al
    Autism-spectrum quotient mediates the relationship between clinical symptoms and quality of life in schizophrenia.
    Schizophr Res. 2024;275:98-106.
    >> Share

  513. DAVIES K, Lappin JM, Briggs N, Isobel S, et al
    Does shame mediate the influence of trauma on psychosis? A systematic review and meta-analytic structural equation modelling approach.
    Schizophr Res. 2024;275:87-97.
    >> Share

  514. BRUNNER G, Gajwani R, Gross J, Gumley A, et al
    Choroid plexus morphology in schizophrenia and early-stage psychosis: A cross-sectional study.
    Schizophr Res. 2024;275:107-114.
    >> Share

  515. JEFFREY C, Penney D, Sauve G, Mendelson D, et al
    Does metacognitive training for psychosis (MCT) improve neurocognitive performance? A systematic review and meta-analysis.
    Schizophr Res. 2024;275:79-86.
    >> Share

  516. COLIJN MA
    16p11.2 duplication syndrome-associated psychosis: An illustrative case and review of the literature.
    Schizophr Res. 2024;275:76-78.
    >> Share

  517. ZURLO L, Dal Bo E, Gentili C, Cecchetto C, et al
    Olfactory dysfunction in schizophrenia and other psychotic disorders: A comprehensive and updated meta-analysis.
    Schizophr Res. 2024;275:62-75.
    >> Share

  518. KIDD SA, D'Arcey J, Tackaberry-Giddens L, Asuncion TR, et al
    App for independence: A feasibility randomized controlled trial of a digital health tool for schizophrenia spectrum disorders.
    Schizophr Res. 2024;275:52-61.
    >> Share

  519. ZHU Z, Roy D, Feng S, Vogler B, et al
    AI-based medication adherence prediction in patients with schizophrenia and attenuated psychotic disorders.
    Schizophr Res. 2024;275:42-51.
    >> Share

  520. ODUOLA S, D'Andrea G, Smimmo D, Menchetti M, et al
    Pathways to care: Source of referral at first-episode psychosis, a cross-country comparison between Bologna and South London.
    Schizophr Res. 2024;275:35-41.
    >> Share

  521. DAZZI F, Shafer A
    Meta-analysis of the factor structure of the Scale for the Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS).
    Schizophr Res. 2024;274:464-472.
    >> Share

  522. BABADI B, Dokholyan K, DeTore NR, Tootell RBH, et al
    Arousal responses to personal space intrusions in psychotic illness: A virtual reality study.
    Schizophr Res. 2024;274:158-170.
    >> Share

    November 2024
  523. SAGER REH, North HF, Weissleder C, Clearwater MS, et al
    Divergent changes in complement pathway gene expression in schizophrenia and bipolar disorder: Links to inflammation and neurogenesis in the subependymal zone.
    Schizophr Res. 2024;275:25-34.
    >> Share

  524. CHONG YY, Chien WT, Mou H, Ip CK, et al
    Acceptance and Commitment Therapy-based Lifestyle Counselling Program for people with early psychosis on physical activity: A pilot randomized controlled trial.
    Schizophr Res. 2024;275:1-13.
    >> Share

  525. LAPPAS AS, Ioannou M, Christodoulou NG
    Histopathological evidence of cellular alterations in the dentate gyrus is associated with aberrant RB1CC1-ATG16L1 expression in the hippocampus among older adults with chronic schizophrenia: A pilot post-mortem study.
    Schizophr Res. 2024;275:14-24.
    >> Share

  526. HARDY A, Taylor KM, Grant A, Christie L, et al
    Co-designing technology to improve psychological therapy for psychosis: SloMo, a blended digital therapy for fear of harm from others.
    Schizophr Res. 2024;274:526-534.
    >> Share

  527. LI J, He J, Ren H, Li Z, et al
    Free-water imaging in subcortical gray matter in schizophrenia patients with persistent auditory verbal hallucinations.
    Schizophr Res. 2024;274:517-525.
    >> Share

  528. KESHAVAN MS, Seif P, Tandon R
    Muscarinic deficits - part of a cholinergic-dopaminergic- glutamatergic imbalance in schizophrenia?
    Schizophr Res. 2024;274:508-510.
    >> Share

  529. CAI H, Shen B, Long JX, Huang XL, et al
    Network analysis of psychotic symptoms in schizophrenia.
    Schizophr Res. 2024;274:501-507.
    >> Share

  530. POKORNY VJ, Sponheim SR, Olman CA
    Orientation-dependent contextual modulation of contrast in schizophrenia.
    Schizophr Res. 2024;274:492-500.
    >> Share

  531. JIMENEZ AM, Green MF
    Self-disturbance in schizophrenia: Updating the research and bridging the gaps.
    Schizophr Res. 2024;274:489-491.
    >> Share

  532. DENIS D, Baran B, Mylonas D, Spitzer C, et al
    Sleep oscillations and their relations with sleep-dependent memory consolidation in early course psychosis and first-degree relatives.
    Schizophr Res. 2024;274:473-485.
    >> Share

  533. SUN X, Li M, Qiu Y, Su Q, et al
    Plasma NGAL, not IFN-gamma, predicts early treatment response in drug-naive Chinese Han schizophrenia patients.
    Schizophr Res. 2024;274:457-463.
    >> Share

  534. LUCKHOFF HK, Del Re EC, Smit R, Kilian S, et al
    Sex versus gender associations with depressive symptom trajectories over 24 months in first-episode schizophrenia spectrum disorders.
    Schizophr Res. 2024;274:450-456.
    >> Share

  535. GEBREEGZIABHERE Y, Habatmu K, Cella M, Alem A, et al
    Validation of the Amharic version of Cognitive Assessment Interview (CAI-A) in people with schizophrenia in Ethiopia.
    Schizophr Res. 2024;274:441-449.
    >> Share

  536. XU L, Yang W, Fan R, Wu Y, et al
    A novel digital intervention for improving cognitive impairment in patients with chronic schizophrenia: A randomized clinical trial.
    Schizophr Res. 2024;274:433-440.
    >> Share

  537. YAEGASHI H, Haga M, Misawa F, Mizuno Y, et al
    Intentional non-adherence to antipsychotic medication in patients with schizophrenia.
    Schizophr Res. 2024;274:427-432.
    >> Share

  538. NI P, Ma Y, Chung S
    Mitochondrial dysfunction in psychiatric disorders.
    Schizophr Res. 2024;273:62-77.
    >> Share

    October 2024
  539. ALI MP, Tiles-Sar N, Simons CJP, Osicka DA, et al
    Does stigma leave its mark? The interplay between negative effects of perceived stigma with positive effect of self-esteem on long-term social functioning in schizophrenia.
    Schizophr Res. 2024;274:417-426.
    >> Share

  540. ANDERSON JC, Seitz DP, Crockford D, Addington D, et al
    Quality indicators for schizophrenia care: A scoping review.
    Schizophr Res. 2024;274:406-416.
    >> Share

  541. BERGSON Z, Ahmed AO, Bell J, Butler PD, et al
    Visual remediation of contrast processing impairments in schizophrenia: A preliminary clinical trial.
    Schizophr Res. 2024;274:396-405.
    >> Share

  542. REZAEI K, Sanchez-Rico M, Garces-Gonzalez MS, Vandel P, et al
    Mortality among older people with late-onset and non-late-onset schizophrenia: A 5-year prospective multicenter study.
    Schizophr Res. 2024;274:393-395.
    >> Share

  543. JUCKEL G
    Reply to Dyadic interaction in schizophrenia - A promising new avenue of investigation?
    Schizophr Res. 2024;274:392.
    >> Share

  544. ABDULLAHI A, Wong TW, Ng SS
    Understanding the potential mechanisms of disease modifying effects of physical activity and exercise in people with schizophrenia.
    Schizophr Res. 2024;274:381-391.
    >> Share

  545. TIAN J, Dong S, Nomura N, Siafis S, et al
    Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials.
    Schizophr Res. 2024;274:360-373.
    >> Share

  546. LI S, Lu C, Liu N, Li Y, et al
    Association between auditory P300 event-related potential and suicidal thoughts and behaviors in first-episode antipsychotic-naive patients with schizophrenia.
    Schizophr Res. 2024;274:352-359.
    >> Share

  547. GENG C, Chen C
    Bidirectional Mendelian randomization to explore the causal relationships between schizophrenia and narcolepsy.
    Schizophr Res. 2024;274:345-351.
    >> Share

  548. ISMAIL Z, Meehan SR, Farovik A, Miguelez M, et al
    Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale.
    Schizophr Res. 2024;274:337-344.
    >> Share

  549. DEWAN M, Campbell Daniels E, Hunt JE, Bryant EA, et al
    Aberrant salience signaling in auditory processing in schizophrenia: Evidence for abnormalities in both sensory processing and emotional reactivity.
    Schizophr Res. 2024;274:329-336.
    >> Share

  550. SABBAH SG, Northoff G
    Basic self-disturbance in schizophrenia: From neuronal to mental topographic dedifferentiation.
    Schizophr Res. 2024;274:327-328.
    >> Share

  551. ULIANA DL, Martinez A, Grace AA
    THPP-1 PDE10A inhibitor reverses the cognitive deficits and hyperdopaminergic state in a neurodevelopment model of schizophrenia.
    Schizophr Res. 2024;274:315-326.
    >> Share

  552. DE BEER F, Wijnen B, Wouda L, Koops S, et al
    Antipsychotic dopamine D(2) affinity and negative symptoms in remitted first episode psychosis patients.
    Schizophr Res. 2024;274:299-306.
    >> Share

  553. ZHOU Y, Zheng Q, Tian J
    Letter to the editor regarding "The effects of mindful exercise on cognition in patients with schizophrenia: A systematic review and meta-analysis of randomized controlled trials".
    Schizophr Res. 2024;274:288-289.
    >> Share

  554. JAMBAWO SM, Owolewa R, Jambawo TT
    The effectiveness of peer support on the recovery and empowerment of people with schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2024;274:270-279.
    >> Share

  555. FOERSTER FR, Joos E, Martin B, Coull JT, et al
    Corrigendum to "Self and time in individuals with schizophrenia: A motor component?" [Schizophr. Res. 272 (2024) 12-19 (October)].
    Schizophr Res. 2024;274:269.
    >> Share

  556. CHENG W, Zhao M, Zhang X, Zhou X, et al
    Schizophrenia and antipsychotic medications present distinct and shared gut microbial composition: A meta-analysis.
    Schizophr Res. 2024;274:257-268.
    >> Share

  557. SARANGI S, Sharma S, Nahak SK, Panda AK, et al
    Association of CACNA1C polymorphisms (rs1006737, rs4765905, rs2007044) with schizophrenia: A meta-analysis and trial sequential analysis.
    Schizophr Res. 2024;274:247-256.
    >> Share

  558. COWAN HR
    Aligning phenomenology and neuroscience of the basic and narrative self in schizophrenia.
    Schizophr Res. 2024;274:245-246.
    >> Share

  559. HAJDUK M, Park S, Pinkham AE
    Dyadic interaction in schizophrenia - A promising new avenue of investigation?
    Schizophr Res. 2024;274:243-244.
    >> Share

  560. BRANDT AS, Nucifora FC Jr, Zandi PP, Margolis RL, et al
    The timing and severity of clozapine-associated neutropenia in the US: Is the risk overstated?
    Schizophr Res. 2024;272:104-109.
    >> Share

  561. BJORNESTAD J, Tjora T, Joa I, Johannessen JO, et al
    Early and later remission from clinical high risk of psychosis. A latent class and predictor analysis.
    Schizophr Res. 2024;274:237-242.
    >> Share

    September 2024
  562. JOHNSTONE S, Hubbard AN, Schenkel A, Ashare RL, et al
    Effects of acute smoking abstinence among people with schizophrenia: A systematic review and meta-analysis of laboratory studies.
    Schizophr Res. 2024;274:220-236.
    >> Share

  563. WRIGHT AC, McKenna A, Tice JA, Rind DM, et al
    A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia.
    Schizophr Res. 2024;274:212-219.
    >> Share

  564. RESTELLINI R, Golay P, Jenni R, Baumann PS, et al
    Winter birth: A factor of poor functional outcome in a Swiss early psychosis cohort.
    Schizophr Res. 2024;274:206-211.
    >> Share

  565. WANG X, Wang RX, Bian C, Liu FY, et al
    Sleep quality, psychological resilience, family resilience, social support, and mental disability in patients with chronic schizophrenia: A cross-sectional study.
    Schizophr Res. 2024;274:199-205.
    >> Share

  566. POLETTI M, Raballo A
    Schizophrenia spectrum disorders in children and adolescents: Clinical, phenomenological, diagnostic, and prognostic features across subtypes.
    Schizophr Res. 2024;274:189-198.
    >> Share

  567. LEE HS, Sangimino M, Baxter T, Buck L, et al
    Self-other boundary under social threat in schizophrenia.
    Schizophr Res. 2024;274:182-188.
    >> Share

  568. LUCKHOFF H, Smit R, Del Re E, Kilian S, et al
    Associations of sexual orientation with symptom profiles in first-episode schizophrenia spectrum disorders.
    Schizophr Res. 2024;274:180-181.
    >> Share

  569. CABUK T, Sevim N, Mutlu E, Yagcioglu AEA, et al
    Corrigendum to "Natural language processing for defining linguistic features in schizophrenia: A sample from Turkish speakers" [Schizophr. Res. 266 (2024) 183-189].
    Schizophr Res. 2024;274:178-179.
    >> Share

  570. ZILBERSTEIN T, Shomron B
    The depiction of people with schizophrenia in news media: A cross-national analysis.
    Schizophr Res. 2024;274:171-177.
    >> Share

  571. PHALEN P, Jones N, Davis B, Sarpal D, et al
    Suicidality among clients in a network of coordinated specialty care (CSC) programs for first-episode psychosis: Rates, changes in rates, and their predictors.
    Schizophr Res. 2024;274:150-157.
    >> Share

  572. PELIZZA L, Leuci E, Quattrone E, Azzali S, et al
    Rates and predictors of service disengagement in first episode psychosis: Results from a 2-year follow-up study in an Italian real-world care setting.
    Schizophr Res. 2024;274:142-149.
    >> Share

  573. MOLHO W, Stiltner B, Raymond N, Kiely C, et al
    Retinal electrophysiological alterations are associated with cognition in early course psychosis.
    Schizophr Res. 2024;274:137-141.
    >> Share

  574. SNELLEKSZ M, Scarr E, Dean B
    Lower levels of kainate receptors, but not AMPA or NMDA receptors, in Brodmann's area (BA) 9, but not BA 10, from a subgroup of people with schizophrenia who have a marked deficit in cortical muscarinic M1 receptors.
    Schizophr Res. 2024;274:129-136.
    >> Share

  575. KIZILAY E, Arslan B, Verim B, Demirlek C, et al
    Automated linguistic analysis in youth at clinical high risk for psychosis.
    Schizophr Res. 2024;274:121-128.
    >> Share

  576. SU Q, Xuekelaiti Z, Ma H, Qiu Y, et al
    The associations between duration of untreated psychosis, growth factors, and neurocognition in patients with drug-naive schizophrenia.
    Schizophr Res. 2024;274:113-120.
    >> Share

  577. SHAKIR M, van Harten PN, Hoogendoorn AW, Willems AE, et al
    Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. The SwAP trial II: Results on side effects.
    Schizophr Res. 2024;274:105-112.
    >> Share

  578. GARTNER SP, Olesen TB, Jensen H, Mortensen LM, et al
    Recognition of schizophrenia and quality of treatment during the COVID-19 pandemic: A Danish nationwide study.
    Schizophr Res. 2024;274:98-104.
    >> Share

  579. WU C, She S, Gong B, Li Q, et al
    Spontaneous neural activity underlying neutral and happy speech recognition in noise and its association with psychiatric symptoms in patients with schizophrenia.
    Schizophr Res. 2024;274:90-97.
    >> Share

  580. SALVI V, Tripodi B, Cerveri G, Migliarese G, et al
    Insulin-resistance as a modifiable pathway to cognitive dysfunction in schizophrenia: A systematic review.
    Schizophr Res. 2024;274:78-89.
    >> Share

  581. LEE R, Griffiths SL, Gkoutos GV, Wood SJ, et al
    Predicting treatment resistance in positive and negative symptom domains from first episode psychosis: Development of a clinical prediction model.
    Schizophr Res. 2024;274:66-77.
    >> Share

  582. HORAN WP, Targum SD, Claxton A, Kaul I, et al
    Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.
    Schizophr Res. 2024;274:57-65.
    >> Share

  583. RAJ V, Stogios N, Agarwal SM, Cheng AJ, et al
    The neuromuscular basis of functional impairment in schizophrenia: A scoping review.
    Schizophr Res. 2024;274:46-56.
    >> Share

  584. KRAMER M, Fink F, Campo LA, Akinci E, et al
    Video analysis of interaction in schizophrenia reveals functionally relevant abnormalities.
    Schizophr Res. 2024;274:24-32.
    >> Share

  585. THOMPSON JL, Silverstein SM, Papathomas TV, Keane BP, et al
    Hallucinations and the depth-inversion illusion in schizophrenia.
    Schizophr Res. 2024;274:21-23.
    >> Share

  586. STARZER M, Hansen HG, Hjorthoj C, Albert N, et al
    Long-term quality of life and social disconnection 20 years after a first episode psychosis, results from the 20-year follow-up of the OPUS trial.
    Schizophr Res. 2024;274:33-45.
    >> Share

  587. ALESSANDRO DL, Leuci E, Quattrone E, Azzali S, et al
    Obsessive-compulsive symptoms in individuals at clinical high risk for psychosis: A 2-year longitudinal study.
    Schizophr Res. 2024;274:11-20.
    >> Share

  588. GREENWAY FT, Weal M, Palmer-Cooper EC
    Hybrid mHealth care: Patient perspectives of blended treatments for psychosis. A systematic review.
    Schizophr Res. 2024;274:1-10.
    >> Share

  589. SMUCNY J, Wood A, Davidson IN, Carter CS, et al
    Are factors that predict conversion to psychosis associated with initial transition to a high risk state? An adolescent brain cognitive development study analysis.
    Schizophr Res. 2024;272:128-132.
    >> Share

  590. TERENZI D, Silvetti M, Zoccolan G, Rumiati RI, et al
    The impact of subclinical psychotic symptoms on delay and effort discounting: Insights from behavioral, computational, and electrophysiological methods.
    Schizophr Res. 2024;271:271-280.
    >> Share

  591. HARVEY PD, Davidson M, Saoud JB, Kuchibhatla R, et al
    Prevalence of prominent and predominant negative symptoms across different criteria for negative symptom severity and minimal positive symptoms: A comparison of different criteria.
    Schizophr Res. 2024;271:246-252.
    >> Share

  592. GONZALO-DE MIGUEL A, Abascal-Peiro S, Cegla-Schvartzman FB, Martinez-Ales G, et al
    Antipsychotic use in a large community sample of patients with delusional disorder.
    Schizophr Res. 2024;271:194-199.
    >> Share

  593. SARPAL DK
    Astrocytic contributions to clozapine response: Potential support for a psychopharmacologic glial process.
    Schizophr Res. 2024;271:142-143.
    >> Share

  594. ARORA S, Suhas S, Gowda GS, Reddi VSK, et al
    DRESS syndrome, seizures, and myocarditis on low dose clozapine - A case report.
    Schizophr Res. 2024;271:391-393.
    >> Share

    August 2024
  595. REAVIS EA, Wynn JK, Green MF
    Pre-stimulus EEG phase coherence predicts visual target detection failures in schizophrenia: A pilot study.
    Schizophr Res. 2024;272:112-119.
    >> Share

  596. ELKIS H, Melzer-Ribeiro DL, Napolitano IC
    Response to Markota et al. "Clinical heterogeneity and ECT in patients with clozapine resistant schizophrenia" SCHRES-D-24-00481.
    Schizophr Res. 2024;272:110-111.
    >> Share

  597. LIZANO P, Karmacharya R
    Harnessing stem cell-based approaches for clinically meaningful discoveries in schizophrenia.
    Schizophr Res. 2024 Aug 29:S0920-9964(24)00377.
    >> Share

  598. SONG SH, Hayirli TC, Shore O, Coconcea C, et al
    Atypical presentation of schizophrenia with ablution avoidance: A case report.
    Schizophr Res. 2024;272:96-97.
    >> Share

  599. MLAKAR V, Akkouh I, Halff EF, Srivastava DP, et al
    Telomere biology and its maintenance in schizophrenia spectrum disorders: Exploring links to cognition.
    Schizophr Res. 2024;272:89-95.
    >> Share

  600. COTTER SJ, Smith CL, Gao CX, Khanna R, et al
    What impact did the COVID-19 pandemic have on psychosis and the delivery of early intervention psychosis services?
    Schizophr Res. 2024;272:79-88.
    >> Share

  601. MARKOTA M, Croarkin PE, Coombes BJ, Gentry MT, et al
    Clinical heterogeneity and ECT in patients with clozapine resistant schizophrenia.
    Schizophr Res. 2024;272:77-78.
    >> Share

  602. SHIRINBAKHSHMASOLEH M, Aboulatta L, Leong C, Riel H, et al
    The impact of COVID-19 public health measures on the utilization of antipsychotics in schizophrenia in Manitoba - A population-based study.
    Schizophr Res. 2024;272:69-76.
    >> Share

  603. TARGUM SD, Ge T, Asgharnejad M, Reksoprodjo P, et al
    Use of video-recordings of site-based interviews for quality assurance in a study of subjects with schizophrenia and persistent negative symptoms.
    Schizophr Res. 2024;272:61-68.
    >> Share

  604. JIMENEZ AM, Green MF
    Disturbance at the self-other boundary in schizophrenia: Linking phenomenology to clinical neuroscience.
    Schizophr Res. 2024;272:51-60.
    >> Share

  605. LIU Z, Sun YH, Ren Y, Perez JM, et al
    Upregulated solute-carrier family genes in the hippocampus of schizophrenia can be rescued by antipsychotic medications.
    Schizophr Res. 2024;272:39-50.
    >> Share

  606. REDLICH BOSSY M, Muller DR, Jabat M, Burrer A, et al
    Relationship between psychopathological symptoms and dimensions in inpatients with schizophrenia: A network analysis.
    Schizophr Res. 2024;272:36-38.
    >> Share

  607. POLETTI M, Raballo A
    Ontogenesis of self-disorders in the schizophrenia spectrum: A phenomenological neuro-developmental model.
    Schizophr Res. 2024;272:26-35.
    >> Share

  608. GU B, Rose J, Kurtz MM
    Cognitive training for schizophrenia: Do race and ethnicity matter?
    Schizophr Res. 2024;272:20-25.
    >> Share

  609. FOERSTER FR, Joos E, Martin B, Coull JT, et al
    Self and time in individuals with schizophrenia: A motor component?
    Schizophr Res. 2024;272:12-19.
    >> Share

  610. LOCHMANN VAN BENNEKOM MWH, IntHout J, Gijsman HJ, Akdede BBK, et al
    Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data.
    Schizophr Res. 2024;272:1-11.
    >> Share

  611. MESSINIS A, Panteli E, Paraskevopoulou A, Zymarikopoulou AK, et al
    Altered lipidomics biosignatures in schizophrenia: A systematic review.
    Schizophr Res. 2024;271:380-390.
    >> Share

  612. HE Q, Zhu P, Liu X, Huo C, et al
    Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis.
    Schizophr Res. 2024;271:371-379.
    >> Share

  613. PIRAS M, Popovic I, Ranjbar S, Grosu C, et al
    Aripiprazole dose associations with metabolic adverse effect: Results from a longitudinal study.
    Schizophr Res. 2024;270:403-409.
    >> Share

  614. KOHLER-FORSBERG O, Hojlund M, Rohde C, Kemp AF, et al
    Efficacy and acceptability of interventions to reduce antipsychotic polypharmacy: A systematic review and meta-analysis of randomized clinical trials.
    Schizophr Res. 2024;270:135-143.
    >> Share

    July 2024
  615. VAN DYNE A, Wu TC, Adamowicz DH, Lee EE, et al
    Longitudinal relationships between BMI and hs-CRP among people with schizophrenia.
    Schizophr Res. 2024;271:337-344.
    >> Share

  616. PROKOPEZ CR, Cesarini JI, Corral RM, Sere L, et al
    Renaming schizophrenia in Argentina: Could a change of name resolve the stigma? Results from a national survey.
    Schizophr Res. 2024;271:334-336.
    >> Share

  617. EACK SM
    Defeatist beliefs about performance are important treatment targets for negative symptoms in the early course of schizophrenia.
    Schizophr Res. 2024;271:332-333.
    >> Share

  618. KENNEDY L, Ku BS, Addington J, Amir CM, et al
    Occasional cannabis use is associated with higher premorbid functioning and IQ in youth at clinical high-risk (CHR) for psychosis: Parallel findings to psychosis cohorts.
    Schizophr Res. 2024;271:319-331.
    >> Share

  619. CHEN CC, Howie J, Ebrahimi M, Teymouri K, et al
    Analysis of the complement component C4 gene with schizophrenia subphenotypes.
    Schizophr Res. 2024;271:309-318.
    >> Share

  620. SALVADE A, Golay P, Abrahamyan L, Bonnarel V, et al
    Gender differences in first episode psychosis: Some arguments to develop gender specific treatment strategies.
    Schizophr Res. 2024;271:300-308.
    >> Share

  621. WANG Y, Ouyang L, Fan L, Zheng W, et al
    Functional and structural abnormalities of thalamus in individuals at early stage of schizophrenia.
    Schizophr Res. 2024;271:292-299.
    >> Share

  622. SICOTTE R, D'Andrea G, Dumais A, Crocker AG, et al
    Aggressive behaviors in first-episode psychosis: Distinction between the premorbid phase and the onset of psychosis.
    Schizophr Res. 2024;271:283-291.
    >> Share

  623. MILLGATE E, Smart SE, Pardinas AF, Kravariti E, et al
    Corrigendum to "Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study" [Schizophr. Res. volume 225 (May 2023) 173-181].
    Schizophr Res. 2024;270:495-496.
    >> Share

  624. ASAI T, Ikegame T, Satomura Y, Kumagai E, et al
    Lower plasma betaine levels in men at clinical high risk for psychosis: Findings from a metabolomics investigation.
    Schizophr Res. 2024;271:281-282.
    >> Share

  625. STEPHENS RL, Leavitt I, Cornea E, Jarskog LF, et al
    Early cognitive development and psychopathology in children at familial high risk for schizophrenia.
    Schizophr Res. 2024;271:262-270.
    >> Share

  626. ABEL DB, Vohs JL, Salyers MP, Wu W, et al
    Social anhedonia in the daily lives of people with schizophrenia: Examination of anticipated and consummatory pleasure.
    Schizophr Res. 2024;271:253-261.
    >> Share

  627. CHEN CR, Lee YW, Chen TT, Hsu CW, et al
    The effects of mindful exercise on cognition in patients with schizophrenia: A systematic review and meta-analysis of randomized controlled trials.
    Schizophr Res. 2024;271:237-245.
    >> Share

  628. CORADDUZZA D, di Lorenzo B, Sedda S, Nivoli AM, et al
    Investigating bilirubin concentrations in schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2024;271:228-236.
    >> Share

  629. SOLEIMANI MF, Ayubi E, Khosronezhad S, Hasler G, et al
    Human endogenous retroviruses type W (HERV-) activation and schizophrenia: A meta-analysis.
    Schizophr Res. 2024;271:220-227.
    >> Share

  630. COSTA DFB, Rossignoli P, Pontarolli DRS, Junior PC, et al
    Increased COVID-19 mortality in patients with schizophrenia: A retrospective study in Brazil.
    Schizophr Res. 2024;271:200-205.
    >> Share

  631. KADIVAR A, Ilapakurti M, Dobkins K, Cadenhead KS, et al
    Visual contrast sensitivity in clinical high risk and first episode psychosis.
    Schizophr Res. 2024;271:186-193.
    >> Share

  632. WINKLER K, Lincoln TM, Wiesjahn M, Jung E, et al
    How does loneliness interact with positive, negative and depressive symptoms of psychosis? New insights from a longitudinal therapy process study.
    Schizophr Res. 2024;271:179-185.
    >> Share

  633. RYCHAGOV N, Del Re EC, Zeng V, Oykhman E, et al
    Gyrification across psychotic disorders: A bipolar-schizophrenia network of intermediate phenotypes study.
    Schizophr Res. 2024;271:169-178.
    >> Share

  634. KENNEDY KP, Zito MF, Marder SR
    Does relapse cause illness progression in first-episode psychosis? A review.
    Schizophr Res. 2024;271:161-168.
    >> Share

  635. CHINTOH A, Liu L, Braun A, Akseer S, et al
    Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis.
    Schizophr Res. 2024;271:153-160.
    >> Share

  636. KOSTER M, van der Pluijm M, van de Giessen E, Schrantee A, et al
    The association of tobacco smoking and metabolite levels in the anterior cingulate cortex of first-episode psychosis patients: A case-control and 6-month follow-up (1)H-MRS study.
    Schizophr Res. 2024;271:144-152.
    >> Share

  637. AL-CHALABI N, Nader G, Fischer C, Graff A, et al
    Effect of DNA methylation and AUDIT-C polygenic scores on alcohol use disorder comorbidity in psychoses: No evidence of epigenetic basis of polygenic risk.
    Schizophr Res. 2024;271:138-141.
    >> Share

  638. CARRION RE, Ku BS, Dorvil S, Auther AM, et al
    Neurocognition in adolescents and young adults at clinical high risk for psychosis: Predictive stability for social and role functioning.
    Schizophr Res. 2024;271:129-137.
    >> Share

  639. LI R, Cao M, Fu D, Wei W, et al
    Deciphering language disturbances in schizophrenia: A study using fine-tuned language models.
    Schizophr Res. 2024;271:120-128.
    >> Share

  640. FEOLA B, Flook EA, Seo DJ, Fox V, et al
    Altered brain and physiological stress responses in early psychosis.
    Schizophr Res. 2024;271:112-119.
    >> Share

  641. KREIS I, Lagerberg TV, Wold KF, Asbo G, et al
    Behind the heterogeneity in the long-term course of first-episode psychosis: Different psychotic symptom trajectories are associated with different patterns of cannabis and stimulant use.
    Schizophr Res. 2024;271:91-99.
    >> Share

  642. LISBOA JRF, Costa O, Pakes GH, Colodete DAE, et al
    Perineuronal net density in schizophrenia: A systematic review of postmortem brain studies.
    Schizophr Res. 2024;271:100-109.
    >> Share

  643. LAK M, Jafarpour A, Shahrbaf MA, Lak M, et al
    The effect of physical exercise on cognitive function in schizophrenia patients: A GRADE assessed systematic review and meta-analysis of controlled clinical trials.
    Schizophr Res. 2024;271:81-90.
    >> Share

  644. MACHIRAJU SN, Wyss J, Light G, Braff DL, et al
    Novel N100 area reliably captures aberrant sensory processing and is associated with neurocognition in early psychosis.
    Schizophr Res. 2024;271:71-80.
    >> Share

  645. BIONDI M, Marino M, Mantini D, Spironelli C, et al
    Unveiling altered connectivity between cognitive networks and cerebellum in schizophrenia.
    Schizophr Res. 2024;271:47-58.
    >> Share

  646. VARATHAN A, Senthooran S, Jeyananthan P
    Role of different omics data in the diagnosis of schizophrenia disorder: A machine learning study.
    Schizophr Res. 2024;271:38-46.
    >> Share

  647. DROSOS P, Johnsen E, Bartz-Johannessen CA, Larsen TK, et al
    Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine.
    Schizophr Res. 2024;271:9-18.
    >> Share

  648. LATRECHE I, Slatnia S, Kazar O, Harous S, et al
    Identification and diagnosis of schizophrenia based on multichannel EEG and CNN deep learning model.
    Schizophr Res. 2024;271:28-35.
    >> Share

  649. DWYER GE, Johnsen E, Hugdahl K
    NMDAR dysfunction and the regulation of dopaminergic transmission in schizophrenia.
    Schizophr Res. 2024;271:19-27.
    >> Share

  650. CORBERA S, Wexler BE, Bell MD, Pittman B, et al
    Disentangling negative and positive symptoms in schizophrenia and autism spectrum disorder.
    Schizophr Res. 2024;271:1-8.
    >> Share

  651. ZAMPERONI G, Tan EJ, Sumner PJ, Rossell SL, et al
    Exploring the conceptualisation, measurement, clinical utility and treatment of formal thought disorder in psychosis: A Delphi study.
    Schizophr Res. 2024;270:486-493.
    >> Share

  652. LIU L, Ren D, Li K, Ji L, et al
    Unraveling schizophrenia's genetic complexity through advanced causal inference and chromatin 3D conformation.
    Schizophr Res. 2024;270:476-485.
    >> Share

  653. BARNBY JM, Haslbeck JMB, Rosen C, Sharma R, et al
    Modelling the longitudinal dynamics of paranoia in psychosis: A temporal network analysis over 20 years.
    Schizophr Res. 2024;270:465-475.
    >> Share

  654. LUI SSY, Lam EHY, Wang LL, Leung PBM, et al
    Negative symptoms in treatment-resistant schizophrenia and its relationship with functioning.
    Schizophr Res. 2024;270:459-464.
    >> Share

  655. THIBAULT M, Romain AJ, Tessier C, Theagene JMJ, et al
    Feasibility and Acceptability of a Physical Activity Group Program Using telerehabilitation during the COVID-19 Pandemic in Multiple early Intervention for Psychosis Services.
    Schizophr Res. 2024;270:451-458.
    >> Share

  656. WOLD KF, Ottesen A, Flaaten CB, Kreis I, et al
    Childhood trauma and treatment resistance in first-episode psychosis: Investigating the role of premorbid adjustment and duration of untreated psychosis.
    Schizophr Res. 2024;270:441-450.
    >> Share

  657. MIHURA JL, Boyette LL, Gorner KJ, Kleiger JH, et al
    Improving dependability in science: A critique on the psychometric qualities of the HiTOP psychosis superspectrum.
    Schizophr Res. 2024;270:433-440.
    >> Share

  658. LIN D, Fu Z, Liu J, Perrone-Bizzozero N, et al
    Association between the oral microbiome and brain resting state connectivity in schizophrenia.
    Schizophr Res. 2024;270:392-402.
    >> Share

  659. GALUBA V, Cordes J, Feyerabend S, Riesbeck M, et al
    Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study.
    Schizophr Res. 2024;270:383-391.
    >> Share

  660. MORRIS A, Reed T, McBride G, Chen J, et al
    Dietary interventions to improve metabolic health in schizophrenia: A systematic literature review of systematic reviews.
    Schizophr Res. 2024;270:372-382.
    >> Share

  661. MORFINI F, Bauer CCC, Zhang J, Whitfield-Gabrieli S, et al
    Targeting the superior temporal gyrus with real-time fMRI neurofeedback: A pilot study of the indirect effects on self-referential processes in schizophrenia.
    Schizophr Res. 2024;270:358-365.
    >> Share

  662. DING Y, Hou W, Wang C, Sha S, et al
    Longitudinal changes in cognitive function in early psychosis: a meta-analysis with the MATRICS consensus cognitive battery (MCCB).
    Schizophr Res. 2024;270:349-357.
    >> Share

  663. HEUSCHEN CBBCM, Bolhuis K, Zantvoord JB, Bockting CL, et al
    Self-reported suicidal ideation among individuals with first episode psychosis and healthy controls: Findings from the international multicentre EU-GEI study.
    Schizophr Res. 2024;270:339-348.
    >> Share

  664. LIU Y, Wu H, Liu B, Chen S, et al
    Multi-omics analysis reveals the impact of gut microbiota on antipsychotic-induced weight gain in schizophrenia.
    Schizophr Res. 2024;270:325-338.
    >> Share

  665. LIN PY, Chen YH, Chang YJ, Chen JW, et al
    Deep learning for schizophrenia classification based on natural language processing-A pilot study.
    Schizophr Res. 2024;270:323-324.
    >> Share

  666. CORRIPIO I, Fraguas D, Garcia-Portilla MP, Olivares JM, et al
    Functioning in schizophrenia: Recommendations of an expert panel.
    Schizophr Res. 2024;270:317-322.
    >> Share

  667. MANA L, Schwartz-Palleja M, Vila-Vidal M, Deco G, et al
    Overview on cognitive impairment in psychotic disorders: From impaired microcircuits to dysconnectivity.
    Schizophr Res. 2024;269:132-143.
    >> Share

  668. ELKIS H, Melzer-Ribeiro DL, Napolitano IC, Correll CU, et al
    The danger of averages in the context of heterogeneity: Response to the letter to the editor of SCZ RES- role of ECT in patients with CRS-Markota et al. 2024.
    Schizophr Res. 2024;269:120-122.
    >> Share

    June 2024
  669. JEONG JH, Kim SW, Yu JC, Won SH, et al
    Clinical, cognitive, and functional characteristics of recent-onset psychosis with autistic features: A 2-year longitudinal study.
    Schizophr Res. 2024;270:304-316.
    >> Share

  670. SOURANDER A, Upadhyaya S, Surcel HM, Hinkka-Yli-Salomaki S, et al
    Maternal vitamin D levels during pregnancy and offspring schizophrenia.
    Schizophr Res. 2024;270:289-294.
    >> Share

  671. HU W, Ran X, Wu Z, Zhu H, et al
    Short-term antipsychotic treatment reduces functional connectivity of the striatum in first-episode drug-naive early-onset schizophrenia.
    Schizophr Res. 2024;270:281-288.
    >> Share

  672. HAMERS IMH, Brand BA, Begemann MJH, Weickert CS, et al
    The association of prolactin and gonadal hormones with cognition and symptoms in men with schizophrenia spectrum disorder: Divergent effects of testosterone and estrogen.
    Schizophr Res. 2024;270:273-280.
    >> Share

  673. IGLESIAS-MARTINEZ-ALMEIDA M, Campos-Rios A, Freiria-Martinez L, Rivera-Baltanas T, et al
    Characterization and modulation of voltage-gated potassium channels in human lymphocytes in schizophrenia.
    Schizophr Res. 2024;270:260-272.
    >> Share

  674. KURTULMUS A, Yildiz FBP
    The potential role of gamma-secretase complex in schizophrenia: Bridging neurodevelopmental and neurodegenerative hypotheses.
    Schizophr Res. 2024;270:258-259.
    >> Share

  675. MURTHY V, Hanson E, DeMartinis N, Asgharnejad M, et al
    INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia.
    Schizophr Res. 2024;270:249-257.
    >> Share

  676. JACOBSEN SL, Kohler-Forsberg O, Rohde C
    Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes?
    Schizophr Res. 2024;270:231-234.
    >> Share

  677. NOGUEIRA GN, Andrade AGM, Guimaraes APC, Gomes SP, et al
    Exploring substance use in first episode psychoses, what can we do more?
    Schizophr Res. 2024;270:229-230.
    >> Share

  678. SKIBA RM, Chinchani AM, Menon M, Lepage M, et al
    Overlap between individual differences in cognition and symptoms of schizophrenia.
    Schizophr Res. 2024;270:220-228.
    >> Share

  679. FILIP TF, Hellemann GS, Ventura J, Subotnik KL, et al
    Defeatist performance beliefs in individuals with recent-onset schizophrenia: Relationships with cognition and negative symptoms.
    Schizophr Res. 2024;270:212-219.
    >> Share

  680. HE H, Long J, Song X, Li Q, et al
    A connectome-wide association study of altered functional connectivity in schizophrenia based on resting-state fMRI.
    Schizophr Res. 2024;270:202-211.
    >> Share

  681. PARNAS J, Sandsten KE
    The phenomenological nature of schizophrenia and disorder of selfhood.
    Schizophr Res. 2024;270:197-201.
    >> Share

  682. TAN EJ, Rossell SL
    Exploring associations between trait symptoms and speech patterns in schizophrenia spectrum disorders: A mediation analysis.
    Schizophr Res. 2024;270:188-190.
    >> Share

  683. WANG C, Zhang Y, Chong JS, Zhang W, et al
    Altered functional connectivity subserving expressed emotion environments in schizophrenia: An fNIRS study.
    Schizophr Res. 2024;270:178-187.
    >> Share

  684. MOHN C, Ueland T, Haatveit B, Saether LS, et al
    Neurocognitive function and delusion severity in schizophrenia spectrum disorders.
    Schizophr Res. 2024;270:172-177.
    >> Share

  685. ZHANG R, Lei X, Ren J, Zhang C, et al
    The roles of extracellular vesicle-derived microRNAs in schizophrenia: A scoping review.
    Schizophr Res. 2024;270:162-164.
    >> Share

  686. TORRES-CARMONA E, Nakajima S, Iwata Y, Ueno F, et al
    Clozapine treatment and astrocyte activity in treatment resistant schizophrenia: A proton magnetic resonance spectroscopy study.
    Schizophr Res. 2024;270:152-161.
    >> Share

  687. BROBAKKEN MF, Nygard M, Vedul-Kjelsas E, Harvey PD, et al
    Everyday function in schizophrenia: The impact of aerobic endurance and skeletal muscle strength.
    Schizophr Res. 2024;270:144-151.
    >> Share

  688. DUNMON D, Schooler NR, Severe JB, Buckley PF, et al
    Insomnia and cardiovascular disease risk in schizophrenia.
    Schizophr Res. 2024;270:132-134.
    >> Share

  689. NASRALLAH HA
    Is self-disturbance in schizophrenia due to inter- and intra-hemispheric white matter dysconnectivity?
    Schizophr Res. 2024;270:129-131.
    >> Share

  690. SAKAKIBARA E, Satomura Y, Matsuoka J, Koike S, et al
    Abnormal resting-state hyperconnectivity in schizophrenia: A whole-head near-infrared spectroscopy study.
    Schizophr Res. 2024;270:121-128.
    >> Share

  691. NIBBIO G, Pinton IC, Barlati S, Stanga V, et al
    Predictors of psychosocial functioning in people diagnosed with schizophrenia spectrum disorders that committed violent offences and in those that did not: Results of the Recoviwel study.
    Schizophr Res. 2024;270:112-120.
    >> Share

  692. CHEN X, Huang H, Pu Z, Shi Y, et al
    Increased risk of atypical antipsychotics-induced metabolic syndrome associated with MIF CATT >5/6 among females with chronic schizophrenia.
    Schizophr Res. 2024;270:94-101.
    >> Share

  693. PANY S, Rawat K, Swami MK
    Sleep patterns in treated and untreated patients of schizophrenia.
    Schizophr Res. 2024;270:111.
    >> Share

  694. SHEINBAUM T, Gizdic A, Kwapil TR, Barrantes-Vidal N, et al
    A longitudinal study of the impact of childhood adversity dimensions on social and psychological factors and symptoms of psychosis, depression, and anxiety.
    Schizophr Res. 2024;270:102-110.
    >> Share

  695. SHEN C, Tong X, Ran J, Sun S, et al
    Associations between residential environments and late-onset schizophrenia in UK Biobank: Interaction with genetic risk factor.
    Schizophr Res. 2024;270:85-93.
    >> Share

  696. MOROSAN L, de Almeida ER, van der Tuin S, van den Berg D, et al
    The impact of daily social support on the associations between daily negative events and daily suspiciousness across different clinical stages of psychosis.
    Schizophr Res. 2024;270:76-84.
    >> Share

  697. DEFAYETTE AB, Silverstein SM, Pisani AR
    Social network structure as a biopsychosocial suicide prevention target for young people at clinical high-risk for psychosis.
    Schizophr Res. 2024;270:63-67.
    >> Share

  698. SANDSTEN KE, Jensen MT, Saebye D, Null K, et al
    Altered cardiac autonomic functioning associates with self-disorders in schizophrenia.
    Schizophr Res. 2024;270:57-62.
    >> Share

  699. CECERSKA-HERYC E, Polikowska A, Serwin N, Michalczyk A, et al
    The importance of oxidative biomarkers in diagnosis, treatment, and monitoring schizophrenia patients.
    Schizophr Res. 2024;270:44-56.
    >> Share

  700. MUKAI Y, Lupinacci R, Marder S, Snow-Adami L, et al
    Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial.
    Schizophr Res. 2024;270:37-43.
    >> Share

  701. ABDOLIZADEH A, Hosseini Kupaei M, Kambari Y, Amaev A, et al
    The effect of second-generation antipsychotics on anxiety/depression in patients with schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2024;270:11-36.
    >> Share

  702. DE LEON J
    Promoting safer and wider worldwide use of clozapine.
    Schizophr Res. 2024;268:1-6.
    >> Share

  703. NIITSU T, Yasui-Furukori N, Inada K, Kanazawa T, et al
    Current practice for clozapine-induced leukopenia in Japanese psychiatric hospitals: A nationwide survey.
    Schizophr Res. 2024;268:82-87.
    >> Share

  704. BAPTISTA T, Motuca M, Serrano A, Perez Lo Presti A, et al
    An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance.
    Schizophr Res. 2024;268:60-65.
    >> Share

  705. KUZO N, Blyzniuk B, Chumakov E, Seifritz E, et al
    Clozapine research standards in former USSR states: A systematic review of quality issues with recommendations for future harmonization with modern research standards.
    Schizophr Res. 2024;268:48-52.
    >> Share

  706. MEYER JM
    Making sense of norclozapine levels: 3 clinical axioms.
    Schizophr Res. 2024;268:289-292.
    >> Share

  707. VERDOUX H, Quiles C, de Leon J
    Optimizing antidepressant and clozapine co-prescription in clinical practice: A systematic review and expert recommendations.
    Schizophr Res. 2024;268:243-251.
    >> Share

  708. ZOLEZZI M, Eltorki Y
    A brief history and challenges of clozapine utilization in the Arab world.
    Schizophr Res. 2024;268:21-24.
    >> Share

  709. YANG Z, Takeuchi H, Yee JY, See YM, et al
    Once-daily versus divided dosing regimens of clozapine: A cross-sectional study in Singapore.
    Schizophr Res. 2024;268:66-73.
    >> Share

  710. MUNOZ-MANCHADO LI, Perez-Revuelta JI, Banerjee A, Galindo-Guarin L, et al
    Influence of time to clozapine prescription on the clinical outcome.
    Schizophr Res. 2024;268:189-192.
    >> Share

  711. SAGUD M, Breznoscakova D, Celofiga A, Chihai J, et al
    An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance.
    Schizophr Res. 2024;268:53-59.
    >> Share

  712. SANKARANARAYANAN A, Kazi S, Andrade C
    Prevalence and predictors of QTc prolongation in patients seen in a clozapine clinic in a real-world setting in Australia.
    Schizophr Res. 2024;268:145-149.
    >> Share

  713. SCHULTE PFJ, Veerman SRT, Bakker B, Bogers JPAM, et al
    Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?
    Schizophr Res. 2024;268:74-81.
    >> Share

  714. KIRILOCHEV O, Chumakov E, Kuzo N, Schoretsanitis G, et al
    A scoping review of literature on clozapine from former USSR states published in Russian language.
    Schizophr Res. 2024;268:38-47.
    >> Share

  715. CARSWELL O, Wilton LR, Nicholls K, Thomas V, et al
    A 12-month audit of clozapine associated myocarditis in a South Australian Local Health Network: The importance of screening and personalised titration.
    Schizophr Res. 2024;268:88-93.
    >> Share

  716. DE LEON J, Wang L, Simpson GM
    The introduction of clozapine at the Nathan Kline Institute in New York and its long-term consequences.
    Schizophr Res. 2024;268:14-20.
    >> Share

  717. LEUNG JG, Allen ND, Markota M
    A case series of clozapine titrations affected by inflammatory processes.
    Schizophr Res. 2024;268:94-97.
    >> Share

  718. KELLY DL, Glassman M, Wonodi I, Vyas G, et al
    Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial.
    Schizophr Res. 2024;268:312-322.
    >> Share

  719. CLARK SR, Wilton LR, Dawson JL, Chiew K, et al
    Dotting the I's and crossing the T's: A South Australian perspective on variability in troponin thresholds for myocarditis risk in clozapine treatment.
    Schizophr Res. 2024;268:114-117.
    >> Share

  720. RUAN CJ, Olmos I, Ricciardi C, Schoretsanitis G, et al
    Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies.
    Schizophr Res. 2024;268:293-301.
    >> Share

  721. LIN SK, Lane HY
    A brief history of clozapine use in Taiwan.
    Schizophr Res. 2024;268:34-37.
    >> Share

  722. GROVER S, Naskar C
    Patient and caregivers perspective about clozapine: A systematic review.
    Schizophr Res. 2024;268:223-232.
    >> Share

  723. KIKUCHI Y, Komatsu H, Otsuka Y, Ito F, et al
    Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects: A retrospective chart review of seven hospitals.
    Schizophr Res. 2024;268:98-106.
    >> Share

  724. SCHORETSANITIS G, Anil Yagcioglu AE, Ruan CJ, Eap CB, et al
    Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition.
    Schizophr Res. 2024;268:302-307.
    >> Share

  725. RUAN CJ, Wang CY, Zang YN, Liu CG, et al
    A brief history of clozapine in China with a look forward.
    Schizophr Res. 2024;268:25-28.
    >> Share

  726. VERDOUX H, Quiles C, de Leon J
    Risks and benefits of clozapine and lithium co-prescribing: A systematic review and expert recommendations.
    Schizophr Res. 2024;268:233-242.
    >> Share

    May 2024
  727. BARRUEL D, Hilbey J, Charlet J, Chaumette B, et al
    Predicting treatment resistance in schizophrenia patients: Machine learning highlights the role of early pathophysiologic features.
    Schizophr Res. 2024;270:1-10.
    >> Share

  728. SABBAH SG, Northoff G
    Global neural self-disturbance in schizophrenia: A systematic fMRI review.
    Schizophr Res. 2024;269:163-173.
    >> Share

  729. GALLESE V, Ardizzi M, Ferroni F
    Schizophrenia and the bodily self.
    Schizophr Res. 2024;269:152-162.
    >> Share

  730. VARAMBALLY S, Holla B, Venkatasubramanian G, Mullapudi T, et al
    Clinical effects of a yoga-based intervention for patients with schizophrenia - A six-month randomized controlled trial.
    Schizophr Res. 2024;269:144-151.
    >> Share

  731. MARKOTA M, Croarkin PE, Gentry MT, Leung JG, et al
    Role of electroconvulsive therapy in patients with clozapine-refractory schizophrenia.
    Schizophr Res. 2024;269:130-131.
    >> Share

  732. REN H, Li J, Zhou J, Chen X, et al
    Grey matter volume reduction in the frontotemporal cortex associated with persistent verbal auditory hallucinations in Chinese patients with chronic schizophrenia: Insights from a 3 T magnetic resonance imaging study.
    Schizophr Res. 2024;269:123-129.
    >> Share

  733. GABBERT T, Scheunemann J, Balzan RP, Doehring N, et al
    The contributions of risk-taking and impulsivity to jumping to conclusions in the psychosis spectrum.
    Schizophr Res. 2024;269:116-119.
    >> Share

  734. VILLA J, Campbell DG, Parrish EM, Jeon ME, et al
    Associations between fearlessness about death and suicidal ideation in individuals with psychosis.
    Schizophr Res. 2024;269:96-102.
    >> Share

  735. ADELINO MPM, Nunes MV, Nunes MFQ, Quarantini LC, et al
    Efficacy of sodium nitroprusside in the treatment of drug-naive subjects in first episode psychosis - An open label study.
    Schizophr Res. 2024;269:114-115.
    >> Share

  736. TORRES-CARMONA E, Ueno F, Iwata Y, Nakajima S, et al
    Elevated intrinsic cortical curvature in treatment-resistant schizophrenia: Evidence of structural deformation in functional connectivity areas and comparison with alternate indices of structure.
    Schizophr Res. 2024;269:103-113.
    >> Share

  737. BOSE A, Agarwal SM, Nawani H, Shivakumar V, et al
    Effect of add-on tDCS therapy for auditory hallucinations on frequency and duration deviant mismatch negativity in schizophrenia.
    Schizophr Res. 2024;269:93-95.
    >> Share

  738. AVERSA S, Ghanem J, Grunfeld G, Lemonde AC, et al
    Sociodemographic and clinical correlates of hallucinations in patients entering an early intervention program for first episode psychosis.
    Schizophr Res. 2024;269:86-92.
    >> Share

  739. ALLIENDE LM, Strauss GP, Yang LH, Mittal VA, et al
    Perceptions of stigma in youth at clinical high risk for psychosis and depressive symptomatology.
    Schizophr Res. 2024;269:79-85.
    >> Share

  740. KIM E, Redwood S, Liu F, Roche DJO, et al
    Pilot study indicates that a gluten-free diet lowers oxidative stress for gluten-sensitive persons with schizophrenia.
    Schizophr Res. 2024;269:71-78.
    >> Share

  741. CHIAPPELLI J, Savransky A, Ma Y, Gao S, et al
    Impact of lifetime stressor exposure on neuroenergetics in schizophrenia spectrum disorders.
    Schizophr Res. 2024;269:58-63.
    >> Share

  742. JOSE BJ, Antonio GA, Reveca GF
    Cortisol response in individuals with genetic risk of schizophrenia. Some considerations.
    Schizophr Res. 2024;269:56-57.
    >> Share

  743. FENG S, Huang Y, Li H, Zhou S, et al
    Dynamic effective connectivity in the cerebellar dorsal dentate nucleus and the cerebrum, cognitive impairment, and clinical correlates in patients with schizophrenia.
    Schizophr Res. 2024 May 9:S0920-9964(24)00184.
    >> Share

  744. ZHU Q, Jiang G, Zheng Y, Fu Z, et al
    The effect of cognitive impairment based on Mini-Mental State Examination (MMSE) on suicidal tendency in patients with schizophrenia: A large cross-sectional study.
    Schizophr Res. 2024;269:48-55.
    >> Share

  745. LI N, Li Y, Yu T, Gou M, et al
    Immunosenescence-related T cell phenotypes and white matter in schizophrenia patients with tardive dyskinesia.
    Schizophr Res. 2024;269:36-47.
    >> Share

  746. WANG Y, Xu Y, Wu P, Zhou Y, et al
    Exploring the interplay between core and mood symptoms in schizophrenia: A network analysis.
    Schizophr Res. 2024;269:28-35.
    >> Share

  747. SHIMADA T, Morimoto T, Nagayama H, Nakamura N, et al
    Effect of individualized occupational therapy on cognition among patients with schizophrenia: A randomized controlled trial.
    Schizophr Res. 2024;269:18-27.
    >> Share

  748. ZHANG C, Liang J, Yan H, Li X, et al
    Fractional amplitude of low-frequency fluctuations in sensory-motor networks and limbic system as a potential predictor of treatment response in patients with schizophrenia.
    Schizophr Res. 2024 May 3:S0920-9964(24)00173.
    >> Share

  749. DAUB J, Brandt GA, Volkmer S, Northoff G, et al
    Arthur Schopenhauer: An underappreciated philosopher in psychiatry and his applied epistemology of body and self- experience.
    Schizophr Res. 2024;267:487-496.
    >> Share

  750. LYNE J, Piacenza F, Radovic J, O'Donoghue B, et al
    The effectiveness of adjunctive cariprazine for treatment of negative symptoms: A systematic review of randomised controlled trials.
    Schizophr Res. 2024;267:213-215.
    >> Share

  751. TIRUPATI S, Arachchi MK
    Reply to "Obesity as a potential confounder of clozapine-induced myocarditis in the Hunter Region of Australia".
    Schizophr Res. 2024;267:191-192.
    >> Share

  752. VAN DER HEIDE DH, Bogers JPAM, Schulte PRFJ
    Recovery from leukopenia after discontinuation of clozapine does not exclude lymphoma.
    Schizophr Res. 2024;267:72-74.
    >> Share

  753. KIKUCHI Y, Komatsu H, Tomita H
    Obesity as a potential confounder of clozapine-induced myocarditis in the Hunter region of Australia.
    Schizophr Res. 2024;267:42-43.
    >> Share

    April 2024
  754. SASS L, Feyaerts J
    Schizophrenia, the very idea: On self-disorder, hyperreflexivity, and the diagnostic concept.
    Schizophr Res. 2024 Apr 30:S0920-9964(24)00122.
    >> Share

  755. ALBEELY AM, Williams OOF, Blight CR, Theriault RK, et al
    Sex differences in neuronal oscillatory activity and memory in the methylazoxymethanol acetate model of schizophrenia.
    Schizophr Res. 2024;267:451-461.
    >> Share

  756. LI H, Huang Y, Liang L, Li H, et al
    The relationship between the gut microbiota and oxidative stress in the cognitive function of schizophrenia: A pilot study in China.
    Schizophr Res. 2024;267:444-450.
    >> Share

  757. LE BARS T, Bulteau S, Bonnot O, Gollier-Briant F, et al
    Home-based transcranial direct current stimulation in schizophrenia: Systematic literature review, a teenager case report with cost-utility analysis.
    Schizophr Res. 2024;267:441-443.
    >> Share

  758. GOGOS A, Sbisa A, van den Buuse M
    Disruption of NMDA receptor-mediated regulation of PPI in the maternal immune activation model of schizophrenia is restored by 17beta-estradiol and raloxifene.
    Schizophr Res. 2024;267:432-440.
    >> Share

  759. AL-CHALABI N, Nader G, Gerretsen P, Fischer C, et al
    Assessing past suicidal behaviour in schizophrenia spectrum disorders using the Columbia-Suicide Severity Rating Scale and the Beck Scale for Suicide Ideation: Analysis across the life-span.
    Schizophr Res. 2024;267:415-421.
    >> Share

  760. MOURA BM, Madeira L, Bakker PR, van Harten P, et al
    The association between alterations in motor and cognitive dimensions of schizophrenia-spectrum disorders: A systematic review.
    Schizophr Res. 2024;267:398-414.
    >> Share

  761. HOLT DJ
    Personal space as a model neurobehavioral system for investigating schizophrenia.
    Schizophr Res. 2024;267:396-397.
    >> Share

  762. TOROUS J, Smith KA, Hardy A, Vinnikova A, et al
    Digital health interventions for schizophrenia: Setting standards for mental health.
    Schizophr Res. 2024;267:392-395.
    >> Share

  763. COHEN M, Roe D, Savir T, Baumel A, et al
    Blended care in psychosis - A systematic review.
    Schizophr Res. 2024;267:381-391.
    >> Share

  764. TAKAHASHI T, Katagiri N, Higuchi Y, Nishiyama S, et al
    Nomenclature for psychosis risk in Japan: Survey results from high-risk individuals, caregivers, and mental health professionals.
    Schizophr Res. 2024;267:373-380.
    >> Share

  765. CELLA M, Parri L, Wang K, Quinn R, et al
    Evaluating remote delivery of cognitive remediation in people with psychosis.
    Schizophr Res. 2024;267:367-372.
    >> Share

  766. MOREIRA-ALMEIDA A, Costa MA, Gattaz WF
    Spiritist anomalous experience is not associated with psychosis.
    Schizophr Res. 2024;267:356-358.
    >> Share

  767. LANDOLT A, Muller M, Ilg Y, Schulz PJ, et al
    Linguistic and (micro)cultural differences in the global debate about re-naming 'schizophrenia': A mixed-methods survey from Switzerland.
    Schizophr Res. 2024;267:341-348.
    >> Share

  768. ROCCA P, Brasso C, Montemagni C, Del Favero E, et al
    The relationship between the resting state functional connectivity and social cognition in schizophrenia: Results from the Italian Network for Research on Psychoses.
    Schizophr Res. 2024;267:330-340.
    >> Share

  769. SHEITMAN A, Bello I, Montague E, Scodes J, et al
    Observed Trajectories of Cannabis Use and Concurrent Longitudinal Outcomes in Youth and Young Adults Receiving Coordinated Specialty Care for Early Psychosis.
    Schizophr Res. 2024;267:313-321.
    >> Share

  770. GOUSE BM, Oblath R, Gibbs JS, Reagan EG, et al
    COVID-19 pandemic and emergency department visits for psychosis: Visit volume, restraint use, medication use, psychiatric hospitalization, and length of stay.
    Schizophr Res. 2024;267:301-307.
    >> Share

  771. DIAO H, Ma J, Jia Y, Jia H, et al
    Abnormalities in motor adaptation to different types of perturbations in schizophreniaperturbations in schizophrenia.
    Schizophr Res. 2024;267:291-300.
    >> Share

  772. CATTARINUSSI G, Di Giorgio A, Sambataro F
    Cerebellar dysconnectivity in schizophrenia and bipolar disorder is associated with cognitive and clinical variables.
    Schizophr Res. 2024 Apr 6:S0920-9964(24)00139.
    >> Share

  773. HO G, Pratt DN, Bridgwater MA, Schiffman J, et al
    Factors impacting intent to seek treatment within youth at clinical high risk for psychosis.
    Schizophr Res. 2024;267:273-281.
    >> Share

  774. KANG MJY, Eratne D, Wannan C, Santillo AF, et al
    Plasma neurofilament light chain is not elevated in people with first-episode psychosis or those at ultra-high risk for psychosis.
    Schizophr Res. 2024;267:269-272.
    >> Share

  775. SKLAR AL, Matinrazm S, Esseku A, Lopez-Caballero F, et al
    Intensity-dependent modulation of the early auditory gamma-band response in first-episode schizophrenia and its association with disease symptoms.
    Schizophr Res. 2024;267:261-268.
    >> Share

  776. MULLIGAN LD, Bojanic L, Hunt IM, Baird A, et al
    Substance use and self-poisoning in schizophrenia: 11-year findings from a national clinical survey of suicide in mental health patients in England.
    Schizophr Res. 2024;267:254-260.
    >> Share

  777. KISELY S, Arnautovska U, Siskind D, Warren N, et al
    Admissions for psychosis following agency-notified child maltreatment at 40-year-follow-up: Results from the Childhood Adversity and Lifetime Morbidity (CALM) cohort.
    Schizophr Res. 2024;267:247-253.
    >> Share

  778. OPLER M, Negash S, Tatsumi K, Liu C, et al
    Use of a novel study insight analytics (SIA) methodology to improve PANSS data quality and signal detection in a global clinical trial in schizophrenia.
    Schizophr Res. 2024;267:239-246.
    >> Share

  779. CEDERLOF E, Holm M, Taipale H, Tiihonen J, et al
    Antipsychotic medications and sleep problems in patients with schizophrenia.
    Schizophr Res. 2024;267:230-238.
    >> Share

  780. VARDEN GJERDE K, Bartz-Johannessen C, Steen VM, Andreassen OA, et al
    Cellular adhesion molecules in drug-naive and previously medicated patients with schizophrenia-spectrum disorders.
    Schizophr Res. 2024;267:223-229.
    >> Share

  781. BISMARK AW, Mikhael T, Mitchell K, Holden J, et al
    Pupillary responses as a biomarker of cognitive effort and the impact of task difficulty on reward processing in schizophrenia.
    Schizophr Res. 2024;267:216-222.
    >> Share

  782. FRANCO-RUBIO L, Puente-Martinez A, Ubillos-Landa S
    Factors associated with recovery during schizophrenia and related disorders: A review of meta-analysis.
    Schizophr Res. 2024;267:201-212.
    >> Share

  783. LI Y, Qiu D, Wu Q, Ni A, et al
    Affiliate stigma and its association with family burden among family members of people living with schizophrenia in China.
    Schizophr Res. 2024;267:193-200.
    >> Share

  784. FUJITA K, Mori Y, Kakumae Y, Takeuchi N, et al
    Pre-emptive ice pack cryotherapy for reducing pain caused by long-acting deltoid injectable antipsychotic treatment: A single-center open-label study.
    Schizophr Res. 2024;266:19-23.
    >> Share

    March 2024
  785. COHEN-LAROQUE J, Grangier I, Perez N, Kirschner M, et al
    Positive and negative symptoms in methamphetamine-induced psychosis compared to schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2024;267:182-190.
    >> Share

  786. DODD K, Legget KT, Cornier MA, Novick AM, et al
    Relationship between functional connectivity and weight-gain risk of antipsychotics in schizophrenia.
    Schizophr Res. 2024;267:173-181.
    >> Share

  787. GAO YN, Wang R, Gu G, Chung R, et al
    Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders.
    Schizophr Res. 2024;267:165-172.
    >> Share

  788. YU B, Sun Z, Li S, Chien IC, et al
    Social isolation and cognitive function in patients with schizophrenia: A two years follow-up study.
    Schizophr Res. 2024;267:150-155.
    >> Share

  789. BENNETT ME, Medoff D, Cowan T, Fang L, et al
    Tobacco smoking and nicotine vaping in persons with first episode psychosis.
    Schizophr Res. 2024;267:141-149.
    >> Share

  790. PELIZZA L, Leuci E, Leucci AC, Quattrone E, et al
    Diagnostic shift in first episode psychosis: Results from the 2-year follow-up of the "Parma Early Psychosis" program.
    Schizophr Res. 2024;267:99-106.
    >> Share

  791. MEHTA DD, Siddiqui S, Ward HB, Steele VR, et al
    Functional and structural effects of repetitive transcranial magnetic stimulation (rTMS) for the treatment of auditory verbal hallucinations in schizophrenia: A systematic review.
    Schizophr Res. 2024;267:86-98.
    >> Share

  792. LHO SK, Kim T, Moon SY, Kim M, et al
    Alteration in left frontoparietal connectivity correlates with impaired cognitive reappraisal in early psychosis.
    Schizophr Res. 2024;267:130-137.
    >> Share

  793. ZHOU R, Ye M, OuYang X, Zhang S, et al
    Insomnia and aggression in stable schizophrenic patients: The mediating role of quality of life.
    Schizophr Res. 2024;267:122-129.
    >> Share

  794. ELAM HB, Perez SM, Donegan JJ, Eassa NE, et al
    Knockdown of Lhx6 during embryonic development results in neurophysiological alterations and behavioral deficits analogous to schizophrenia in adult rats.
    Schizophr Res. 2024;267:113-121.
    >> Share

  795. EL HAJ M, Raffard S, Besche-Richard C
    Decoding schizophrenia: ChatGPT's role in clinical and neuropsychological assessment.
    Schizophr Res. 2024;267:84-85.
    >> Share

  796. NAIR N, Xavier S, Rabouin D, Mohan G, et al
    Patient-reported outcome measures in early psychosis: A cross-cultural, longitudinal examination of the self-reported health and self-reported mental health measures in Chennai, India and Montreal, Canada.
    Schizophr Res. 2024;267:75-83.
    >> Share

  797. ARSLAN B, Kizilay E, Verim B, Demirlek C, et al
    Automated linguistic analysis in speech samples of Turkish-speaking patients with schizophrenia-spectrum disorders.
    Schizophr Res. 2024;267:65-71.
    >> Share

  798. OZER D, Dissiz M
    The effect of online group based acceptance and commitment therapy on psychotic symptoms and functioning levels of individuals with early psychosis.
    Schizophr Res. 2024;267:55-64.
    >> Share

  799. MELVIN E, Green M, Keiller E, Parmar C, et al
    A systematic review of dramatherapy interventions used to support adults with psychosis.
    Schizophr Res. 2024;267:44-54.
    >> Share

  800. TZARTOS J, Karagiorgou K, Pechlivanidou M, Tzartos S, et al
    Absence of neuronal nicotinic acetylcholine receptor antibodies in sera and CSF from schizophrenia patients.
    Schizophr Res. 2024;267:39-41.
    >> Share

  801. KETCHAM E, Schooler NR, Severe JB, Buckley PF, et al
    Longitudinal study of insomnia, suicidal ideation, and psychopathology in schizophrenia.
    Schizophr Res. 2024;267:34-38.
    >> Share

  802. JOLLY AJ, Parmar A, Ghadigaonkar DS, Andrade C, et al
    Reflections on a study of electroconvulsive therapy for clozapine-refractory schizophrenia.
    Schizophr Res. 2024;267:32-33.
    >> Share

  803. LLORCA-BOFI V, Madero S, Amoretti S, Cuesta MJ, et al
    Inflammatory blood cells and ratios at remission for psychosis relapse prediction: A three-year follow-up of a cohort of first episodes of schizophrenia.
    Schizophr Res. 2024;267:24-31.
    >> Share

  804. DOLLFUS S, Letourneur F, Metivier L, Moulier V, et al
    Self-assessment scale of auditory verbal hallucinations (SAVH): A novel tool for patients with schizophrenia.
    Schizophr Res. 2024;267:19-23.
    >> Share

  805. DYKINS MM, Keedy SK, Sweeney JA, Hill SK, et al
    Characterizing cognitive heterogeneity in first-episode psychosis.
    Schizophr Res. 2024;267:16-18.
    >> Share

  806. MCLEAN RT, Buist E, St Clair D, Wei J, et al
    Autoantibodies against acetylcholine receptors are increased in archived serum samples from patients with schizophrenia.
    Schizophr Res. 2024;267:8-13.
    >> Share

  807. LI S, Liu W, Huang Z, Lin H, et al
    Sex-specific associations between sex hormones and clinical symptoms in late-life schizophrenia.
    Schizophr Res. 2024;267:1-7.
    >> Share

  808. LE TP, Ventura J, Subotnik KL, Nuechterlein KH, et al
    Intrinsic motivation predicts cognitive and functional gains during coordinated specialty care for first-episode schizophrenia.
    Schizophr Res. 2024;266:249-255.
    >> Share

  809. SLOT MIE, van Hell HH, Rossum IW, Dazzan P, et al
    A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort.
    Schizophr Res. 2024;266:237-248.
    >> Share

  810. KING B, Kempton MJ, Broberg BV, Merritt K, et al
    A letter to the editor: The effects of alcohol use on brain glutamate in first episode psychosis.
    Schizophr Res. 2024;266:234-236.
    >> Share

  811. STEPHANE M, Dzemidzic M, Yoon G
    Altered corollary discharge in the auditory cortex could reflect louder inner voice experience in patients with verbal hallucinations, a pilot fMRI study.
    Schizophr Res. 2024;265:14-19.
    >> Share

  812. LOPEZ-SILVA P, Harrow M, Jobe TH, Tufano M, et al
    'Are these my thoughts?': A 20-year prospective study of thought insertion, thought withdrawal, thought broadcasting, and their relationship to auditory verbal hallucinations.
    Schizophr Res. 2024;265:46-57.
    >> Share

    February 2024
  813. GARCIA-RIZO C, Crespo-Facorro B, Oliveira C, Gomez-Revuelta M, et al
    Anthropometry in antipsychotic-naive first-episode psychosis patients: An exploratory approach to the role of environmental early life events in two independent samples.
    Schizophr Res. 2024;266:216-226.
    >> Share

  814. ZAHER F, Diallo M, Achim AM, Joober R, et al
    Speech markers to predict and prevent recurrent episodes of psychosis: A narrative overview and emerging opportunities.
    Schizophr Res. 2024;266:205-215.
    >> Share

  815. ISAYEVA U, Manchia M, Collu R, Primavera D, et al
    Symptomatic remission and recovery in major psychosis: Is there a role for BDNF? A secondary analysis of the LABSP cohort data.
    Schizophr Res. 2024;266:197-204.
    >> Share

  816. SAVILL M, Loewy RL, Niendam TA, Porteus AJ, et al
    The diagnostic accuracy of screening for psychosis spectrum disorders in behavioral health clinics integrated into primary care.
    Schizophr Res. 2024;266:190-196.
    >> Share

  817. CABUK T, Sevim N, Mutlu E, Yagcioglu AEA, et al
    Natural language processing for defining linguistic features in schizophrenia: A sample from Turkish speakers.
    Schizophr Res. 2024;266:183-189.
    >> Share

  818. ZHAO W, Cannon TD
    Moral learning and positive schizotypy: Social cognitive mechanisms in psychosis- proneness.
    Schizophr Res. 2024;266:156-164.
    >> Share

  819. BAKER SC, Messer SJ, Girgis RR, Horga G, et al
    Prior overweighting relates to delusional ideation in individuals at clinical high-risk for psychosis.
    Schizophr Res. 2024;266:153-155.
    >> Share

  820. TIBIRICA L, Kohn J, Patapoff M, Williams AP, et al
    Acculturation and clinical symptoms of schizophrenia among Latine adults in the United States.
    Schizophr Res. 2024;266:145-152.
    >> Share

  821. PENG Z, Li Q, Liu X, Zhang H, et al
    A new schizophrenia screening instrument based on evaluating the patient's writing.
    Schizophr Res. 2024;266:127-135.
    >> Share

  822. MAKIPELTO V, Tuulio-Henriksson A, Hakulinen C, Niemela S, et al
    Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia.
    Schizophr Res. 2024;266:118-126.
    >> Share

  823. BALLERINI M, Magnani F, Amorosi S, Dell'Anna C, et al
    Anomalous Self-Experiences are predictive of social dysfunction in people with schizophrenia.
    Schizophr Res. 2024;266:116-117.
    >> Share

  824. TORREGROSSA LJ, Liu J, Armstrong K, Heckers S, et al
    Interplay between childhood trauma, bodily self-disturbances, and clinical phenomena in schizophrenia spectrum disorders: A network analysis.
    Schizophr Res. 2024;266:107-115.
    >> Share

  825. MILEY K, Bronstein MV, Ma S, Lee H, et al
    Trajectories and predictors of response to social cognition training in people with schizophrenia: A proof-of-concept machine learning study.
    Schizophr Res. 2024;266:92-99.
    >> Share

  826. IMAM I, Johnson KA, Saluja A, Mesholam-Gately RI, et al
    Advancing equity & access for psychosis care in Massachusetts: Proceedings from the 2023 Mass-STEP Conference.
    Schizophr Res. 2024;266:85-87.
    >> Share

  827. GURUSAMY J, Gandhi S, Damodharan D, Palaniappan M, et al
    Effect of lifestyle modification intervention (LMI) on metabolic syndrome in schizophrenia in a residential mental health care setting-A mixed method study.
    Schizophr Res. 2024;266:75-84.
    >> Share

  828. ZAKI JK, Lago SG, Spadaro B, Rustogi N, et al
    Exploring peripheral biomarkers of response to simvastatin supplementation in schizophrenia.
    Schizophr Res. 2024;266:66-74.
    >> Share

  829. BORA E, Eyuboglu MS, Cesim E, Demir M, et al
    Neurocognition and social cognition in youth and young adults at ultra-high-risk for psychosis and bipolar disorder.
    Schizophr Res. 2024;266:58-65.
    >> Share

  830. GARCIA-LEON MA, Fuentes-Claramonte P, Soler-Vidal J, Ramiro-Sousa N, et al
    Cortical volume abnormalities in schizophrenia: Correlations with symptoms and cognitive impairment.
    Schizophr Res. 2024;266:50-57.
    >> Share

  831. EKIN M, Akdal G, Bora E
    Antisaccade error rates in first-episode psychosis, ultra-high risk for psychosis and unaffected relatives of schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2024;266:41-49.
    >> Share

  832. MAAS IL, Bohlken MM, Gangadin SS, Rosema BS, et al
    Personal recovery in first-episode psychosis: Beyond clinical and functional recovery.
    Schizophr Res. 2024;266:32-40.
    >> Share

  833. WARREN N, O'Gorman C, Horgan I, Weeratunga M, et al
    Inflammatory cerebrospinal fluid markers in schizophrenia spectrum disorders: A systematic review and meta-analysis of 69 studies with 5710 participants.
    Schizophr Res. 2024;266:24-31.
    >> Share

  834. CHANEN AM, Kerslake R, Berube FA, Nicol K, et al
    Psychopathology and psychosocial functioning among young people with first-episode psychosis and/or first-presentation borderline personality disorder.
    Schizophr Res. 2024;266:12-18.
    >> Share

  835. KRAUS J, Cavojska N, Harvanova S, Hajduk M, et al
    Interpersonal distance in schizophrenia: A systematic review.
    Schizophr Res. 2024;266:1-11.
    >> Share

  836. MCILWAINE SV, Mughal S, Ferrari M, Rosengard R, et al
    Pre-onset subthreshold psychotic symptoms are associated with differential treatment delays before a first episode of psychosis: Initial evidence and implications.
    Schizophr Res. 2024;264:549-556.
    >> Share

  837. JEYAPALAN J, Sassi P, Mittendorfer Rutz E, Tiihonen J, et al
    Characteristics of incident substance-induced psychosis compared to first-episode psychotic disorders: A nationwide register-linkage study from Sweden.
    Schizophr Res. 2024;264:526-533.
    >> Share

  838. PERALTA V, de Jalon EG, Moreno-Izco L, Peralta D, et al
    The effect of anticholinergic burden of psychiatric medications on major outcome domains of psychotic disorders: A 21-year prospective cohort study.
    Schizophr Res. 2024;264:386-393.
    >> Share

    January 2024
  839. WANG Y, Ding R, Luo Y, He P, et al
    Does college education reduce the risk of schizophrenia? Evidence from a college enrollment expansion policy in China.
    Schizophr Res. 2024;264:519-525.
    >> Share

  840. TORDAI C, Hathy E, Gyergyak H, Vincze K, et al
    Probing the biological consequences of a previously undescribed de novo mutation of ZMYND11 in a schizophrenia patient by CRISPR genome editing and induced pluripotent stem cell based in vitro disease-modeling.
    Schizophr Res. 2024 Jan 29:S0920-9964(24)00024.
    >> Share

  841. KANE JM, Schoretsanitis G, Rubio JM, Correll CU, et al
    Clozapine in treatment-resistant schizophrenia: Reflections from the Hallmark US clinical trial and beyond.
    Schizophr Res. 2024 Jan 29:S0920-9964(24)00035.
    >> Share

  842. FADEN J, Citrome L
    A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder.
    Schizophr Res. 2024 Jan 29:S0920-9964(23)00420.
    >> Share

  843. LOZANO-GOUPIL J, Marin L, Aubin L, Decombe A, et al
    Impaired perception of a partner's synchronizing behavior reduces positive attitude toward humanoid robot in schizophrenia patients.
    Schizophr Res. 2024;264:511-518.
    >> Share

  844. MACDOUGALL AG, Wiener JC, Puka K, Price E, et al
    Effectiveness of a mindfulness-based intervention for persons with early psychosis: A multi-site randomized controlled trial.
    Schizophr Res. 2024;264:502-510.
    >> Share

  845. MURPHY SM, Flores AT, Wojtalik JA, Keshavan MS, et al
    Symptom contributors to quality of life in schizophrenia: Exploratory factor and network analyses.
    Schizophr Res. 2024;264:494-501.
    >> Share

  846. ESCANDON K
    Toward non-stigmatizing media and language in mental health: Addressing the social stigma of schizophrenia.
    Schizophr Res. 2024;264:491-493.
    >> Share

  847. ZEDAN SA, Zahid A, Best MW
    Examining the effects of diagnostic awareness, positive symptoms, and negative symptoms on stigmatizing attitudes and social exclusion towards schizophrenia.
    Schizophr Res. 2024;264:482-490.
    >> Share

  848. BHARGAV H, Keshavan M
    Why and how might yoga differ from other mind-body approaches in schizophrenia?
    Schizophr Res. 2024;264:479-481.
    >> Share

  849. VAN DER PLUIJM M, Alting M, Schrantee A, Edden RAE, et al
    Glutamate and GABA levels in the anterior cingulate cortex in treatment resistant first episode psychosis patients.
    Schizophr Res. 2024;264:471-478.
    >> Share

  850. LIU H, Tang E, Guan C, Li J, et al
    Not socially blind: Unimpaired perception of social interaction in schizophrenia.
    Schizophr Res. 2024;264:448-450.
    >> Share

  851. GRADY S, Twomey C, Cullen C, Gaynor K, et al
    Does affect mediate the relationship between interpersonal trauma and psychosis? A systematic review and meta-analysis.
    Schizophr Res. 2024;264:435-447.
    >> Share

  852. D'ARCEY JN, Zhao H, Wang W, Voineskos AN, et al
    An SMS text messaging intervention to improve clinical engagement in early psychosis: A pilot randomized-controlled trial.
    Schizophr Res. 2024;264:416-423.
    >> Share

  853. CHEN MY, Wang YY, Si TL, Liu YF, et al
    Poor sleep quality in schizophrenia patients: A systematic review and meta-analyses of epidemiological and case-control studies.
    Schizophr Res. 2024;264:407-415.
    >> Share

  854. CAI Y, Zhu ZH, Qi Q, Yin XY, et al
    The negative association of serum complement 3 and 4 levels with visuospatial/constructional function in first-episode patients with schizophrenia.
    Schizophr Res. 2024;264:404-406.
    >> Share

  855. SHANKAR A, Tripathi A
    Comments on "The effect on relapse rate and psychiatric symptomatology: Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. A
    Schizophr Res. 2024;264:402-403.
    >> Share

  856. NG BHM, Yu BCL, Leung JSY
    Investigation on the association between perceived family expressed emotion, self-stigma, and subjective quality of life in people with early psychosis in Hong Kong: A cross-sectional approach.
    Schizophr Res. 2024;264:394-401.
    >> Share

  857. GHIEH R, Krezolek M, Gaweda L
    Self-monitoring deficits in schizophrenia: A cross-sectional study of the underlying cognitive mechanisms.
    Schizophr Res. 2024;264:378-385.
    >> Share

  858. LAWRENCE RE, Appelbaum PS
    Ethics in placebo-controlled, acute treatment trials in schizophrenia: Two rival ethical frameworks.
    Schizophr Res. 2024;264:372-377.
    >> Share

  859. BOWERSOX NW, Smith CM, Austin K, Bradford DW, et al
    Mortality and suicidality in veterans health administration patients with newly-identified early episode psychosis.
    Schizophr Res. 2024;264:362-369.
    >> Share

  860. SONDERGAARD A, Gregersen M, Wilms M, Brandt JM, et al
    Exploring the relationship between attributional style measured in virtual reality and bullying among children at familial high risk of schizophrenia or bipolar disorder compared with controls.
    Schizophr Res. 2024;264:354-361.
    >> Share

  861. THAKKAR KN, Silverstein SM, Fattal J, Bao J, et al
    Stronger tilt aftereffects in individuals diagnosed with schizophrenia spectrum disorders but not bipolar disorder.
    Schizophr Res. 2024;264:345-353.
    >> Share

  862. PENTZ AB, O'Connel KS, van Jole O, Timpe CMF, et al
    Mismatch negativity and polygenic risk scores for schizophrenia and bipolar disorder.
    Schizophr Res. 2024;264:314-326.
    >> Share

  863. IBRAHIM K, Iturmendi-Sabater I, Vasishth M, Barron DS, et al
    Neural circuit disruptions of eye gaze processing in autism spectrum disorder and schizophrenia: An activation likelihood estimation meta-analysis.
    Schizophr Res. 2024;264:298-313.
    >> Share

  864. WANG P, Jiang Y, Biswal BB
    Aberrant interhemispheric structural and functional connectivity within whole brain in schizophrenia.
    Schizophr Res. 2024;264:336-344.
    >> Share

  865. OKADA H, Morimoto T, Ikeda N
    Exploratory; study on driving ability of people with schizophrenia: Relationships among cognitive function, symptoms, and brain activity.
    Schizophr Res. 2024;264:290-297.
    >> Share

  866. XIONG J, Ding Y, Wu X, Zhan J, et al
    Association between serum insulin-like growth factor 1 levels and the improvements of cognitive impairments in a subgroup of schizophrenia: Preliminary findings.
    Schizophr Res. 2024;264:282-289.
    >> Share

  867. DEAM MM, Gupta T, Bridgwater MA, Haas GL, et al
    Associations between interpersonal trauma and social impairments in adolescents with and without a family history of psychosis.
    Schizophr Res. 2024;264:280-281.
    >> Share

  868. CHEN YL, Chen PY, Pan CH, Chen PH, et al
    Prevalence and 3-year incidence of physical illnesses after schizophrenia diagnosis: Comparison with general population.
    Schizophr Res. 2024;264:272-279.
    >> Share

  869. DONMEZLER S, Sonmez D, Yilbas B, Ozturk HI, et al
    Thalamic nuclei volume differences in schizophrenia patients and healthy controls using probabilistic mapping: A comparative analysis.
    Schizophr Res. 2024;264:266-271.
    >> Share

  870. SU Y, Pan X, Li H, Zhang G, et al
    Effects of mind-body therapies on schizophrenia: A systematic review and network meta-analysis.
    Schizophr Res. 2024;264:236-247.
    >> Share

  871. MILLER M, Braun A, Cadenhead KS, Cornblatt BA, et al
    Self-perceptions and depression in youth at risk of psychosis.
    Schizophr Res. 2024;264:231-232.
    >> Share

  872. CHANG Y, Wang X, Liao J, Chen S, et al
    Temporal hyper-connectivity and frontal hypo-connectivity within gamma band in schizophrenia: A resting state EEG study.
    Schizophr Res. 2024;264:220-230.
    >> Share

  873. LEGRAND A, Moyal M, Deschamps C, Louveau C, et al
    Catatonia and genetic variant in GABA receptor: A case report involving GABRB2.
    Schizophr Res. 2024;263:191-193.
    >> Share

  874. KARL S, Sartorius A, Aksay SS
    Catatonia and ECT across the lifespan.
    Schizophr Res. 2024;263:246-251.
    >> Share

  875. HIRJAK D, Brandt GA, Fritze S, Kubera KM, et al
    Distribution and frequency of clinical criteria and rating scales for diagnosis and assessment of catatonia in different study types.
    Schizophr Res. 2024;263:93-98.
    >> Share

  876. WADDINGTON JL
    From operational diagnostic to dimensional-continuum concepts of psychotic and non-psychotic illness: Embracing catatonia across psychopathology and intrinsic movement disorder in neural network dysfunction.
    Schizophr Res. 2024;263:99-108.
    >> Share

  877. SAINI A, Begum N, Matti J, Ghanem DA, et al
    Clozapine as a treatment for catatonia: A systematic review.
    Schizophr Res. 2024;263:275-281.
    >> Share

    December 2023
  878. KLAASSEN AL, Michel C, Stuble M, Kaess M, et al
    Reduced anterior callosal white matter in risk for psychosis associated with processing speed as a fundamental cognitive impairment.
    Schizophr Res. 2023;264:211-219.
    >> Share

  879. RASMUSSEN AR
    Anomalies of imagination and development of psychosis: A phenomenological account.
    Schizophr Res. 2023;264:204-210.
    >> Share

  880. SABE M, Kohler R, Perez N, Sauvain-Sabe M, et al
    Mindfulness-based interventions for patients with schizophrenia spectrum disorders: A systematic review of the literature.
    Schizophr Res. 2023;264:191-203.
    >> Share

  881. DOLLFUS S, Letourneur F, Metivier L, Moulier V, et al
    A digital tool for self-assessment of auditory verbal hallucinations in schizophrenia.
    Schizophr Res. 2023;264:188-190.
    >> Share

  882. MYERS EJ, Abel DB, Mickens JL, Russell MT, et al
    Meta-analysis of the relationship between metacognition and disorganized symptoms in psychosis.
    Schizophr Res. 2023;264:178-187.
    >> Share

  883. MELZER-RIBEIRO DL, Napolitano IC, Leite SA, Alencar de Souza JA, et al
    Randomized, double-blind, sham-controlled trial to evaluate the efficacy and tolerability of electroconvulsive therapy in patients with clozapine-resistant schizophrenia.
    Schizophr Res. 2023 Dec 26:S0920-9964(23)00421.
    >> Share

  884. BAHLINGER K, Lincoln TM, Clamor A
    Do deficits in subjective stress recovery predict subsequent stress sensitivity and symptoms in schizophrenia spectrum disorders?
    Schizophr Res. 2023;264:170-177.
    >> Share

  885. ZINELLU A, Mangoni AA
    The pathophysiological role of circulating adhesion molecules in schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2023;264:157-169.
    >> Share

  886. BARBALAT G, Marechal L, Plasse J, Chereau-Boudet I, et al
    Functioning, clinical severity, education and sex moderate the inverse relationship between insight and quality of life in patients with schizophrenia.
    Schizophr Res. 2023;264:149-156.
    >> Share

  887. TROISI A, Brune M
    The ethological method for studying facial behavior in schizophrenia.
    Schizophr Res. 2023;264:147-148.
    >> Share

  888. HYATT A, Mullin B, Hasler V, Madore D, et al
    Predictors of relapse and engagement in care one year after ending services in an urban safety net coordinated specialty care program for first episode psychosis.
    Schizophr Res. 2023;264:140-146.
    >> Share

  889. JI Y, Pearlson G, Bustillo J, Kochunov P, et al
    Identifying psychosis subtypes use individualized covariance structural differential networks and multi-site clustering.
    Schizophr Res. 2023;264:130-139.
    >> Share

  890. HUANG TY, Chen LC, Li XP, Li WH, et al
    Elevated triglycerides and low triiodothyronine: Key risk factors for coronary artery calcification in patients with schizophrenia.
    Schizophr Res. 2023;264:113-121.
    >> Share

  891. DONDE C, Coulon N, Turbe H, Andre M, et al
    Clinical and cognitive characteristics of subjects with schizophrenia and childhood attention-deficit/hyperactivity disorder: Results from the multicentric FACE-SZ cross-sectional dataset.
    Schizophr Res. 2023;264:105-112.
    >> Share

  892. MORERA D, Miller BJ
    Meta-analysis of a family history of diabetes in schizophrenia.
    Schizophr Res. 2023;264:90-94.
    >> Share

  893. GUAN X, Chen Y, Wang X, Xiu M, et al
    Total antioxidant capacity, obesity and clinical correlates in first-episode and drug-naive patients with schizophrenia.
    Schizophr Res. 2023;264:81-86.
    >> Share

  894. SAPIENZA J, Agostoni G, Dall'Acqua S, Sut S, et al
    The kynurenine pathway in treatment-resistant schizophrenia at the crossroads between pathophysiology and pharmacotherapy.
    Schizophr Res. 2023;264:71-80.
    >> Share

  895. BOIKO DI, Chopra H, Bilal M, Kydon PV, et al
    Schizophrenia and disruption of circadian rhythms: An overview of genetic, metabolic and clinical signs.
    Schizophr Res. 2023;264:58-70.
    >> Share

  896. LIEBRAND M, Katsarakis A, Josi J, Diezig S, et al
    EEG microstate D as psychosis-specific correlate in adolescents and young adults with clinical high risk for psychosis and first-episode psychosis.
    Schizophr Res. 2023;264:49-57.
    >> Share

  897. CADENHEAD KS, Mirzakhanian H, Achim C, Reyes-Madrigal F, et al
    Peripheral and central biomarkers associated with inflammation in antipsychotic naive first episode psychosis: Pilot studies.
    Schizophr Res. 2023;264:39-48.
    >> Share

  898. LIU S, Zhang L, Fan X, Wang G, et al
    Lactate levels in the brain and blood of schizophrenia patients: A systematic review and meta-analysis.
    Schizophr Res. 2023;264:29-38.
    >> Share

  899. TANDON R, Nasrallah H, Akbarian S, Carpenter WT Jr, et al
    The schizophrenia syndrome, circa 2024: What we know and how that informs its nature.
    Schizophr Res. 2023;264:1-28.
    >> Share

  900. GARCIA-MARTI G, Escarti MJ, Nacher J, Perez-Rando M, et al
    Progressive loss of cortical gray matter in first episode psychosis patients with auditory hallucinations.
    Schizophr Res. 2023 Dec 2:S0920-9964(23)00423.
    >> Share

  901. LE TP, Green MF, Wynn JK, Iglesias JE, et al
    Effort-based decision-making as a determinant of supported employment outcomes in psychotic disorders.
    Schizophr Res. 2023;262:149-155.
    >> Share

  902. VIROLLE J, Redon M, Montastruc F, Taib S, et al
    What clinical analysis of antipsychotic-induced catatonia and neuroleptic malignant syndrome tells us about the links between these two syndromes: A systematic review.
    Schizophr Res. 2023;262:184-200.
    >> Share

    November 2023
  903. YU S, Qu Y, Du Z, Ou M, et al
    The expression of immune related genes and potential regulatory mechanisms in schizophrenia.
    Schizophr Res. 2023 Nov 21:S0920-9964(23)00419.
    >> Share

  904. SCHAUG JP, Storebo OJ, Pedersen MB, Haahr UH, et al
    How first-episode psychosis patients' subjective beliefs about their childhood trauma's causal effect provide support for potential schizophrenia subtypes.
    Schizophr Res. 2023;262:175-183.
    >> Share

  905. FU X, Baranova A, Cao H, Liu Y, et al
    miR-9-5p deficiency contributes to schizophrenia.
    Schizophr Res. 2023;262:168-174.
    >> Share

  906. TANG W, Zhou LJ, Zhang WQ, Jia YJ, et al
    Adverse perinatal pregnancy outcomes in women with schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2023;262:156-167.
    >> Share

  907. DEL RE EC, Keshavan MS
    Childhood trauma and psychosis-Searching for causes and mechanisms.
    Schizophr Res. 2023;262:146-148.
    >> Share

  908. VAN HOOIJDONK CFM, van der Pluijm M, de Vries BM, Cysouw M, et al
    The association between clinical, sociodemographic, familial, and environmental factors and treatment resistance in schizophrenia: A machine-learning-based approach.
    Schizophr Res. 2023;262:132-141.
    >> Share

  909. MOE AM, Kilicoglu MFV, Angers K, Huang K, et al
    Coordinated specialty care for first-episode psychosis: Effects on social motivation and social pleasure.
    Schizophr Res. 2023;262:130-131.
    >> Share

  910. EL KIRAT H, Khattabi A, Khalis M, Belrhiti Z, et al
    Effects of physical activity and nutrient supplementation on symptoms and well-being of schizophrenia patients: An umbrella review.
    Schizophr Res. 2023;262:112-120.
    >> Share

  911. TIEN YT, Wang LJ, Lee Y, Lin PY, et al
    Comparative predictive efficacy of atherogenic indices on metabolic syndrome in patients with schizophrenia.
    Schizophr Res. 2023;262:95-101.
    >> Share

  912. BURKE T, Holleran L, Mothersill D, Lyons J, et al
    Bilateral anterior corona radiata microstructure organisation relates to impaired social cognition in schizophrenia.
    Schizophr Res. 2023;262:87-94.
    >> Share

  913. XU S, Xu L
    Childhood emotional maltreatment increases the "wear-and-tear" of physiological systems, especially neuroendocrine changes in schizophrenia.
    Schizophr Res. 2023;262:84-86.
    >> Share

  914. STEENHUIS LA, Harms T, Nauta MH, Bartels-Velthuis AA, et al
    The dynamics of social activation and suspiciousness in individuals at ultra-high risk for psychosis.
    Schizophr Res. 2023;262:67-75.
    >> Share

  915. BARUTH JM, Bateman DR, Kovacs RJ, Bateman PV, et al
    Cardiac healthcare disparities and electrocardiography (ECG) differences in schizophrenia at end of life.
    Schizophr Res. 2023;262:60-66.
    >> Share

  916. OH H, Karcher NR, Schiffman J, Anglin DM, et al
    A broader conceptualization of premorbid risk in psychoses can motivate primordial prevention.
    Schizophr Res. 2023;262:53-54.
    >> Share

  917. PANIKRATOVA YR, Lebedeva IS, Akhutina TV, Tikhonov DV, et al
    Executive control of language in schizophrenia patients with history of auditory verbal hallucinations: A neuropsychological and resting-state fMRI study.
    Schizophr Res. 2023 Nov 1:S0920-9964(23)00388.
    >> Share

  918. HAHN B, Holzel ES
    Nicotine insensitivity and cue-controlled smoking behavior in people with schizophrenia.
    Schizophr Res. 2023;262:51-52.
    >> Share

  919. EACK SM, Wojtalik JA, Keshavan MS
    Anticholinergic medications in the treatment of psychoses: Pharmacological subtraction is better than addition.
    Schizophr Res. 2023;262:40-41.
    >> Share

  920. RINCON-CORTES M, Grace AA
    Sex-dependent emergence of prepubertal social dysfunction and augmented dopamine activity in a neurodevelopmental rodent model relevant for schizophrenia.
    Schizophr Res. 2023;262:32-39.
    >> Share

  921. VAZIRI N, Marques D, Greenway SC, Bousman CA, et al
    The cellular mechanism of antipsychotic-induced myocarditis: A systematic review.
    Schizophr Res. 2023;261:206-215.
    >> Share

    October 2023
  922. WU X, Ao H, Wu X, Cao Y, et al
    Sulfur-containing amino acids and risk of schizophrenia.
    Schizophr Res. 2023;262:8-17.
    >> Share

  923. CLAUSS-KOBAYASHI JME, Bonah C, Danion-Grilliat A, Scarfone M, et al
    Reshaping the diagnostic borders: Historical analysis of the diagnostic changes following the introduction of the schizophrenia concept.
    Schizophr Res. 2023;262:21-29.
    >> Share

  924. STAINTON A, Cheng N, Bryce S, Dalton A, et al
    Cognition is a treatment priority for young people with psychosis: Findings from the Your Mind, Your Choice survey.
    Schizophr Res. 2023;262:30-31.
    >> Share

  925. LAMSMA J, Harte JM, Cahn W
    Risk factors for violent behaviour before and after the onset of schizophrenia spectrum disorder: A naturalistic case-control study in the Netherlands.
    Schizophr Res. 2023;262:1-7.
    >> Share

  926. ROGERS E, Gresswell M, Durrant S
    The relationship between sleep and suicidality in schizophrenia spectrum and other psychotic disorders: A systematic review.
    Schizophr Res. 2023;261:291-303.
    >> Share

  927. HUO L, Qu D, Pei C, Wu W, et al
    Alexithymia in chronic schizophrenia and its mediating effect between cognitive deficits and negative symptoms.
    Schizophr Res. 2023;261:275-280.
    >> Share

  928. WILSON M, Harris M, Pereira M, Buckle J, et al
    Predictors of hospitalisation and recovery following full antipsychotic discontinuation in first episode psychosis. A naturalistic retrospective cohort study.
    Schizophr Res. 2023;261:269-274.
    >> Share

  929. FERNANDEZ-ABASCAL B, Suarez-Pinilla M, Cobo-Corrales C, Crespo-Facorro B, et al
    Lifestyle intervention based on exercise and behavioural counselling and its effect on physical and psychological health in outpatients with schizophrenia spectrum disorders. An exploratory, pragmatic randomized clinical trial.
    Schizophr Res. 2023;261:256-268.
    >> Share

  930. POORGANJI M, Goeke K, Zomorrodi R, Voineskos D, et al
    The use of theta burst stimulation in patients with schizophrenia - A systematic review.
    Schizophr Res. 2023;261:245-255.
    >> Share

  931. BESTERMAN AD
    A genetics-guided approach to the clinical management of schizophrenia.
    Schizophr Res. 2023 Oct 7:S0920-9964(23)00353.
    >> Share

  932. STONE WS, Phillips MR, Yang LH, Kegeles LS, et al
    Is schizophrenia neurodevelopmental, neurodegenerative or something else: A reply to Murray et al. (2022).
    Schizophr Res. 2023;261:234-235.
    >> Share

  933. OLOGUNDUDU OM, Palaniyappan L, Cipriano LE, Wijnen BFM, et al
    Risk stratification for treating people at ultra-high risk for psychosis: A cost-effectiveness analysis.
    Schizophr Res. 2023;261:225-233.
    >> Share

  934. LUTHER L, Westbrook A, Ayawvi G, Ruiz I, et al
    The role of defeatist performance beliefs on cognitive effort-cost decision-making in schizophrenia.
    Schizophr Res. 2023;261:216-224.
    >> Share

  935. CHEUK NKW, Tse W, Tsui HKH, Ma CF, et al
    A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia.
    Schizophr Res. 2023 Oct 1:S0920-9964(23)00338.
    >> Share

    September 2023
  936. KERKOVA B, Knizkova K, Vecerova M, Sustova P, et al
    Inflammation and cognitive performance in first-episode schizophrenia spectrum disorders: The moderating effects of childhood trauma.
    Schizophr Res. 2023;261:185-193.
    >> Share

  937. PESA J, Liu Z, Fu AZ, Campbell AK, et al
    Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia.
    Schizophr Res. 2023;261:170-177.
    >> Share

  938. HUANG LY, Parker DA, Ethridge LE, Hamm JP, et al
    Double dissociation between P300 components and task switch error type in healthy but not psychosis participants.
    Schizophr Res. 2023;261:161-169.
    >> Share

  939. STEPHAN NM, van Sprang ED, Wiebenga JXM, Dickhoff J, et al
    Risk factors for suicidality across psychosis vulnerability spectrum.
    Schizophr Res. 2023;261:152-160.
    >> Share

  940. KANG N, Kim SH, Kim J, Kim S, et al
    Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospital.
    Schizophr Res. 2023 Sep 26:S0920-9964(23)00340.
    >> Share

  941. OU M, Du Z, Jiang Y, Zhou Q, et al
    Causal relationship between schizophrenia and sex hormone binding globulin: A Mendelian randomization study.
    Schizophr Res. 2023 Sep 19:S0920-9964(23)00341.
    >> Share

  942. GURCAN G, Senol SH, Yagcioglu AEA, Ertugrul A, et al
    Effect of clozapine on suicidality in patients with schizophrenia at a university hospital in Turkey.
    Schizophr Res. 2023 Sep 19:S0920-9964(23)00297.
    >> Share

  943. LI X, Lafit G, van Aubel E, Vaessen T, et al
    Emotion regulation in daily life in early psychosis: The role of contextual appraisals.
    Schizophr Res. 2023;261:130-138.
    >> Share

  944. CHEN Q, Li X, Weng K, Zhang Y, et al
    Inflammatory mediators and the effect of electroconvulsive therapy in patients with schizophrenia.
    Schizophr Res. 2023;261:125-127.
    >> Share

  945. DAMIANI S, Zarbo C, Stolarski M, Zamparini M, et al
    Time will tell: Associations between unbalanced time perspectives and symptom severity in individuals with schizophrenia spectrum disorders.
    Schizophr Res. 2023;261:116-124.
    >> Share

  946. HEGDE S, Keshavan MS
    The brain on the beat: How music may heal schizophrenia.
    Schizophr Res. 2023;261:113-115.
    >> Share

  947. ZHANG L, James SH, Strauss GP
    Environmental resource reductions predict greater severity of negative symptoms in schizophrenia.
    Schizophr Res. 2023;261:94-99.
    >> Share

  948. PENTZ AB, Timpe CMF, Normann EM, Slapo NB, et al
    Mismatch negativity in schizophrenia spectrum and bipolar disorders: Group and sex differences and associations with symptom severity.
    Schizophr Res. 2023;261:80-93.
    >> Share

  949. GAUDIANO BA, Ellenberg S, Johnson JE, Mueser KT, et al
    Effectiveness of acceptance and commitment therapy for inpatients with psychosis: Implementation feasibility and acceptability from a pilot randomized controlled trial.
    Schizophr Res. 2023;261:72-79.
    >> Share

  950. QI W, Wen Z, Chen J, Capichioni G, et al
    Aberrant resting-state functional connectivity of the globus pallidus interna in first-episode schizophrenia.
    Schizophr Res. 2023;261:100-106.
    >> Share

  951. SAUER A, Grent-'t-Jong T, Zeev-Wolf M, Singer W, et al
    Spectral and phase-coherence correlates of impaired auditory mismatch negativity (MMN) in schizophrenia: A MEG study.
    Schizophr Res. 2023;261:60-71.
    >> Share

  952. GOVANI V, Shastry AM, Iosifescu DV, Govil P, et al
    Augmentation of learning in schizophrenia by d-serine and auditory remediation is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
    Schizophr Res. 2023;260:205-208.
    >> Share

  953. SORIA BRETONES C, Roncero Parra C, Cascon J, Borja AL, et al
    Automatic identification of schizophrenia employing EEG records analyzed with deep learning algorithms.
    Schizophr Res. 2023;261:36-46.
    >> Share

  954. MATSUI K, Kuriyama K, Yoshiike T, Kawamura A, et al
    Relapse of schizophrenia associated with comorbid delayed sleep-wake phase disorder but not with evening chronotype.
    Schizophr Res. 2023;261:34-35.
    >> Share

  955. PANCHAL Y, Gannon JM, Tatar JM, Balasubramani GK, et al
    COVID-19 vaccination among patients with schizophrenia prescribed clozapine.
    Schizophr Res. 2023;261:31-33.
    >> Share

  956. FERRARA M, Guloksuz S, Hazan H, Li F, et al
    The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service.
    Schizophr Res. 2023;260:198-204.
    >> Share

  957. GOLAY P, Abrahamyan Empson L, Mebdouhi N, Conus P, et al
    A better understanding of the impact of childhood trauma on depression in early psychosis: A differential item functioning approach.
    Schizophr Res. 2023;261:18-23.
    >> Share

  958. PATEL R, Chan KMY, Palmer EOC, Valko M, et al
    Associations of comorbid substance use disorders with clinical outcomes in schizophrenia using electronic health record data.
    Schizophr Res. 2023;260:191-197.
    >> Share

  959. SCHOTTLE D, Wiedemann K, Correll CU, Janetzky W, et al
    Response prediction in treatment of patients with schizophrenia after switching from oral aripiprazole to aripiprazole once-monthly.
    Schizophr Res. 2023;260:183-190.
    >> Share

  960. GANGADIN SS, Germann M, de Witte LD, Gelderman KA, et al
    Complement component 4A protein levels are negatively related to frontal volumes in patients with schizophrenia spectrum disorders.
    Schizophr Res. 2023;261:6-14.
    >> Share

  961. HINKLEY LBN, Haas SS, Cheung SW, Nagarajan SS, et al
    Reduced neural connectivity in the caudate anterior head predicts hallucination severity in schizophrenia.
    Schizophr Res. 2023;261:1-5.
    >> Share

  962. POLETTI M, Raballo A
    Subjective self-experiences at the mirror in patients with schizophrenia.
    Schizophr Res. 2023;260:180-182.
    >> Share

  963. WANG T, Codling D, Bhugra D, Msosa Y, et al
    Unraveling ethnic disparities in antipsychotic prescribing among patients with psychosis: A retrospective cohort study based on electronic clinical records.
    Schizophr Res. 2023;260:168-179.
    >> Share

  964. ROBINSON N, Ploner A, Muller-Eberstein R, Lichtenstein P, et al
    Migration and risk of schizophrenia and bipolar disorder: A Swedish national study.
    Schizophr Res. 2023;260:160-167.
    >> Share

  965. GRANRUD OE, Rodriguez Z, Cowan T, Masucci MD, et al
    Alogia and pressured speech do not fall on a continuum of speech production using objective speech technologies.
    Schizophr Res. 2023;259:121-126.
    >> Share

    August 2023
  966. HONIGFELD G
    Clozapine in treatment-resistant schizophrenia: Who designed that famous US clinical trial?
    Schizophr Res. 2023 Aug 31:S0920-9964(23)00287.
    >> Share

  967. GRIFFITHS K, Smart SE, Barker GJ, Deakin B, et al
    Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia.
    Schizophr Res. 2023;260:152-159.
    >> Share

  968. CLEMENTZ BA, Chattopadhyay I, Trotti RL, Parker DA, et al
    Clinical characterization and differentiation of B-SNIP psychosis Biotypes: Algorithmic Diagnostics for Efficient Prescription of Treatments (ADEPT)-1.
    Schizophr Res. 2023;260:143-151.
    >> Share

  969. GOFF DC, Santacatterina M, Capichioni G, Ando F, et al
    Levetiracetam effects on hippocampal blood flow and symptoms in medication-free individuals with nonaffective first episode psychosis (letter).
    Schizophr Res. 2023;260:140-142.
    >> Share

  970. MUESER KT, Sussman RF, DeTore NR, Eberlin ES, et al
    The impact of early intervention for first episode psychosis on cognitive functioning.
    Schizophr Res. 2023;260:132-139.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016